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The use of sodium bicarbonate (NaHCO3) as an ergogenic aid has been widely researched and 
also practiced by the athletic community. Despite this, fundamental issues have not been 
addressed, including a full profile of NaHCO3’s effects on the bicarbonate ion (HCO3
-), the 
dose-dependent effects on performance and gastrointestinal discomfort (GI), and the most 
optimal timing of ingestion. Recently, an individualised NaHCO3 ingestion strategy has been 
advocated, which entails supplementing NaHCO3 at a pre-determined time to peak pH or 
HCO3
-. The reproducibility of both the blood and performance responses using this strategy 
remains unknown however, and therefore Study 1 investigated the reproducibility of the blood 
acid base balance responses following NaHCO3 ingestion in two separate doses of 0.2 g
.kg-1 
BM (SBC2) and 0.3 g.kg-1 BM NaHCO3 (SBC3). This study revealed that pH and HCO3
- 
kinetics following both doses were highly reproducible, although HCO3
- displayed greater 
reproducibility. Furthermore, both doses increased pH and HCO3
- to a level that would suggest 
ergogenic benefits could be elicited. As a result, both the reproducibility of the performance 
responses (Study 2) and the performance effects against a placebo (Study 3) were investigated 
following both SBC2 and SBC3, administered at a pre-determined individual time to peak 
HCO3
-. Both SBC treatments revealed highly reproducible performance responses, and 
displayed similar improvements in performance compared to a placebo during a 4 km cycling 
time trial (TT). Once methods to enhance the application of NaHCO3 to exercise performance 
in normoxia were identified, this supplement was then applied to acute hypoxia and recovery. 
Study 4 investigated the effects of NaHCO3 ingestion on 4 km TT performance at acute 
moderate hypoxia (~3000 m). Again, both SBC treatments improved performance compared 
to placebo. The acid base balance recovery profile following exercise was also monitored for 
40 min post-exercise, whereby both SBC treatments displayed a similar magnitude of acid base 
balance recovery compared to a placebo. Study 5 therefore investigated the effects of both 
SBC2 and SBC3 on repeated 4 km TT (TT1 and TT2) cycling, interspersed by a 40 min recovery 
at acute moderate hypoxic conditions (~3000 m). Repeated efforts were improved more greatly 
following SBC3, revealing significant improvements vs. placebo in both TT1 and TT2, and a 
greater magnitude of effect compared to SBC2. Collectively, these studies highlight the 
importance of the dose, and timing of NaHCO3 ingestion to improve exercise performance both 
at normoxia and hypoxia.  
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1.1 Introduction  
Athletes are continuously on the quest to find every possible legal advantage to improve their 
performance and gain a competitive advantage over opponents. A widely considered important 
part of this is the use of nutritional ergogenic aids, which have been extolled as a key strategy 
to capitalise on ‘marginal gains’. Subsequently, ingestion of such ergogenic aids have been 
reported to be highly prevalent amongst competitive athletes (Knapik et al., 2016). Most 
common are those aimed at enhancing human physiology during exercise, particularly ones 
aimed at limiting the cellular components of fatigue (Burke, 2017). Examples of these include 
creatine monohydrate (Cooper et al., 2012), lactate (Oliveira et al., 2017), beta alanine 
(Saunders et al., 2017) and sodium bicarbonate (NaHCO3) (McNaughton et al., 2016).  
 
The latter, NaHCO3, has arguably been the most widely researched supplement in sports 
performance. Common practice has been ingestion of 0.3 g.kg-1 BM NaHCO3 between 60 and 
90 min prior to exercise (McNaughton, 1992a, Price and Singh, 2008). This dose is sufficient 
to raise pH to a level reflective of metabolic alkalosis (>0.04), and raise HCO3
- over the +5 
mmol.l-1 threshold suggested to result in a likely ergogenic effect on performance (Carr, 
Hopkins and Gore, 2011a). These biochemical changes are primarily associated with enhanced 
extracellular H+ blood buffering during high-intensity exercise, by protecting intracellular acid 
base balance status (Bishop et al., 2004).  
 
Whilst this has revealed an overall positive effect on mean power by 1.7% (± 2.0%) during 
exercise of between 1 and 10 min in multiple meta-analyses (Carr et al., 2011a, Peart, Siegler 
and Vince, 2012, Christensen et al., 2017), a large inter-individual response has been observed. 
As a result, it has been suggested there are ‘responders’ and ‘non-responders’ to NaHCO3 
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supplementation (Flinn et al., 2014, Saunders et al., 2014a, Dias et al., 2015). Therefore, the 
use of NaHCO3 in some individuals is sub-optimal. 
 
One source of variation could be the ingestion strategy. To date, the pH and HCO3
- kinetics 
following NaHCO3 ingestion are not fully understood, which is largely due to infrequent 
sampling and only group mean responses being reported (Renfree, 2007, Price and Singh, 2008, 
Carr et al., 2011b). Recent work supports this, showing individual time to peak alkalosis can 
vary between 10 and 180 min (Miller et al., 2016, Deb et al., 2017, Deb et al., 2018a). In 
response, supplementation of NaHCO3 at individual time to peak alkalosis is arguably required 
to maximise pH and HCO3
- prior to exercise and thus, heighten the chances of an ergogenic 
effect (McNaughton et al., 2016). It is unknown, however, if such an individual time to peak 
alkalosis is reproducible, which may affect the usability of this strategy. Furthermore, a mixed 
approach has been employed to date, whereby either peak pH or HCO3
- has been used to 
determine the individualised time to peak strategy. Consequently, it is unclear which analyte is 
the most appropriate. Examining the reproducibility of time to peak pH and HCO3
- will 
therefore allow athletes to identify the analyte that should determine the individualised 
NaHCO3 strategy. 
 
A further concern of nutritional ergogenic aids is the paucity of literature examining the 
reproducibility of the potential performance improvements upon repeated use. This is 
important to athletes who wish to obtain consistent positive effects across a season or race 
series. Indeed, research to date investigating the reproducibility of both the blood and 
performance responses following NaHCO3 ingestion is equivocal (Bird, Wiles and Robbins, 
1995, Carr et al., 2012, Dias et al., 2015). Indeed, Carr et al. (2012) reported a low CV of 2.1% 
between two repeated 2 km rowing TT’s following NaHCO3 ingestion within a group of highly 
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trained rowers, suggesting the reproducibility of the performance responses are high. 
Conversely, Dias et al. (2015) reported a 7.4% CV in a cycling task to exhaustion at 110% peak 
power output in recreational athletes. Furthermore, both Carr et al. (2012) and Dias et al. (2015) 
reported the ergogenic benefits following NaHCO3 were not reproducible, which questions the 
suitability of this supplement to consistently improve performance. It is plausible that if 
NaHCO3 was supplemented at individual time to peak pH or HCO3
- the reproducibility of the 
performance responses would have been greater, as this would have limited the variation in 
blood parameters prior to exercise within the cohort. If this is the case is unknown however, 
and as a result, investigating the consistency of both the blood and performance responses 
following an individualised NaHCO3 ingestion strategy will allow athletes to assess if this 
supplement can consistently elicit ergogenic effects on performance.   
 
Athletes may avoid NaHCO3 ingestion due to the occurrence of gastrointestinal (GI) 
discomfort, as this might cause either negative effects on performance (Cameron et al., 2010, 
Saunders et al., 2014a), or result in the athlete being unable to exercise (Jones et al., 2016, 
Gough et al., 2017). A plausible method to mitigate this is to lower the dose of NaHCO3, as 
this has been shown to reduce the severity and instances of GI discomfort (McNaughton, 
1992a, Jones et al., 2016). The performance responses following a lower dose of less than 0.3 
g.kg-1 BM NaHCO3 is equivocal, however limited research is available (McNaughton, 1992a, 
McKenzie et al., 1986). Interestingly, by supplementing NaHCO3 at a time corresponding to 
an individual time to peak pH or HCO3
-, increases from 0.2 g.kg-1 BM suggest an ergogenic 
benefit could be realised (Jones et al., 2016). Nonetheless, no research to date has investigated 
the dose-dependent effects of NaHCO3 on the corresponding GI discomfort and performance 
responses. By conducting this research, athletes can assess if a lower dose of NaHCO3 is 
valuable to mitigate GI discomfort, yet still improve their performance.  
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The effectiveness of nutritional ergogenic aids depends on the context to which they are 
applied. Beyond NaHCO3 being applied to sports performance in normoxia, over the last 15 
years NaHCO3 has been applied to contextual scenarios such as acute hypoxia and recovery, 
as a supplement to mitigate the reduction in performance observed in this environment (Deb et 
al., 2018b). There has been a recent growth of accessible methods to include a hypoxic stimulus 
within training such as hypoxic tents, chambers and masks, which allow both elite and 
recreational athletes the opportunity to train/perform in hypoxia. Furthermore, according to the 
World Health Organisation approximately 35 million people visit terrains of 3000 m and above 
every year. In respect of exercise performance, these points combined necessitate the need to 
understand how to best prepare an individual for both chronic exposure to a hypoxic 
environment, but also during intermittent hypoxic schedules such as ‘live-low, train-high’. The 
use of NaHCO3 may be important in acute hypoxic conditions, particularly compared to 
normoxia, as a greater accumulation of H+ occurs in this environment for the same absolute 
exercise in normoxia (Adams and Welch, 1980, Hogan, Richardson and Haseler, 1999, Romer 
et al., 2007). Therefore, the use of NaHCO3 may mitigate this acid base balance disturbance 
and thus, maintain training volume and intensity. Recent research is mixed however, with some 
(Deb et al., 2017, Deb et al., 2018a), but not all (Flinn et al., 2014, Saunders et al., 2014b) 
reporting positive effects on performance following 0.3 g.kg-1 BM NaHCO3 ingestion.  
 
In addition, research investigating post-exercise recovery kinetics following NaHCO3 in acute 
hypoxia are scant. Only one study to date has investigated the post-exercise acid base balance 
recovery kinetics and displayed that NaHCO3 accelerated the speed and magnitude of recovery 
compared to a placebo (Robergs et al., 2005). This study however, was conducted at a low 
level of terrestrial altitude (1570 m) and featured no subsequent performance bout. 
Investigating the effects of NaHCO3 on high-intensity exercise, post-exercise acid base balance 
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recovery, and subsequent performance in moderate acute hypoxia will therefore allow athletes 
to assess the efficacy of NaHCO3. This is particularly important to address whether athletes 
can use NaHCO3 to support the maintenance of training volume and intensity during 
intermittent hypoxic training schedules, such as ‘live-low, train-high’.  
 
In turn, the aims of this thesis are:  
 To establish whether the time to peak pH and HCO3- following repeated NaHCO3 
ingestion are reproducible. 
 To establish whether the performance responses following repeated NaHCO3 ingestion 
at a pre-determined individual time to peak alkalosis are reproducible. 
 To evaluate the dose-dependent relationship of NaHCO3 ingestion at a pre-determined 
individual time to peak alkalosis on cycling TT performance.  
 To evaluate the effects of NaHCO3 ingested at a pre-determined individual time to peak 
alkalosis on cycling TT performance in acute hypoxia.  
 To evaluate the efficacy of NaHCO3 to accelerate post-exercise acid base balance 
recovery and improve subsequent high-intensity exercise performance in acute 
hypoxia. 
 
Based on the following aims, this review of literature will begin by introducing the 
fundamentals of acid base balance and mechanisms of fatigue during high-intensity exercise. 
To follow, NaHCO3’s potential mechanisms of action with a specific focus on how the 
ingestion timing and dose can affect these mechanisms, shall then be discussed. Hereafter, the 
current research conducted on short distance/duration TT’s following NaHCO3 ingestion shall 
be critically reviewed. Lastly, the potential importance of NaHCO3 as a supplement to enhance 
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performance and recovery in acute hypoxia shall be discussed. The final literature search for 


























































2.1 Review of literature 
2.2 Fundamentals of acid base balance 
2.2.1 Traditional approach 
Acid base balance is a complex process both physiological and biochemical in nature that acts 
to maintain a stable pH within the blood. Maintenance is an essential requirement for normal 
physiological functions including metabolic processes such as glycolytic enzyme function and 
the transport of protons in both intracellular and extracellular compartments (Atherton, 2003). 
Derangements both above and below homeostatic levels can have important implications, as 
for example, a characteristic of chronic obstructive pulmonary disease (COPD) is a state of 
respiratory acidosis, which has negative effects on normal exercise functions due to the lack of 
efficiency to expel carbon dioxide (CO2). Close maintenance of acid base balance is therefore 
important, and researchers and clinicians alike monitor the gases of both blood and muscle to 
calculate pH. This is depicted via the Henderson-Hasselbalch equation that serves as the basis 
for traditional acid base balance interpretation (Siggaard-Andersen, 1977, Worthley, 1999) 
(Equation 1).  
 
(1) pH = pKa + log10 [HCO3-]/αPCO2 
 
Accepted values to represent homeostasis are between 7.35 and 7.45 for blood (Goel and 
Calvert, 2012), and 7.38 to 7.42 for muscle (Atherton, 2003). Alterations in pH are dependent 
upon the acid/alkali load produced from both exogenous sources such as dietary intake and 
endogenous sources such as the kidney and lungs. Chemical reactions in water with associated 
compounds are the determinants to a change in pH, where in short, an acid is a compound that 
donates H+ (proton donor), whilst a base will accept H+ (proton acceptor) (Poupin et al., 2012). 
The greatest threat to acid base balance is derived from endogenous sources, such as the 
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intermediary/end products of metabolism from processes such as glycolysis (step-wise 
conversion of muscle glycogen or free glucose to lactate) and ATP hydrolysis (combination of 
1 ATP and 2 water molecules to ADP) (Robergs, Ghiasvand and Parker, 2004). Both chemical 
reactions threaten pH homeostasis by eliciting significant perturbation of acid base balance, 
due to the exacerbated hydrogen ion (H+) production (Goel and Calvert, 2012). This is best 
depicted by the inverse relationship of pH and H+ in the equation below (Equation 2). 
 
(2) pH = -log (10) [H+] 
 
Exacerbated H+ production is a common occurrence during high-intensity exercise, as the 
exercise intensity/ATP demand is too high to allow either pyruvate or H+ to be utilised during 
mitochondrial respiration, such as the Krebs cycle (Robergs et al., 2004). In this scenario H+ 
accumulation occurs within the cell, and pH falls concomitantly. One example of this is a 4 km 
cycling time trial (TT), as Callaghan et al. (2016) reported [H+] increased by 31.1 mmol.l-1 
(58%) from rest to post-exercise (38.0 mmol.l-1 vs. 69.1 mmol.l-1). Likewise, Hultman, Del 
Canale and Sjöholm (1985) reported a greater decline in muscle pH, elicited via ingestion of 
an acid supplement (NH4Cl), resulted in a 21% greater decline in intracellular buffering 
capacity compared to a control after 75 s of quadriceps stimulation at 50% maximally voluntary 
force. High-intensity exercise is therefore defined as, for the purpose of this thesis, as an 
exercise intensity that increases beyond the point where H+ accumulation displays exponential 
growth, and is not utilised by the mitochondria.  
 
To uphold pH homeostasis during high-intensity exercise there is a set of sophisticated, 
interrelated mechanisms that are time-dependent that attempt to minimise disturbances. This is 
achieved through maintaining a balance between H+ accumulation and H+ removal. The 
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immediate response is physicochemical buffering, which is a process that eliminates either a 
strong acid or base and replaces it with a weaker one. Initially, this is carried out at the 
intracellular level primarily by proteins (histidine and carnosine), phosphates (inorganic and 
organic), and haemoglobin, which provides around 64% of total buffering, with the remaining 
36% contribution from intracellular carbonic acid (H2CO3)/bicarbonate (HCO3
-) (Poupin et al., 
2012). This is quickly exceeded however, due to the lack of capacity of this system to fully 
counteract a decline in pH, and return pH back to resting levels.  
 
Extracellular buffering occurs through the transport of protons out of the muscle cell into the 
blood. Proton-linked monocarboxylate transporters one (MCT1) and four (MCT4) are 
responsible for this, which act in response to H+ accumulation outweighing removal in the 
intracellular system (Halestrap and Wilson, 2012). This is to preserve the intracellular pH 
through providing rapid translocation of protons (lactate and H+ coupled) across the plasma 
membrane; which is primarily carried out by the lactate - H+ transporter. The most prominent 
is MCT4 due to its high expression in glycolytic type IIb muscle fibers, and cells with a high 
glycolytic rate (Halestrap and Wilson, 2012). As a result, the bicarbonate buffer is the most 
prominent, providing around 86% of total extracellular buffering, although this does vary 
depending on the exercise duration and intensity (Poupin et al., 2012). This buffer system is 
based on the relationship between carbon dioxide (CO2) and bicarbonate (HCO3
-) via the 
reversible equation below (Equation 3). 
 
(3) CO2 + H2O  H2CO3  H+ + HCO3- 




In short, too much base (metabolic alkalosis) leads to increased CO2 retention through 
hypoventilation and the formation of carbonic acid (H2CO3), and therefore the H
+ concentration 
increases and pH declines. Whereas, under high H+ efflux (metabolic acidosis) HCO3
- is 
expended to combine with H+ and form H2CO3, which is subsequently converted to CO2 and 
H2O by carbonic anhydrase (Poupin et al., 2012). The latter leads to the release of CO2 via the 
lungs, whilst the converted H2O is used as metabolic water, or it increases plasma volume 
(Mueller et al., 2013). 
 
Considerable research exists debating why the bicarbonate buffer is of such importance, 
considering the respective acid dissociation constant (pKa) of HCO3
- and H2CO3 is a pH of 
10.2 and 3.8. The pKa is commonly used in chemistry to provide a quantitative measure to 
predict the extent of acid dissociation, such that at a solution with a pKa closer to resting pH 
7.4 should have a large effect on pH. The aforementioned levels of pH (10.2 and 3.8) are not 
physiologically achievable within the exercising human however, and therefore it is unclear 
how the bicarbonate buffer operates almost instantly after a disturbance to pH. Nonetheless, 
unlike most buffers, the bicarbonate buffer is not solely dependent on acid base qualities alone 
(Robergs, 2002, Robergs et al., 2004). Rather, the bicarbonate buffer is unique in a way that it 
is dependable on the available HCO3
-, the enzyme carbonic anhydrase, and both gaseous and 
dissolved CO2 in water (Lehninger, Nelson and Cox, 2004). This contrasts with the traditional 
representation of the bicarbonate buffer (H+ + NaHCO3  H2CO3), such that the three 
reaction constants depicted below are suggested to be a more valid reflection of this buffer, 
with K3 commonly overlooked (Robergs, 2002) (Equation 4).  
 
(4) K1 = [H
+] [HCO3
-] / [H2CO3] 
K2 = [H2CO3] / [CO2d] [H2O] 
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K3 = [CO2d] / [CO2g] 
Where CO2d = dissolved CO2, and CO2g = gaseous CO2 
 
The resulting reactions mean the bicarbonate buffer is operational in blood at a pH of 7.4, and 
therefore it is of paramount importance to defend against disturbances of acid base balance. 
Whilst this process is sufficient for the initial minutes of exercise, it cannot provide protection 
in isolation, and therefore further compensation mechanisms are required to expel the 
accumulated CO2. Accordingly, respiratory compensation operates within minutes to work 
synergistically with physicochemical buffering to limit disturbances of the acid base balance 
by increasing ventilation. This increase aims to meet both the O2 demand for the given exercise 
and to remove excess CO2 (Stringer, Casaburi and Wasserman, 1992). Similar to 
physicochemical buffering however, these changes still only limit the disturbance and are 
unable to maintain pH levels at resting levels. Otherwise, renal compensation is arguably the 
most important for long-term acid base adjustments typically working across days to 
continuously reabsorb filtered HCO3
-, and excrete H+ upon entering the kidney (Poupin et al., 
2012). Consequently, the contribution of the kidney to dampen H+ accumulation during high-
intensity exercise is limited. Considering the aims of the present thesis (acid base balance 
disturbances during high-intensity exercise), both physicochemical and respiratory 
compensation will be discussed hereafter, as adjustments from renal compensation fall outside 
(days) of the typical time frame of high-intensity exercise (mins).  
 
2.2.2 Modified approach to interpretation of acid base balance 
In 1978, Stewart introduced a complimentary analysis of the interpretation of acid base balance 
status. Stewart argued that HCO3
- concentration is invalid to determine pH as it is a dependent 
variable, meaning HCO3
- cannot independently manipulate pH without other chemical 
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reactions to occur (Stewart, 1983). Instead, pH is directly manipulated by three main 
independent variables including the strong ion difference (SID), the total concentration of weak 
acids (ATOT) and PCO2 (Stewart, 1983). In exercise science therefore, the modified approach 
can potentially elucidate further mechanisms of fatigue with reference to muscle contraction 
apparatus (Lindinger and Heigenhauser, 1991, McKenna, 1992, Tenan et al., 2011). 
 
The SID is the balance of the fully dissociated cations and anions in intracellular and 
extracellular fluid, and is commonly calculated as sodium [Na+] + potassium [K+] + calcium 
[Ca2+] + magnesium [Mg2+] - chloride [Cl-] - lactate [Lac-]. These concentrations should always 
be equal to each other in accordance with conservation of mass, the law of electrical neutrality, 
and the dissociation equilibrium of water and weak acids (for formula see Stewart, 1983). The 
supplementary components of the modified approach include ATOT and PCO2, however these 
are suggested to have limited effects on the H+ concentration. Work by Lindinger and 
colleagues has showed that changes in the SID accounts for around 80% of the total H+ 
concentration (Lindinger and Heigenhauser, 1991, Lindinger, McKelvie and Heigenhauser, 
1995). In relation to muscle contraction, the importance of the SID is suggested to be the impact 
on the action potential pathway along the sarcolemma and the T tubule (Lindinger, Kowalchuk 
and Heigenhauser, 2005). Specifically, a reduction can lead to failure of sufficient electrical 
excitation, consequently reducing membrane potential, muscle action potentials, and cell 
membrane excitability through impeding maximal Na+, K+ - ATPase activity (Fitts, 1994, 
Cairns and Lindinger, 2008). Importantly, traditional pH and HCO3
- kinetics do not explain all 
of these factors, therefore the use of the SID can offer a greater mechanistic view of fatigue 




Much of the previous literature conducted in vitro has not calculated the SID, instead reporting 
ionic shifts independently of each other. Decreases in intracellular K+, combined with increases 
in interstitial and extracellular K+ are recognised effectors that depress muscle excitability 
(McKenna, 1992, Allen, Lamb and Westerblad, 2008a, Cairns and Lindinger, 2008). Changes 
in K+ are not independent however, with other strong cations (and anions) playing integral 
synergistic roles. Shifts in Cl- can also exert significant effects on K+, by driving K+ back to 
the muscle fiber through inward rectifier channels, which assist in returning the cell back to 
resting membrane potential (Lindinger and Heigenhauser, 1991, Cairns and Lindinger, 2008). 
Moreover, a raised Na+ gradient is suggested to lead to a greater stimulation of Na+, K+ - 
ATPase activity, therefore protecting against action potential failure. This was best displayed 
by Bouclin, Charbonneau and Renaud (1995), as with either of the ions altered independently 
limited effects on tetanic force were observed, however when changed in combination, a 
greater reduction was observed. Cairns et al. (1998) also displayed the contributory effect of 
Ca2+ metabolism on disturbances to the K+ - Na+ gradient, whereby tetanic force loss under 
stimulation was reversed with high Ca2+ (10 mM), compared with a low Ca2+ concentration 
(1.3 mM). Changes in K+ alone consequently fail to explain the changes in action potentials 
and muscle contraction. The collective input of the strong cations and anions should be 
therefore be considered to appropriately interpret the effects on the action potential and muscle 
excitability and the subsequent effects on muscle force production.   
 
2.3 Fatigue during high-intensity exercise in normoxia 
2.3.1 Introduction 
Generally, the study of fatigue has been characterised by the decline in muscle power 
production through a reduction in both contraction force and velocity (Enoka and Duchateau, 
2008, Fitts, 2008). Fatigue can be clearly identified subjectively during exercise, however the 
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mechanisms to explain why this occurs are controversial and therefore presents a complex 
phenomenon. Due to the dependency of competitive exercise performance on delaying the 
onset of fatigue, it is important for both athletes and physiologists to determine the contributing 
mechanisms. 
 
Characteristics of fatigue consist of inhibition of various processes along the motor pathway, 
and are typically derived from central or peripheral factors (Schillings et al., 2003). Central 
factors refer to a decline in force or rate of processes residing within the central nervous system 
(CNS) (Gandevia, 2001), which are mainly reliant upon group III and IV muscle afferent, and 
efferent feedback. This system minimises the development of peripheral fatigue by increasing 
ventilation, cardiac output, and blood flow in response to exercise (Amann et al., 2015). This 
cannot be sustained indefinitely however, due to the lack of central motor drive to the muscle, 
which leads to a phenomenon termed ‘central fatigue’ (Noakes, St Clair Gibson and Lambert, 
2005). In comparison, ‘peripheral fatigue’ refers to the alterations within the cross-bridge cycle 
at both the neuromuscular junction and sarcolemma. This includes a lack of excitation-
contraction coupling due to insufficient ion transportation, accumulation of metabolites such 
as H+ and inorganic phosphate causing perturbation to acid base balance, and the depletion of 
energy production (Westerblad, Allen and Lännergren, 2002, Allen et al., 2008a). The 
contribution from each factor is determined by the task dependency of the given exercise, 
which is typically determined by the intensity of the exercise (Enoka and Stuart, 1992).  
 
Short duration high-intensity exercise is characterised predominantly by peripheral factors; 
although this still operates synergistically with central factors (Enoka and Stuart, 1992, 
Gandevia, 1992). Thomas et al. (2015) reported a 4 km cycling time trial (TT) was more 
affected by peripheral fatigue compared to a 20 and 40 km TT, as potentiated twitch force (a 
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marker of peripheral fatigue) was reduced by 40%, compared to 31% and 29% in the other 
conditions respectively. Moreover, Schillings et al. (2003) reported that peripheral fatigue 
accounted for around 90% of the force loss after two continuous minutes of voluntary isometric 
contraction of the biceps brachii; and other literature is synonymous with these findings 
(Gandevia et al., 1996, Kent-Braun, 1999). As a result, in line with the exercise model 
employed throughout this thesis, only peripheral factors will be discussed as limiting factors 
of performance herein. The reader is directed to supplementary literature for a more hollistic 
view of fatigue (Gandevia, 1992, Amann, 2011).  
 
2.3.2 Exercise-induced metabolic acidosis and H+ appearance 
During high-intensity exercise there is an increased metabolic flux due to the demand for 
adenosine triphosphate (ATP) to sustain muscle contraction (MacDougall and Sale, 2014). 
Oxidative pathways (i.e. oxidative phosphorylation) are not sufficient to supply ATP as the 
rate of production is low and cannot meet the metabolic demand. Energy supply must therefore 
be primarily derived from non-oxidative pathways.  
 
Anaerobic glycolysis provides rapid generation of ATP from either glycogen stores in both 
liver and muscle, or free glucose (Baker, McCormick and Robergs, 2010). The use of glycogen 
as a primary fuel source consists of nine step-wise reactions beginning with glucose-6-
phosphate and ending with pyruvate formation. In comparison, glucose requires an extra step 
(ten in total) in the reaction chain (Robergs et al., 2004). Most of the energy for glycolysis is 
derived from the breakdown of glycogen, as the concentration of muscle glycogen is 
approximately 40 times greater than free glucose (Robergs et al., 2004). The end product of 
such reactions is lactic acid which as a strong acid (pKa of 3.87) dissociates into lactate and H+ 
and these metabolites rise in an exponential manner (Robergs, 2002). Increases in H+ will in 
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turn reduce pH within both intracellular and extracellular compartments, and as a result, have 
been associated with fatigue (Robergs, 2002, Cairns, 2006). Controversially however, rises in 
lactate have also been implicated in this process (Robergs, 2002, Cairns, 2006).  
 
Following high-intensity exercise, lactate typically rises to around 40 mmol.l-1 in muscle, and 
25 mmol.l-1 in plasma (Fitts, 1994). Early work showed as intense exercise (or stimulation of 
isolated muscle) was performed, an exponential increase in lactate was observed until fatigue 
in isolated frog muscle and the exercising human (Fletcher and Hopkins, 1907, Hill and Lupton, 
1923). This process was later termed the ‘lactic acid hypothesis for muscle fatigue’. Research 
for a further 70 years supported this hypothesis, such that electrically stimulated frog muscle 
reported a correlation between increases in lactate and reductions in contractile force (r = -0.99, 
p <0.001) (Fitts and Holloszy, 1976). These findings were later corroborated in multiple human 
research studies (Dawson, Gadian and Wilkie, 1978, Spriet, 1992). Since the early 2000’s 
however, these finding have been heavily contested, suggesting the exponential rise in lactate 
is correlation rather than causation and that it may acutally have beneficial roles on exercise 
metabolism (Cairns, 2006, Robers et al. 2004). Biochemically, lactate is a key, if not the most 
important substrate for gluconeogenesis through the conversion of lactate to glucose in the 
liver, thereby creating an energy source during exercise (Gladden, 2008). Furthermore, 
Robergs et al. (2004) showed through the lactate dehydrogenase reaction of pyruvate to lactate 
and NAD+, a proton is consumed and hence, an alkalinizing effect on the cell is observed. 
Morris et al. (2011) supports this, reporting a 7% increase in HCO3
- following exogenous 
lactate supplementation (27.6 ± 1.7 vs. 29.6 ± 2.0 mmol.l-1). Lactate accumulation therefore is 
not causative of acid base balance perturbation and hence, the ‘lactic acid hypothesis for muscle 




The last end-product from glycolysis (H+) is more likely to contribute to fatigue, as it causes a 
decline pH and subsequently metabolic acidosis (section 2.1). Nonetheless, both the 
mechanism by which H+ is generated and the total number of H+ produced during high fluxes 
of glycolysis has been widely debated. Robergs (2002) and colleagues (Robergs et al., 2004) 
suggest the production of H+ is a result of ATP hydrolysis, producing an approximate 3:1 ratio 
between H+ and lactate production. Other studies (Bangsbo et al., 1993, Juel, 1998) corroborate 
this, reporting a similar 3:1 ratio of H+ and lactate production. This contrasts with traditional 
biochemical theory however, which suggests the same metabolites increase in a 1:1 ratio as a 
result of glycogenolysis (glycogen + 3ADP + 3Pi  3ATP + 2lactate + 2H+) (Juel and 
Halestrap, 1999, Böning et al., 2005, Kemp, 2005). The latter authors argue as Bangsbo et al. 
(1993) and Juel (1988) consider the base excess and bicarbonate component of acid base 
balance, they do not reflect a valid measure of H+ production. Whilst this thesis does not intend 
to solve this dispute, both bodies of research display that H+ is produced in significant quantities 
during glycolysis reactions, which might also be significantly greater compared to lactate 
accumulation. It is intuitive to suggest therefore, that such increases in H+ need to be mitigated 
due to the negative effects on acid base balance.  
 
High-intensity exercise elicits the largest increases of H+ in both blood, muscle, and the 
instititial spaces (Kowalchuk et al., 1988, Street et al., 2005). Indeed, Kowalchuck et al., (1988) 
reported immediately post-exercise that muscle H+ was 328 nEq/L compared to 132 nEq/L at 
rest (60% change). Street et al. (2005) also reported a two-fold increase in H+ within the institial 
space during knee extensor exercise until fatigue (40 ± 5 vs. 80 ± 6 nM), whilst findings in 
plasma have corroborated this (Bishop et al., 2004, Deb et al., 2017). The resulting effect of 
such increased H+ flux is a decline in both blood and muscle pH, which can reach as low as 6.2 
in active musculature and 6.9 in blood (Fitts, 2008). Consequently, these two factors (high H+ 
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and low pH) have been implicated, in part, to be associated with fatigue during high-intensity 
exercise (Cairns, 2006, Allen et al., 2008a, Fitts, 2008, 2016). 
 
The primary fatigue mechanisms associated with these biochemical changes are inhibited Ca2+ 
metabolism and handling, the disruption of key enzymes in the glycolysis pathway, and 
reductions in the SID (Hultman and Sahlin, 1980, Fitts 2008, Fitts, 2016, Hollidge-Horvat et 
al., 1999, McKenna, 1992). The former is associated with inhibited Ca2+ uptake by the 
sarcoplasmic reticulum, which in turn, reduces membrane depolarization and failure of 
excitation-contraction coupling (Allen et al., 2008b). Increases in H+ also provide competition 
to Ca2+ at the troponin binding site, directly hindering the opening of actin sites to myosin cross 
bridges (Fabiato and Fabiato, 1978, Knuth et al., 2006). Moreover, a low pH (7.0 vs. 6.2) 
reduces maximal muscle-shortening velocity and peak isometric force (markers of Ca2+ 
activation and cross-bridge formation), with reductions of up to 32% at 30º C in stimulated 
type II muscle fibres reported (Knuth et al., 2006). Glycolytic enzymes such as 
phosphofructokinase (PFK) and phosphorylase are also inhibited at a low pH, such that Spriet 
et al. (1987) have shown glycolytic intermediates (G-6-P and F-6-P) are progressively inhibited 
in conjunction with a decreasing pH during electrical stimulation of human quadriceps muscle. 
Hollidge-Horvat et al. (1999) supports this, displaying ingestion of an acidosis inducing 
supplment caused a significant reduction (-26%) in mole fraction percentage of phosphorylase. 
It is worth noting however, these effects on both Ca2+ metabolism and glycolytic enzymes are 
not universally observed in other studies, and have been recently strongly contested. 
 
Westerblad (2016) questions the validity of the work conducted to date, particularly in vitro, 
suggesting the methods adopted in studies showing pH is a contributor to fatigue are not 
reflective of physiological muscle temperature, or pH levels observed in humans during high-
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intensity exercise. The author also suggests that as muscle force begins to recover following 
exercise, however pH shows no change or continues to decline, acidosis is not important. 
Indeed, pH has been shown to continually fall in the short phases of recovery from high-
intensity exercise, despite muscle force showing recovery (Degroot et al., 1993). The recovery 
from exercise is a different physiological process however, whereby in recovery the inhibition 
of key muscle pumps (i.e. Na+-K+) are reversed. Subsequently, this may explain why muscle 
force begins to recover in the early stages following high-intensity exercise, despite a low pH. 
Moreover, Westerblad (2016) cites an in vitro study by Pate et al. (1995) showing maximal 
isometric force was reduced by a smaller magnitude at physiological muscle temperatures 
compared to colder temperatures (~50% at 10º C, ~20% at 30º C). It could be argued however, 
that a 20% decline in muscle force is still meaningful in terms of fatigue and exercise 
performance. Furthermore, other in vitro studies have contested Westerblad’s (2016) assertion 
by displaying a greater decline in force at temperatures more reflective of physiological 
temperatures (~30 º C) compared to colder temperatures (~10º C) (Knuth et al., 2006, Nelson 
and Fitts, 2014, Nelson, Debold and Fitts, 2014). In summary, whilst Westerblad (2016) 
presents credible arguments to suggest the effects of a low pH on muscle force production is 
minimal, the reduction in muscle force is arguably still substantial. Therefore, further research 
exploring preventative strategies to reduce the negative effects a low pH on muscle contraction 
and force production are warranted. 
 
2.4 Buffering processes and the mechanisms of action: sodium bicarbonate 
A buffer solution acts to resist pH changes in response to either high proton, or base loads. As 
a result, either H+ are donated or removed within the intramuscular and extracellular spaces. 
Alkalotic buffers eliminate H+ and consist of a weak base and salt and possess a high pH (>7). 
Common alkalotic buffers are sodium citrate, sodium bicarbonate (NaHCO3), sodium lactate, 
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and calcium lactate (Lancha Junior et al., 2015). The most extensively researched to date has 
been NaHCO3, and it is suggested to be more effective to improve exercise performance 
compared to any other alkalotic buffer (Van Montfoort et al., 2004, Carr et al. 2011a, Lancha 
Junior et al., 2015). The precise mechanism by which NaHCO3 exerts ergogenic effects is 
widely debated however, although it is largely due to the buffering of exacerbated H+ 
accumulation.  
 
Ingestion of NaHCO3 creates a more alkalotic environment within the extracellular 
compartments, as HCO3
- is impervious to the muscle cell (McNaughton, Siegler and Midgley, 
2008). Increases of around 0.03 to 0.05 units in pH, and 4 to 6 mmol.l-1 in HCO3
- can be 
expected following 0.3 g.kg-1 BM NaHCO3; although this does display high inter-individual 
variation (Jones et al., 2016, McNaughton et al., 2016). Hereafter, increases in the efflux of 
both H+ and lactate from active musculature occurs due to an upregulation of the lactate-H+ co-
transporter, which is mediated by the increased pH gradient between the extracellular and 
intracellular compartments (Mainwood and Worsley-Brown, 1975, Bishop et al., 2004). 
Bishop et al. (2004) supports this, reporting a 44% increase in buffering capacity 
(∆lactate/∆pH) following ingestion of 0.3 g.kg-1 BM NaHCO3 prior to repeated maximal 
sprints, which was largely explained by the greater increase in lactate following NaHCO3. An 
alternative mechanism is that NaHCO3 ingestion increases the bioavailability of HCO3
-, which 
leads to increased proton elimination as HCO3
- combines with H+ to be expelled in the form of 
CO2 (section 2.1). Combined, this evidence displays NaHCO3 ingestion increases proton 
transport and elimination, which protects both intracellular and extracellular pH from reaching 
levels where the associated effects on fatigue may be observed. These changes may 




An increase in post-exercise blood lactate concentration following NaHCO3 compared to a 
placebo is suggestive of enhanced glycolytic flux (Hollidge-Horvat et al., 1999, Percival et al., 
2015). Hollidge-Horvat et al. (1999) reported that glycogen utilization was greater in a control 
condition compared to an acidic condition during a cycling task at 75% VO2max (+34%; 157 ± 
18 vs. 103 ± 15 mmol.kg-1 dw), whilst lactate concentration at the end of exercise was 
significantly increased (+28%; 6.5 vs. 4.7 mmol.l-1). No alkalotic condition was employed in 
this study, however as acidosis displayed a reduction in both glycogen utilisation and blood 
lactate, these findings imply enhanced glycogen utilization may be observed with alkalosis. 
Percival et al. (2015) reported an increase in glycogen utilisation however during intermittent 
high-intensity exercise (10 × 60-s cycling intervals at an individualized absolute workload 
selected to elicit ∼90% HRmax) (+137%; 126 ± 47 vs. 53 ± 38 mmol.kg-1 dw), with an adjoining 
increase in lactate (+24%; 12.9 ± 2.5 vs. 10.4 ± 2.7 mmol.l-1). Nevertheless, the workloads 
were matched, and therefore it is unclear if these effects would translate into an improved 
performance. Lopes-Silva et al. (2018) has recently showed nonetheless, a 31% increase of 
glycolytic energy contribution during simulated judo performance compared to a placebo, 
which also significantly improved performance. This suggests enhanced glycolytic flux is 
important to performance. Some studies however, have failed to report an improved 
performance following NaHCO3 ingestion, despite significant increases in lactate compared to 
a placebo. Higgins, James and Price (2013) for instance reported an increase in post-exercise 
lactate of >2.0 mmol.l-1 in all cycling conditions (100%, 110% and 120% Wpeak to exhaustion), 
however only reported a performance improvement at 100% Wpeak. In combination, whilst 
lactate responses can infer changes in glycogen utilization, the importance of this on 




The cited mechanism of enhanced glycolytic flux following NaHCO3 ingestion has been 
criticised, such that Granier et al. (1996) suggested increases in lactate may be due to a 
reduction in use of inactive tissue. Whilst, Morales-Alamo et al. (2015) displayed that 
glycolysis was not inhibited at the end an incremental exercise to exhaustion, and therefore 
metabolite accumulation is not a limiting factor of fatigue. Granier et al. (1996) nonetheless, 
also hypothesised that the increase in lactate could also be due to an enhanced anaerobic 
contribution during exercise, which is akin to the findings of Lopes-Silva et al. (2018). 
Similarly, Morales-Alamo et al. (2015) employed an incremental test to exhaustion lasting over 
10 min, which would not sufficiently stress the anaerobic energy systems. As a result, it is 
unsurprising they found that H+ accumulation was not a limiting factor to performance. Based 
on the findings of Lopes-Silva et al. (2018) showing an enhanced glycolytic contribution to 
exercise and improved performance following NaHCO3 ingestion, it is more likely therefore 
the increase in post-exercise lactate supports the enhanced glycolytic flux mechanism. 
Nonetheless, considering the variation in performance responses observed by Higgins et al. 
(2013) despite increases in post-exercise lactate following NaHCO3, further research is needed 
to explore which exercise durations and intensities this enhanced glycolytic contribution can 
positively affect.  
 
Alternatively, the ergogenic effect of NaHCO3 ingestion may be explained by the intracellular 
and extracellular balance of the strong ions (Cairns and Lindinger, 2008). Limited research has 
investigated the changes in the SID following NaHCO3 ingestion however, despite Matson and 
Tran (1993) suggesting this was required 25 years ago. Indeed, Siegler and Hirscher  (2010) 
reported a significant 7.5% increase in punch efficacy during a boxing simulation and an 
adjoining reduced K+ pre-exercise (PLA 5.3 ± 0.4 vs. NaHCO3 4.9 ± 0.3 mmol.l
-1) and post-
exercise (PLA 4.0 ± 0.1 vs. NaHCO3 4.6 ± 0.2 mmol.l
-1) following NaHCO3. This finding 
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suggests the ionic movements of K+ may have led to preservation of K+ in active musculature 
and therefore, improved action potential and membrane excitability. Only singular ion 
movements were considered however, whereas reporting the SID may have offered a more in-
depth view (section 2.1.2). Only Sostaric et al. (2006) has reported an increased SID following 
NaHCO3, which was explained by reductions in K
+ and Cl-. Importantly, this also translated 
into a 25% improvement in time to exhaustion during finger flexion at 75% Wpeak. A limitation 
of this study however, is the ionic movements elicited would be more extreme compared to 
whole-body exercise considering the small muscle mass used (Sejersted and Sjøgaard, 2000). 
Further research is therefore necessary investigating the role of collective ionic movements 
during whole-body exercise, to elucidate if this is an acting mechanism following NaHCO3 
ingestion.  
 
2.5 Sodium bicarbonate ingestion strategy to elicit performance improvements 
2.5.1 Ingested amount 
The level of alkalosis following NaHCO3 ingestion is dose-dependent. In a meta-analysis, Carr 
et al. (2011a) reported a moderate correlation (r = 0.33) between the increase in HCO3
- and the 
resulting increase in power, suggesting an increase of around 5 mmol.l-1 is likely required. It is 
intuitive therefore to suggest that the level of alkalosis, and specifically HCO3
- should be 
maximised to at least this level. Caution should still be taken however, as an earlier meta-
analysis reported the HCO3
- difference was not even weakly associated with the resulting effect 
size of improvement (r = 0.10, p >0.10) (Matson and Tran, 1993). This is likely to be due to 
the high inter-individual variation in the absolute changes in HCO3
- from baseline following 
NaHCO3 ingestion (Jones et al., 2016). Despite this, from a biochemical perspective, 
individuals should maximise increases in pH and HCO3




A minimum of 0.2 g.kg-1 BM NaHCO3 is likely required to increase pH and/or HCO3
- 
sufficiently to reinforce buffering capacity. Jones et al. (2016) reported that 0.1 g.kg-1 BM 
NaHCO3 resulting in a 3.6 mmol.l
-1 mean change of HCO3
-, whilst only 1/16 participants 
reached the 5 mmol.l-1 threshold proposed by Carr et al. (2011a) to suggest a high probability 
of an ergogenic effect. Whereas, all participants achieved at least a 5 mmol.l-1 increase 
following both 0.2 g.kg-1 BM and 0.3 g.kg-1 BM NaHCO3 (+6.1 ± 0.9 mmol.l
-1 and +8.2 ± 1.4 
mmol.l-1). This study featured no performance measure however, so it is unclear if these dose-
dependent changes in HCO3
- translated to an improved performance. An early study by 
McNaughton (1992a) however, reported that 0.1 g.kg-1 BM NaHCO3 was not sufficient to 
improve TWD during a 60 s cycling TT compared to a placebo, while doses of between 0.2 to 
0.5 g.kg-1 BM NaHCO3 all significantly improved performance. This evidence suggests 0.1 
g.kg-1 BM NaHCO3 is insufficient to elicit the changes in HCO3
- required to improve 
performance, meaning doses of ≥0.2 g.kg-1 BM are required.  
 
Importantly, McNaughton (1992a) reported 0.3 g.kg-1 BM NaHCO3 improved performance to 
the greatest extent, suggesting this is the ‘optimal’ dose to result in a performance benefit. As 
a result, this dose of NaHCO3 has become the most commonly employed strategy in practice 
and research. In a 2011 meta-analysis, 19/25 (75%) studies opted for 0.3 g.kg-1 BM whilst only 
4/25 (16%) employed 0.2 g.kg-1 BM NaHCO3 (Carr et al. 2011a). It is surprising this has 
occurred however, considering McNaughton (1992a) only featured one exercise type, duration, 
mode, and featured only nine recreationally active participants. Whilst, the difference between 
the NaHCO3 treatments (0.2 to 0.5 g
.kg-1 BM) were also not significantly different. Moreover, 
Mckenzie et al. (1986) also reported no dose-dependent effects between 0.15 g.kg-1 BM and 
0.3 g.kg-1 BM NaHCO3 during an intermittent bout of high-intensity exercise, as both TWD 
during the bout, and time to exhaustion on the last sprint were not different. Both doses also 
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improved performance compared to a placebo. Based on this evidence, the use of 0.3 g.kg-1 
BM instead of 0.2 g.kg-1 BM NaHCO3 is arguably not substantial enough to rationalise the 
popularity of this dose in a performance setting. Further research comparing the dose-
dependent effects of NaHCO3 is therefore required. Such investigations should begin with 0.2 
g.kg-1 BM, considering this is the smallest amount of NaHCO3 that increases HCO3
- to a level 
that would suggest an ergogenic effect would be realised.  
 
2.5.2 Gastrointestinal discomfort   
Ingestion of 0.3 g.kg-1 BM NaHCO3 is associated with the occurrence of gastrointestinal (GI) 
discomfort symptoms such as nausea, stomach ache, stomach cramp, diarrhoea, and vomiting 
common (Cameron et al., 2010, Kahle et al., 2013, Saunders et al., 2014a, Miller et al., 2016, 
Gough et al., 2017). In a severe case, one study featuring eleven endurance trained men 
reported 91% (10/11) suffered from diarrhoea following 0.3 g.kg-1 BM NaHCO3 (Kahle et al., 
2013). The mechanism causing this disturbance may be associated with the high Na+ load 
which draws water into the jejunum and leads to a disturbance of the stomachs acid base 
balance (Sladen, 1971, Heigenhauser, 1991). In this case, a 0.3 g.kg-1 BM dose of NaHCO3 is 
riskier than 0.2 g.kg-1 BM NaHCO3, as the latter dose of NaHCO3 will half the Na
+ load (3.7g 
vs. 6.5 g). This may subsequently explain why the instances of GI discomfort increases in line 
with the NaHCO3 dose (McNaughton, 1992a). In response, athletes may consider lowering the 
0.3 g.kg-1 BM NaHCO3 dose, however to date the GI discomfort responses from lower doses 
are largely unknown.  
 
Both the occurrence and severity of GI discomfort displays high inter-individual variation from 
0.3 g.kg-1 BM NaHCO3 (Saunders et al., 2014a, Gough et al., 2017), such that some individuals 
display good tolerance to doses ≥0.3 g.kg-1 BM NaHCO3. McNaughton and Thompson (2001) 
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reported no instances of GI discomfort following 0.5 g.kg-1 BM NaHCO3, with other studies 
reporting minimal GI discomfort following similar doses (Goldfinch, McNaughton and Davies, 
1988, Verbitsky et al., 1997, Krustrup, Ermidis and Mohr, 2015). These findings would perhaps 
suggest doses of 0.3 g.kg-1 BM NaHCO3 and above cause limited effects on GI discomfort. 
Conversely, severe GI discomfort has led to participants withdrawing from research 
participation following 0.3 g.kg-1 BM NaHCO3 (Jones et al., 2016, Gough et al., 2017). As a 
result, an individualised approach to NaHCO3 use has been recommended (Price, Moss and 
Rance, 2003, Dias et al., 2015, Gough et al., 2017). Considering such variation, there is 
arguably a requirement to determine the contributing factors to the onset of GI discomfort.  
 
Despite limited research, it is conceivable individuals of higher body mass could suffer more, 
due to the higher absolute dose of NaHCO3. Indeed, Cameron et al. (2010) reported within a 
group of elite rugby players of 95 ± 13 kg mean body mass, over 50% suffered from vomiting. 
Whereas, Van Montfoort et al. (2004) only reported mild GI discomfort within a group of 
trained runners of 74 ± 2 kg mean body mass, despite almost identical ingestion regimes. 
Alternatively, Jones et al. (2016) reported the time to peak change in Na+ concentration broadly 
corresponded (~105 min) with the peak incidence of GI discomfort (~90 min). The authors also 
reported individuals showing a greater absolute change in Na+ from baseline to peak, tended to 
report greater GI discomfort. The severity and symptoms of GI discomfort were not explicitly 
measured in this study however, and therefore, further research is required to determine the 
contributors to GI discomfort.  
  
Despite the positive performance outcomes of NaHCO3 ingestion during laboratory protocols, 
the fear of GI discomfort has led to infrequent use amongst some athletes (Carr et al., 2011b). 
This reinforces the need to identify methods to alleviate GI discomfort from this supplement, 
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as this will increase the use in a practical setting. Few studies have quantified the GI discomfort 
responses within their respective study design however, and this lack of documented side 
effects is not helpful when consulting an individual on appropriate NaHCO3 ingestion 
strategies. In one study nonetheless, a range of NaHCO3 dosing protocols (all 0.3 g
.kg-1 BM) 
including capsule, liquid, and co-ingestion with a small carbohydrate meal were employed to 
assess the resulting GI discomfort (Carr et al., 2011b). The co-ingestion of a small carbohydrate 
meal marginally, but not significantly reduced GI discomfort compared to all other treatments. 
No exercise bout was included in this study however, which is important as reducing GI 
discomfort is not suitable if the ingestion strategy negates the ergogenic effects. On this 
premise, several studies have staggered the NaHCO3 dose into smaller amounts prior to 
exercise to reduce GI discomfort (Saunders et al., 2014a, 2014b, Dias et al., 2015, Callahan et 
al., 2016). Whilst these studies have typically achieved similar increases in pH and HCO3
- 
following ingestion, no positive effects on exercise performance have been reported and issues 
with GI discomfort have also arisen, subsequently questioning the suitability of a split dose 
strategy. Therefore, based on the unsuccessful methods to alleviate GI discomfort to date, a 
logical option would be to reduce the NaHCO3 dose. As a result, further research is warranted 
to quantify if 0.2 g.kg-1 BM can sufficiently lower GI discomfort that would make this dose 
valuable. Whilst, it is equally important that this dose still improves performance. 
 
The occurrence of GI discomfort following NaHCO3 ingestion is commonly cited as a reason 
for an ergolytic effect on performance (Cameron et al., 2010, Saunders et al., 2014a, Dias et 
al., 2015). Indeed, Saunders et al. (2014a) reported only upon the removal of four participants 
suffering from GI discomfort was TWD significantly improved by 4.8% during a cycling test 
to exhaustion (110% of peak power). The mean differences between groups (no GI discomfort 
vs. GI discomfort) was small however (Hedges g effect size = 0.17) and could be explained by 
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the 1.3 kJ typical error of the test (48.4 ± 9.3 vs. 46.8 ± 9.1 kJ). In addition, a total of 12 
participants failed to improve performance despite only 4 suffering from GI discomfort, 
suggesting other external influences may have affected the outcomes of this study. Cameron et 
al. (2010) reports similar findings, such that GI discomfort was negatively associated with 
sprint performance in linear regression analysis (r2 = 0.1, p = 0.09). Nonetheless, this 
relationship is very weak and non-significant. Therefore, these findings combined suggest that 
GI discomfort does not elicit ergolytic effects on performance. A caveat to this however, are 
the reports that participants have withdrew from research due severe GI discomfort following 
0.3 g.kg-1 BM NaHCO3 (Jones et al., 2016, Gough et al., 2017), such that Gough et al. (2017) 
reported one participant was unable to exercise due to severe symptoms of diarrhoea almost 
immediately following NaHCO3 ingestion. This reinforces the need to mitigate GI discomfort 
regardless if the impact on exercise performance is minimal or non-existent at all, as an inability 
to exercise would have serious implications on competition success and/or training availability.  
 
A further aspect for athletes to consider is the repeatability of the GI discomfort responses 
following NaHCO3 ingestion. If this displays a high intra-individual variation, this may again 
highlight the need to either lower the NaHCO3 dose or determine the factors that cause such 
occurrences. To date, minimal research has investigated the reproducibility of GI discomfort 
following NaHCO3, whereby the responses from 0.3 g
.kg-1 BM NaHCO3 displayed 
inconsistencies (Dias et al., 2015). Limited description was provided by the authors on how the 
GI discomfort response varied however, or whether this occurred in all individuals. The 
reproducibility of GI discomfort is therefore warranted, to evaluate the usefulness of using this 





2.5.3 Ingestion timing  
The point at which peak alkalosis occurs following NaHCO3 has been extensively examined 
since the late 2000’s (Renfree, 2007, Price and Singh, 2008, Carr et al., 2011b, Green and 
Siegler, 2016, Jones et al., 2016, Miller et al., 2016). Until this body of research, the timing of 
ingestion was commonly 60 to 90 min prior to exercise, following the ergogenic effects on 
performance reported employing this time frame (McNaughton, 1992a, 1992b). Despite this, 
the optimal timing of ingestion to elicit maximum changes in pH and HCO3
- is still unclear. 
Indeed, Renfree (2007) reported peak plasma [H+] was lowest between 60 and 90 mins 
following 0.3 g.kg-1 BM NaHCO3 (39.6 nmol.l
-1 and 39.4 nmol.l-1). Price and Singh (2008) 
supported this outcome, reporting that peak pH and HCO3
- occurred between the same time 
points (60 to 90 min). Conversely, later work reported whilst peak pH occurred at 120 min, 
peak HCO3
- did not occur until 180 min (Siegler et al., 2012). Further confusion followed, as 
Carr et al. (2011b) reported 150 min were required for peak pH and HCO3
- to occur. There are 
several caveats to explain these varied results however, including the frequency of blood 
sampling, method of data analysis, and the inter-individual variability in blood responses. 
Specifically, blood samples have been obtained every 30 min (Renfree, 2007, Price and Singh, 
2008, Carr et al., 2011b) or 60 min (Siegler et al., 2012), which consequently may have missed 
important absorption characteristics leading to a misrepresentation of time to peak alkalosis. 
Similarly, acid base balance responses have largely been reported using a group mean 
approach, and considering such contrasting times reported (between 60 and 180 min), it 
suggests a large inter-individual variation is occurring. As a result, it is prudent to suggest time 
to peak alkalosis requires individual analysis.  
 
Contemporary research has addressed these limitations by employing a higher sampling rate 
and reporting individual responses (Green and Siegler, 2016, Miller et al., 2016, Jones et al., 
32 
 
2016, Deb et al., 2017, Deb et al., 2018a). Both Miller et al. (2016) and Deb et al. (2017) for 
instance, identified individual time to peak pH following NaHCO3 by obtaining samples every 
5 to 10 min for a total of 90 min. Interestingly, only 3 out of the 11 participants peaked at the 
same time, with peaks ranging between 10 min and 90 min (Miller et al., 2016). Similarly, 
Jones et al. (2016) reported whilst peak HCO3
- was achieved at 105 min following 0.2 g.kg-1 
BM NaHCO3 and 120 min following 0.3 g
.kg-1 BM NaHCO3, only 3 out of the 16 participants 
in each treatment achieved peak HCO3
- at this time point. These findings explain why a high 
variation in time to peak alkalosis is found when group mean responses are reported. 
Consequently, NaHCO3 ingestion should not take place at a set time point prior to exercise for 
all individuals, as this is unlikely to attain peak individual buffering capacity. Instead, NaHCO3 
ingestion should commence at a pre-determined individual time to peak alkalosis, as to date 
positive performance responses when employing this strategy have been found (Miller et al., 
2016, Deb et al., 2017, 2018a). Furthermore, these increases in performance contrast with 
previous research supplementing NaHCO3 at a set time frame for all participants that have 
reported no ergogenic effect (Vanhatalo et al., 2010), or a reduced magnitude of improvement 
(Bishop et al., 2004) in similar exercise protocols. Collectively, these findings display 
identifying individual time to peak pH or HCO3
- is important to obtain ergogenic benefits to 
performance, and therefore, future work should employ this strategy. 
 
2.5.4 Summary 
Despite over 80 years of research, fundamental questions surrounding the application of 
NaHCO3 to elicit consistent ergogenic effects are still unanswered. Commonly a dose of 0.3 
g.kg-1 BM has been employed, yet neither the dose-response relationship has been addressed, 
nor have the issues with GI discomfort. This requires addressing due to the prevalence of GI 
discomfort symptoms commonly reported following 0.3 g.kg-1 BM NaHCO3, which has 
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resulted in athletes being discouraged from using this strategy. Offering plausible solutions 
such as a lower amount (0.2 g.kg-1 BM), or by identifying potential predictors of GI discomfort 
may subsequently heighten the prevalence of NaHCO3 use within the athletic community. 
Moreover, contemporary research has highlighted that individualising the timing of NaHCO3 
ingestion to a pre-determined time to peak pH or HCO3
- is important, to which both 0.2 g.kg-1 
BM and 0.3 g.kg-1 BM may be appropriate to elicit suitable increases in pH and HCO3
- to 
improve exercise performance. The dose-response relationships on both the GI discomfort and 
performance responses following an individual time to peak alkalosis strategy are unknown 
however, and therefore require investigation. 
 
2.6 Sodium bicarbonate use for whole body exercise performance 
2.6.1 Overview 
Research evaluating NaHCO3 as an ergogenic aid is not an innovative concept, since as early 
as 1931, Dennig et al. (1931) reported an improved ability to accumulate an oxygen debt during 
15 min of steady state running. Shortly after however, research failed to corroborate with 
Dennig et al. (1931), reporting no ergogenic benefits following NaHCO3 ingestion (Johnson 
and Black, 1953, Margaria, Aghemo and Sassi, 1971, Poulus, Docter and Westra, 1974). This 
was likely due to insufficient doses of NaHCO3, or that an aerobic exercise protocol was 
employed. By the late 1970’s to mid-1980’s however, Jones et al. (1977) and Sutton, Jones and 
Toews (1981) displayed ergogenic benefits following 0.3 g.kg-1 BM NaHCO3 on time to 
exhaustion at 95% maximal power output and maximal oxygen uptake (VO2max), respectively. 
Following this, two key papers from McNaughton (1992a, 1992b) identified the most 
appropriate amount of NaHCO3 was likely to be 0.3 g
.kg-1 BM, and exercise of 2 to 4 min 
displayed a greater positive effect compared to exercise of 10 and 30 s duration. Despite these 
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early findings, today, the use of NaHCO3 as an ergogenic aid has produced equivocal 
performance responses (McNaughton et al., 2016).  
 
Several reasons including training status, exercise intensity, GI discomfort, and the timing of 
NaHCO3 ingestion have been associated with the equivocal performance responses (Requena 
et al., 2005, Peart et al., 2012, McNaughton et al. 2016). Peart et al. (2012) performed a meta-
analysis that suggested the ergogenic effects of NaHCO3 are likely to be more pronounced in 
non-trained compared to trained individuals. A later review however, has suggested the 
ergogenic effects are in fact more pronounced in trained participants, particularly in cycling 
tasks (McNaughton et al., 2016). It is currently unknown therefore to what extent training status 
explains the varied performance responses, considering no study has compared the trained 
versus untrained responses to NaHCO3 ingestion. A further notion is that the exercise intensity 
may determine the ergogenic effects of NaHCO3. Higgins et al. (2013) reported that whilst 
NaHCO3 elicited significant improvements in performance at 100% peak mean minute power 
(Wpeak), no improvements were found at 110% and 120% Wpeak. Whilst, other studies have 
reported no effect of NaHCO3 on exercise performance at supramaximal intensities of 110% 
peak power output (Saunders et al., 2014a, Dias et al., 2015). The lack of effect has been 
associated with the rate of change in pH during exercise, such that faster changes (induced by 
the greater exercise intensities) can negate the ergogenic effects (Price et al., 2003, Messonnier 
et al., 2007, Higgins et al., 2013). As a result, it is likely that the ergogenic effects of NaHCO3 
are more pronounced at intensities equal to or below maximal intensities. Further research to 
determine exercise protocols in which NaHCO3 can elicit ergogenic effects is therefore 




The timing of ingestion may have also contributed to the previously observed variability in 
performance responses. Based on the large variation in time to achieve peak alkalosis following 
NaHCO3 previously discussed (section 2.4.3), insufficient increases in buffering capacity may 
have occurred in some individuals and consequently led to varied effects (McNaughton et al., 
2016). In response, studies have begun individualising NaHCO3 to either a pre-determined 
peak pH or HCO3
- and reported promising ergogenic effects on performance (Miller et al., 
2016, Deb et al., 2017, 2018a). Some questions remain on the applicability of this strategy to 
sports performance however, including which analyte between pH and HCO3
- is the most 
appropriate to determine the individualised strategy, and the reproducibility of this time to peak 
alkalosis. Furthermore, no study to date has investigated the individualised NaHCO3 ingestion 
strategy on a self-paced exercise, such as a TT. Therefore, in line with the present thesis aims, 
a critical review of the effects of NaHCO3 on short duration TT performance will follow.  
 
2.6.2 Short duration (<10 min) time trial performance 
Most research investigating TT performance has focused on running, rowing, and cycling 
(Table 2.1). In an early running study, Kindermann, Keul and Huber (1977) reported no effect 
of 0.2 g.kg-1 BM NaHCO3 on 400 m performance, leading the authors to question the 
importance of pH homeostasis as a performance limiting factor in exercise. Goldfinch et al. 
(1988) nonetheless, reported a 1.5 s improvement compared to placebo during the same 
distance TT (2.9%, Hedges g effect size = 0.69). This was likely due to the doubling of the 
NaHCO3 dose to 0.4 g
.kg-1 BM in the latter study however, as superior rises in pH compared 
to Kindermann et al. (1977) were reported (0.08 vs. 0.02 units), which would have heightened 
buffering capacity more greatly. In longer distance TT’s employing 0.3 g.kg-1 BM NaHCO3, 
Wilkes, Gledhill and Smyth (1983) reported 800 m running performance was significantly 
improved compared to a placebo (-2.2 s, 1.8%; g = 1.0). These findings were also replicated in 
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1500 m running performance, as NaHCO3 improved performance by 2.9 s compared to a 
placebo (1.1%, d = 0.23) (Bird, Wiles and Robbins, 1995). Conversely, Tiryaki and Atterbom 
(1995) displayed no effect of NaHCO3 on 600 m running performance. However, this may 
have been the sub-optimal NaHCO3 ingestion strategy employed by the latter study of 2.5 hours 
prior to exercise. Specifically, the increases in both pH and HCO3
- were smaller compared to 
Wilkes et al. (1983), despite the same absolute amount of NaHCO3 (pH = no change, HCO3
- 
+3.4 mmol.l-1 vs. Wilkes et al. pH = +0.09 units, HCO3
- = +8.3 mmol.l-1). Consequently, this 
ingestion timing failed to elicit sufficient changes in pH (>0.03) and HCO3
- (>5 mmol.l-1) 
suggested to be required to improve performance. These findings therefore display that running 
TT performance is only improved when both the amount, and timing of NaHCO3 ingestion 
elicits sufficient increases in pH and HCO3
-. 
 
Research in rowing has typically focussed on 2 km TT’s, however this has provided ambiguous 
evidence to suggest NaHCO3 could benefit performance. Carr et al. (2011c) for example, 
reported no change in performance within a group of eight well trained rowers (NaHCO3 6:44.4 
± 23.4 vs. placebo 6:43.8 ± 23.4 s). The placebo condition entailed ingestion of a matched 
amount of glucose capsules however, which is a performance enhancing supplement (Davis et 
al., 1997). This subsequently may explain the lack of effect from NaHCO3. Nonetheless, Carr 
et al. (2012) later reported that NaHCO3 had no effect on two repeated 2 km TT rowing efforts 
compared to a placebo, despite employing an appropriate calcium carbonate placebo. Similarly, 
Christensen et al. (2014) reported no effect of NaHCO3 ingestion during a 6 min all-out TT 
within a group of 12 elite rowers. Combined, these studies question the suitability of NaHCO3 




Work by Hobson et al. (2013, 2014) provide a caveat to these findings however, reporting 
potential ergogenic effects of NaHCO3 in large sample size studies (both n = 20). Specifically, 
a 3.2 ± 8.8 s improvement compared to a placebo during a 2 km TT was observed, which was 
determined as a ‘likely’ benefit in magnitude based inferences analysis (Hobson et al., 2013). 
Hobson et al. (2014) later reported NaHCO3 ‘likely’ enhanced performance during the same 
distance TT; although importantly this improvement seemed to occur during the last 500 m 
split (‘very likely’ beneficial). This may suggest the ergogenic benefits of NaHCO3 are 
dependent on the pacing strategy, as the positive effects reported in the last segments of a TT 
also correspond to the time when the anaerobic reserves are maximally taxed (i.e. negative 
pacing strategy) (Foster et al., 2004). In turn, this could infer that in these latter stages, NaHCO3 
enhanced glycolytic function (Hollidge-Horvat et al., 1999, Lopes-Silva et al., 2018). Despite 
this potential mechanism however, the overall effect in both studies by Hobson et al. (2013, 
2014) revealed no significant effect. In addition, a high inter-individual variability in 
performance was also observed. Therefore, whilst NaHCO3 may increase athletic performance 
when a negative pacing strategy is employed, further research is required.  
 
Early investigations in TT cycling of a fixed duration were akin to the running studies showing 
positive performance improvements following NaHCO3 ingestion. McNaughton (1992a) 
demonstrated doses of between 0.2 g.kg-1 BM to 0.5 g.kg-1 BM NaHCO3 improved 60 s cycling 
performance within a group of nine healthy males; although 0.3 g.kg-1 BM NaHCO3 improved 
performance to the greatest magnitude. The same author then displayed NaHCO3 ingestion 
improved TWD and mean power output significantly in both 120 and 240 s exercise, yet 
ergolytic effects were observed with exercise of 10 and 30 s duration within a group of eight 
health males (McNaughton, 1992b). Nonetheless, the lack of effect in exercise of less than 1 
min may be attributed to exercise of this duration not sufficiently taxing maximal anaerobic 
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capacity or inducing maximal lactate accumulation, as this is where NaHCO3 is most likely to 
provide ergogenic effects (Driss and Vandewalle, 2013). McNaughton, Ford and Newbold 
(1997) later reported the ergogenic effects of NaHCO3 were not restricted to males, reporting 
90 s maximal cycling was improved in moderately trained females. At this point therefore, 
positive effects had been observed following NaHCO3 ingestion and hence, offered a suitable 
option for athletes to acquire ergogenic effects on their performance.  
 
More recent research has failed to corroborate such positive findings, reporting equivocal 
performance responses to NaHCO3 ingestion (McNaughton et al., 2016). Marx et al. (2002) 
reported contrasting effects to McNaughton (1997), such that NaHCO3 had no effect on 90 s 
maximal cycling. One key difference was the training status between studies, as Marx et al. 
(2002) employed untrained individuals, compared to the trained individuals in McNaughton 
(1997). This may explain these discrepancies, considering trained subjects are suggested to 
gain greater ergogenic effects from NaHCO3 in cycling exercise (McNaughton et al., 2016). 
More recent findings in cycling TT’s support this, as Driller et al. (2012) reported a significant 
3.3% ± 2.0% increase in average power during a 4 min TT within a group of 8 highly trained 
cyclists. Whilst Bellinger et al. (2012) reported similar positive findings following NaHCO3, 
within a group of 14 highly trained cyclists. In contrast, Peart et al. (2011) observed no effect 
of NaHCO3 during a 4 min TT within a group of seven recreationally active males; as did 
Vanhatalo et al. (2010) during a 3 min all-out critical power test. It is unclear why trained 
participants can take advantage of an enhanced buffering capacity, however speculatively, it 
may be that trained individuals have a higher maximal rate of glycolysis (Requena et al., 2005), 
or that untrained individuals reduce the reliability and therefore sensitivity of exercise tests 
(Currell and Jeukendrup, 2008). This has been countered by Peart et al. (2011) however, 
suggesting as buffering capacity has already been augmented to physiological limits in trained 
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individuals, NaHCO3 elicits negligible effects. Nonetheless, based on the current evidence 
NaHCO3 seems to elicit greater ergogenic effects in short duration TT’s within individuals of 
at least a moderate training status. 
 
It is important to note nonetheless, that two contemporary studies have reported no significant 
effects of NaHCO3 ingestion on 4 km TT performance in trained, or recreationally trained 
cyclists (Callahan et al., 2016, Oliveira et al., 2017). Indeed, Oliveira et al. (2017) reported 
both time to complete and mean power were not influenced by NaHCO3 ingestion 100 min 
prior to exercise. Interestingly however, Callaghan et al. (2017) reported a non-significant 2.3 
s (Hedges g = 0.13) improvement in time to complete and a 10 W increase in mean power 
following NaHCO3 ingested 150 min prior to exercise. Whilst these changes did not reach 
statistical significance, a change in mean power output of >6 W (2% change) would reflect a 
meaningful change in 4 km TT performance (Stone et al., 2011), and therefore these changes 
may still represent worthwhile changes. Moreover, a limitation of these studies is the set time 
frame of NaHCO3 ingestion. Consequently, the changes in HCO3
- from baseline to peak in both 
studies were small (mean difference Callaghan et al., 2.4 mmol.l-1; Oliveira et al., 5.3 mmol.l-
1). These biochemical acid base balance changes were also comparable to Marx et al. (2002), 
showing no ergogenic effects on a 90 s cycling TT. Furthermore, these changes were smaller 
compared to studies utilising an individual time to peak alkalosis strategy, where mean 
increases of over 8 mmol.l-1 have been reported (Jones et al., 2016, Deb et al., 2017). It is 
plausible to suggest therefore, if an individualised NaHCO3 strategy was employed by 
Callaghan et al. (2017) and Oliveira et al. (2017), a greater alkalotic state may have been 
induced, subsequently leading to a more pronounced ergogenic effect. It is too early therefore 




2.6.3 Reproducibility of blood acid base balance and performance following sodium 
bicarbonate 
Sports performance is possibly the most difficult component to measure in an athlete, yet it is 
one of the most commonly used to interpret scientific findings, particularly for ergogenic aids 
research. Performance testing protocols should therefore have a high level of reliability to 
protect against showing a performance improvement that might simply be explained by 
measurement error, or inter-individual differences (Stevens and Dascombe, 2015). This 
however, still does not determine the intra-individual reliability on performance of an 
ergogenic aid. To identify this, repeating the experimental intervention is plausible, as this 
permits the athlete to determine if an ergogenic aid can provide consistent benefits to 
performance (Burke, 2017). Despite this, the reproducibility of the effects on performance are 
often overlooked in relation to ergogenic aids research. 
 
In a study by Bird et al. (1995), two 1500 m running TT’s were completed by 10 trained 
distance runners following 0.3 g.kg-1 BM NaHCO3. Whilst the authors did not produce any 
reliability statistics, individual analysis reflected an ICC of r = 0.91, p <0.001 and a CV of 1%, 
therefore suggesting the performance responses following NaHCO3 ingestion are reproducible. 
Importantly, this study also reported a significant improvement in performance following 
NaHCO3 compared to the placebo. Since this early study however, the reproducibility of the 
performance responses has been mixed. Dias et al. (2015) reported a large CV (7.4%) in 
performance responses following NaHCO3 in four separate cycling trials to exhaustion (110% 
peak power), within a group of 15 recreationally active males. As a result, the ergogenic effects 
versus placebo also displayed a high inter-individual variation. Nonetheless, Carr et al. (2012) 
did report a low CV of 2.1% between two repeated 2 km rowing TT’s for mean power within 
a group of seven highly trained rowers, following NaHCO3. This study reported no 
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performance effect from NaHCO3 ingestion however, which may have been due to the high 
variability in HCO3
- responses (trial 1 = 32.4 ± 2.1, trial 2 = 31.9 ± 2.2 mmol.l-1; TE = 2.4%, 
CV = 7.3%). Albeit, no data on the absolute change in HCO3
- from baseline was reported, 
which would have been a more useful marker of reproducibility. Performances may have been 
more reproducible in the studies by Carr et al. (2012) and Bird et al. (1995) due to the higher 
training status of participants compared to Dias et al. (2015), suggesting trained athletes can 
obtain more consistent performances (Currell and Jeukendrup, 2008). Nonetheless, as 
equivocal responses were still observed in respect of the ergogenic effects, further research is 
warranted.  
 
A clear limitation of the research to date are the reliability statistical tests that have been 
employed. Specifically, CV was commonly reported, which does not adequately assess the 
agreement between two measures (Atkinson and Nevill, 1998). Admittedly, Carr et al. (2012) 
did include TE which is a recommended statistical procedure (Hopkins, 2000), however, 
important changes such as the change from baseline to peak HCO3
- and the performance times 
for the 2000 m rowing TT were not analysed. Consequently, these studies provide confusion 
amongst individuals wanted to assess whether NaHCO3 can produce reproducible performance 
and blood responses. To assess reproducibility most appropriately, the use of limits of 
agreement (LOA), or Intraclass correlation coefficient (ICC) analysis is recommended 
(Atkinson and Nevill, 1998, 2000). Future investigations are required therefore employing such 
statistical tests, to assess if the blood and performance responses are consistent following 
NaHCO3. 
 
Positive findings on performance have recently been reported following an NaHCO3 ingestion 
strategy individualised to either a pre-determined peak pH or HCO3
- (Miller et al., 2016, Deb 
42 
 
et al., 2017, 2018a). Indeed, Miller et al. (2016) reported an 11% increase in TWD during a 
repeated sprint ability cycling test, whilst Deb et al. (2017) reported a 5.6% increase in TWD 
during a 3-min all out critical power test. Whilst promising, the reproducibility of the blood 
and performance responses employing this ingestion strategy are unknown. This is important, 
as if the blood or performance responses are not reproducible, this could hinder the usability 
of this strategy. Only Deb et al. (2017) has reported an ICC r value of 0.6 for the absolute 
change in pH from baseline on two repeated NaHCO3 trials. This only reflects a fair to good 
level of reproducibility however, suggesting there was some degree of intra-individual 
variation. In addition, the absolute change in HCO3
- in the repeated trial was not reported. 
Based on these limited findings, the reproducibility of the performance responses following 
NaHCO3 is therefore needed. In turn, this will allow athletes to assess if the individualised 





Table 2.1 – An overview of time trial performance in running, cycling and rowing following NaHCO3 ingestion.  
Authors Exercise 
protocol 





Running       
Kinderman et 
al. (1977) 
400 m TT 10 healthy males 0.2 g.kg-1 BM 100 min 
prior to exercise 
No change in completion time N NA 
Wilkes et al. 
(1983) 
800 m TT 6 male track 
athletes 
0.3 g.kg-1 BM 120 min 
prior to exercise 





400 m TT 6 trained males 
athletes 
0.4 g.kg-1 BM 60 min 
prior to exercise 
1.5 s (2.9%) faster in the NaHCO3 
condition 
Y 0.69 
Bird et al. 
(1995) 
1500 m TT 12 male distance 
runners 
0.3 g.kg-1 BM in two 
doses 120 min and 60 
min prior to exercise 
2.9 s (1.1%) improvement in 





600 m TT 11 female track 
athletes and 4 
trained female 
non-athletes 
0.3 g.kg-1 BM 2.5 
hours prior to exercise 
No change in completion time N NA 
Cycling       
McNaughton 
(1992a) 
60 s TT 9 active males 0.1 to 0.5 g.kg-1 BM 
60 min prior 
Doses of 0.2 to 0.5 g.kg-1 BM all 
significantly improved 
performance, however 0.3 g.kg-1 






10, 30, 120, 
and 240 s TT 
 
8 male subjects 
 
0.3 g.kg-1 BM 90 min 
prior to exercise 
 
Improvements in exercise of 120 



















60 s TT 10 moderately 
active females 
0.3 g.kg-1 BM 90 min 
prior to exercise 
5.8% Increase in TWD Y 1.3 
Marx et al. 
(2002) 
90 s TT 10 healthy men 0.3 g.kg-1 BM 45 min 
prior to exercise 
No effect on mean power N NA 
Vanhatalo et 
al. (2010) 
3 min critical 
power cycling 
TT 
8 habitually active 
males 
0.3 g.kg-1 BM 60 min 
prior to exercise 
No differences in TWD, or peak 
power 
N 0.01 
Driller et al. 
(2012) 
4 min TT 8 well-trained male 
cyclists 
0.3 g.kg-1 BM 90 min 
prior to exercise 
~3% improvement in mean power Y 0.6 
Peart et al. 
(2012) 
4 min TT 7 recreationally 
active males 
0.3 g.kg-1 BM 90 min 
prior to exercise 
No change in mean power N NA 
Bellinger et 
al. (2013) 
4 min TT 14 highly trained 
cyclists 
0.3 g.kg-1 BM – 90 
min prior to exercise 
Increase of 3.1% in mean power Y NA 
Callaghan et 
al. (2017) 
4 km TT 8 endurance 
trained cyclists 
0.3 g.kg-1 BM 2.5 
hours prior to exercise 
Non-significant 2.3 s improvement 
in completion time following 
NaHCO3, however this was not 
significant 
N 0.13 
Oliveira et al. 
(2017) 
4 km TT 11 recreationally 
trained cyclists 
0.3 g.kg-1 BM 100 min 
prior to exercise 




Deb et al. 
(2017) 
 




11 male trained 
cyclists 
 
0.3 g.kg-1 BM 
ingestion at a pre-
determined individual 





Significant increase in TWD and 















Rowing       
Carr et al. 
(2011c) 
2 km TT 7 well trained 
rowers 
0.3 g.kg-1 BM 90 min 
prior to exercise 
No change in completion time or 
mean power 
N NA 
Carr et al. 
(2012) 
2 km TT 8 well trained 
rowers 
0.3 g.kg-1 BM 120 min 
prior to exercise 
No change in completion time or 
mean power 
N NA 
Hobson et al. 
(2013) 
2 km TT 20 well trained 
rowers 
0.2 g.kg-1 BM four 
hours before the TT 
and 
0.1 g.kg-1 BM two 
hours before the TT 
3.2 s improvement in completion 
time and a ‘likely’ benefit of 
NaHCO3 supplementation in 
magnitude based inferences 
analysis, however no significant 
effect. 
N 0.16 
Hobson et al. 
(2014) 
2 km TT 20 well trained 
rowers 
0.2 g.kg-1 BM four 
hours before the TT 
and 
0.1 g.kg-1 BM two 
hours before the TT 
1.3 s improvement in completion 
time and a ‘likely’ benefit of 
NaHCO3 supplementation in 
magnitude base inferences 




et al. (2014) 
6 min TT 12 international 
level rowers 
0.3 g.kg-1 BM 75 min 
prior to exercise 
No change in total distance 






2.6.4 Four-kilometre time trial to assess the efficacy of sodium bicarbonate  
Research evaluating NaHCO3’s ergogenic effects on ecologically valid protocols which match 
the participant cohort is limited, despite a plethora of research existing. This is particularly 
important in cycling, considering multiple studies have reported no effect on cycling TT 
performance when utilising non-specifically cycling trained individuals compared to positive 
effects in trained cyclists (McNaughton et al., 2016). Whereas, the use of a 4 km cycling TT 
provides an exercise protocol that is common practice amongst track and road cyclists (outdoor 
velodrome), with events such as the individual and team pursuit. This distance can also be 
applied to longer duration events such as the points race, omnium, or a 16 km road TT, that all 
require bursts of power for the duration of a typical 4 km TT completion time (~6 min). 
Importantly, the protocol has also demonstrated high test-retest reliability within well-trained 
cyclists, as Stone et al. (2011) reported a low TE in three repeated 4 km TT’s of 0.9% (between 
trial 1 and 2) and 0.8% (between trial 2 and 3), with completion times within 0.4 s of each 
other. This protocol therefore is appropriate to detect worthwhile changes in performance with 
NaHCO3 ingestion, based on the high reliability of the protocol, and the small changes in mean 
power output required to show a meaningful effect. 
 
A further factor to consider is whether NaHCO3’s acting mechanism is being tested during the 
selected exercise protocol. A 4 km TT provides this, as Ward et al. (2016) reported both pH 
and HCO3
- declined significantly within a group of eleven trained cyclists (pH -0.26; HCO3
- -
13.6 mmol.l-1). As a result, NaHCO3 ingestion may be suitable to mitigate this acid base 
balance perturbation, based on the enhanced H+ buffering this supplement can provide (section 
2.3). Furthermore, the typical completion time for a 4 km TT is just under 4 min (world class 
times) and up to 7 min (recreational rider), which falls within the 1 to 7 min window that 
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NaHCO3 is suggested to exert ergogenic effects (Carr et al., 2011a). Therefore, the selection of 
a 4 km TT is an appropriate test of NaHCO3’s proposed acting mechanisms.  
 
2.6.5 Summary 
Despite plentiful literature examining the efficacy of NaHCO3 on TT performance within a 
range of modalities, the ergogenic effects remain mixed (McNaughton et al., 2016). In relation 
to cycling TT performance, it seems trained individuals can obtain the ergogenic effects of 
NaHCO3 compared to their untrained counterparts (McNaughton et al., 2016). Nonetheless, 
some studies using a 4 km TT protocol and trained subjects have revealed none, or very small 
ergogenic effects following NaHCO3 (Callaghan et al., 2017, Oliviera et al. 2017). These 
studies employed a sub-optimal NaHCO3 ingestion strategy however, that possibly failed to 
elicit peak individual buffering capacity. Moreover, recent research has demonstrated 
ergogenic effects following NaHCO3 ingestion at a pre-determined peak pH (Miller et al., 
2016, Deb et al., 2017), or HCO3
- (Deb et al., 2018a), suggesting the timing of NaHCO3 is 
crucial to obtain ergogenic benefits. The reproducibility of this time to peak is unknown 
however, which may plausibly be affected by multiple factors (Reddy et al., 2012, Dias et al., 
2015); whilst it is unclear which analyte is more optimal for consistent performance benefits. 
Current evidence suggests the reproducibility of performance displays greater reproducibility 
in trained individuals compared to their untrained counterparts (Bird et al., 1995, Carr et al., 
2012, Dias et al., 2015). Further research is therefore required to address the reproducibility of 
both the blood and performance responses following NaHCO3 in trained individuals. These 
investigations should aim to employ appropriate reproducibility statistics and employ an 
exercise protocol that is reliable and sensitive to detect meaningful changes in performance, 




2.7 Application of sodium bicarbonate to acute hypoxia and recovery 
2.7.1 Overview of metabolic and physiological mechanisms in hypoxia 
Hypoxic training schedules are used for a period of between four to eight weeks, predominantly 
by both professional and amateur athletes (Alvarez-Herms et al., 2015). Recent technical 
advancements such as hypoxic chambers, tents, and portable devices have made a hypoxic 
stimulus more popular and readily conceivable (Álvarez-Herms et al., 2015, Deb et al., 2018b). 
Compared to a sojourn to terrestrial altitude, the use of alternative hypoxic chambers are cost-
effective to the consumer, require little or no travel, and do not require an acclimatization 
period. This allows individuals to include either a ‘live low-train high’ or ‘live high-train low’ 
hypoxic stimulus within a training regime to potentially induce favourable molecular and 
physiological adaptations, however without leaving their pre-established lifestyle (Green, 
2000). This method of training is often termed intermittent hypoxic training (IHT). 
Subsequently, a large and growing body of evidence has been created to elucidate methods to 
maximise outcomes from such hypoxic stimuli (for review see Murray, 2009, Sinex and 
Chapman, 2015). 
 
Two primary physiological changes occur at terrestrial altitude in response to the atmospheric 
changes, such that both the partial pressure of oxygen (PO2) and barometric pressure display a 
step-wise decline as the level of altitude increases (Table 2.2). A normobaric hypoxic chamber 
is the most popular to replicate the physiological changes at altitude, which adjusts for PO2 
only (normobaric hypoxia; NH). Whilst, hypobaric chambers were designed to replicate 
changes in both PO2 and barometric pressure (hypobaric hypoxia; HH); although the financial 


















0 760 159 20.9  
1000 674 141  18.7 Low 
1500 634 133 17.3  
2000 596 125 16.4 Moderate 
3000 526 110 14.5  
4000 462 97 12.7  
5000 405 85 11.2  
6000 354 74 9.7  
7000 308 64 8.7 High 
8000 267 56 7.7  
9000 230 48 6.8  
 
Debate exists as to whether NH replicates the physiological changes compared to terrestrial 
altitude and HH, considering the former fails to adjust for barometric pressure. A point-
counterpoint article (Millet, Faiss and Pialoux, 2012) highlighted the need to distinguish 
between NH and HH, based on many studies reporting disparity in physiological and metabolic 
responses. Specifically, higher ventilation is commonly observed in NH compared to HH at 
the same level of simulated altitude, which is attributed to the greater alveolar dead space at 
HH (Savourey et al., 2003, Millet et al., 2012, Coppel et al., 2015). Furthermore, it is suggested 
NH is less effective at reducing acute mountain sickness in the preparatory phase for a sojourn 
to altitude; although the mechanism is unknown (Fulco, Beidleman and Muza, 2013). More 
recently, evidence has suggested the performance decrement at HH is much greater compared 
to NH (Beidleman et al., 2014, Saugy et al., 2014). Indeed, during a 5 min cycling TT, 
performance declined from sea level by 65 ± 24% in HH (PO2 93 mmHg) compared to only 36 
± 14% in NH (4300m) (Beidleman et al., 2014). This study employed a matched groups design 
however, and therefore the large inter-individual hypoxia sensitivity within individuals could 
explain this result (Chapman, Stray-Gundersen and Levine, 1998, Chapman, 2013). In respect 
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of this, in a crossover designed study, a much smaller 8% difference between HH and NH 
(3450 m) was observed during a 250 kJ TT (Saugy et al., 2016). This suggests the decrement 
between HH and NH is not as large as first suggested, meaning NH is appropriate to replicate 
the primarily physiological changes that occur at altitude. Lastly, the studies to date have 
entailed exposure to hypoxia for ≥24 hours, and therefore differences between NH and HH 
with shorter exposures are likely to be negligible. 
 
Whilst a full review of the differences between NH and HH is beyond the scope of this thesis, 
it is important to acknowledge some small physiological differences may be present. Instead, 
the reader is directed to more pertinent literature on this specific topic (see Coppel et al., 2012, 
Millet et al., 2012). Furthermore, the present thesis aims to use acute NH to reduce PO2 and 
perturb acid base balance, not prepare the athlete for a sojourn to terrestrial altitude; therefore 
the use of a NH chamber is considered valid. Hereafter, the main physiological changes from 
a reduction in PO2 will now be reviewed. 
 
Acute NH is characteristically a reduction of ambient PO2, which causes a concomitant decline 
in the PO2 of arterial blood. The decline in ambient PO2 will continue to fall in response to 
elevated altitudes whereby sea level ambient PO2 is 159 mmHg, while, the summit of Everest 
is between 25 to 30 mmHg (West, 2006) (Table 2.2). In turn, a concomitant decline in the 
saturation of arterial oxy-haemoglobin (SaO2) will occur, which describes the affinity of 
haemoglobin to receive O2 at the cellular level from the alveoli (Nielsen et al., 2003). Typical 
oxygen saturation (SpO2) is 98 ± 1% at sea level, however this can fall to below 90% at 
moderate altitudes (≥2000 m) (Luks and Swenson, 2011). Such deductions in SpO2 will lower 
arterial oxygen content (CaO2), which in turn, can reduce exercise performance through a 
reduction in O2 supply to active musculature (Bassett and Howley, 2000). The physiological 
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changes are not exclusive to CaO2 however, as the cardiorespiratory system is also important 
to transport O2 to active musculature. Other limiting factors include the perfusion pressure, and 
the failure of compensatory mechanisms to increase cardiac output and blood flow in response 
to a reduction in PO2 (Bassett and Howley, 2000, Calbet et al., 2009). 
 
Perfusion pressure refers to the pathway of O2 from the alveolar capillary membrane and tissue 
barriers to the extracellular matrix between the cell and the mitochondria (Leach and Treacher, 
1998). Briefly, the O2 tension gradient and diffusion distance between the cell and intracellular 
space increases in a dose-response manner, meaning as the PO2 progressively declines the 
distance becomes greater. This is unfavourable, as this will reduce SaO2 and therefore reduce 
the O2 supply to active muscular during maximal exercise. This effect is exclusive to the FiO2 
at acute hypoxia, meaning, this will occur regardless of exercise intensity, training status or 
any other external influences. In contrast, cardiac output and blood flow act in response to 
hypoxia, although to what extent is determined by the level of hypoxia, intensity of exercise 
and hypoxia sensitivity within an individual (Chapman et al., 1998, Nielsen et al., 2003, 
Chapman, 2013). In submaximal exercise, physiological mechanisms such as the increases in 
cardiac output and skeletal muscle blood flow can compensate for the reduction in PO2 and 
CaO2 (Koskolou et al., 1997, Calbet, 2000, Peltonen, Tikkanen and Rusko, 2001, Moon et al., 
2016). Moon et al. (2016) for instance reported during 30 min submaximal exercise (117 ± 20 
W) cardiac output was progressively significantly increased, with a reduction in FiO2 from 
16.5% to 11.2%. Whilst, at a fixed FiO2 of 12% (4500 m altitude equivalent), Gonzalez-
Alonso, Richardson and Saltin (2001) reported blood flow was significantly increased (+32%) 
compared to normoxia during 5 min of submaximal knee extensions at 41 ± 1% peak knee-
extensor power output. These compensatory mechanisms therefore provide suitable protection 
to maintain O2 transport to skeletal muscle for submaximal exercise. 
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During maximal exercise the compensatory O2 transport mechanisms appear to be absent, as 
both cardiac function and blood flow are either reduced, or display no change (Calbet, 2000, 
Noakes, Peltonen and Rusko, 2001). Indeed, Peltonen et al. (2001) reported a 9% reduction in 
cardiac output during maximal exercise at a FiO2 of 15% (2600 m) compared to normoxia (26.0 
± 3.4 vs. 28.5 ± 2.4 l.min-1). Whilst, Fukuda et al. (2010) reported a 11.5% decline in cardiac 
output at a higher elevation (14.4% FiO2; 3000 m). These findings are similar for blood flow, 
such that Calbet et al. (2003) reported a 4 l.min-1 reduction during maximal leg extensions at 
hypoxia (FiO2 = 10.5%; 5500 m equivalent altitude) compared to normoxic exercise; whilst 
other studies have corroborated this (Hartley, Vogel and Landowne, 1973, Richardson et al., 
2006). The failing of these mechanisms to uphold O2 transport and delivery to active 
musculature during hypoxic maximal exercise explains, in part, the large reduction in maximal 
exercise performance compared to normoxia. 
 
In acute hypoxia, the reduction of O2 delivery and supply during maximal exercise leads to a 
greater and earlier reliance on glycolysis (Adams and Welch, 1980, Hogan, Cox and Welch, 
1983, Hogan, Richardson and Haseler, 1999, Lühker et al., 2017). This is due to the increase 
in relative work rate required in hypoxia for any given absolute work rate in normoxia. Briefly, 
as VO2max performance is reduced in a step-wise manner with increasing elevations (Wehrlin 
and Hallén, 2006, Mollard et al., 2007), this will raise the percentage of VO2max required to 
produce the same power output. Consequently, athletes will be working at a higher exercise 
intensity, which potentially could be above lactate or ventilatory threshold (Levine, Stray-
Gundersen and Mehta, 2008). Moreover, Romer et al. (2007) reported that in hypoxic 
conditions (FiO2 = 13%) a greater decrease in potentiated twitch force (marker of peripheral 
fatigue) was reduced by a greater amount compared to normoxia (-39 ± 4 vs. -24 ± 3%, p 




This process is causative of a greater metabolic perturbation including a more rapid 
accumulation of H+ and inorganic phosphate (Adams and Welch, 1980; Hogan et al., 1999), 
and greater decrements in the SID in hypoxic conditions (Lühker et al., 2017); all of which 
have been associated with fatigue (Allen et al., 2008a). There is also a notion that such 
deleterious effects on peripheral mechanisms arises from a further impairment of (Ca2+) release 
from the sarcoplasmic reticulum, although the studies investigating this have failed to agree. 
In a series of studies (Dunhamel et al., 2004a; 2004b), no differences in Ca2+ metabolism were 
found between the normoxic and hypoxic conditions during prolonged 90 min exercise (50% 
VO2max in norm; ~64% VO2max in hypoxia) or exercise to fatigue in hypoxia at workloads 
corresponding to 50% - 90% of normoxic VO2max. A limitation of this work however is the 
lack of matched workloads, and that the exercise bouts were not of a high-intensity or short 
duration. Therefore, it is difficult to determine the true effects of hypoxic conditions on Ca2+ 
metabolism. Hereafter, this section will focus on the primary disturbance to acid base balance 
that occurs during high-intensity exercise within an acute hypoxic setting. 
 
2.7.2 Effects of acute hypoxia on H+ appearance and the strong ion difference  
Early work by Hogan et al. (1988) reported H+ was exacerbated during 3 min of electrical 
stimulation exercise in dog gastrocnemius muscle at a PaO2 of 21 torr (>8000 m), compared to 
that of sea level (80 torr). A similar increase in H+ was observed by Howlett and Hogan (2007) 
during 8 min of electrical stimulation within rat gastrocnemius muscle exposed to 10% FiO2 
(~5800 m) (vs. 21% FiO2; normoxia). The application of these study findings to humans is not 
clear however, as the level of hypoxia employed is much greater than typical elevations used 
by humans in hypoxic training schedules (i.e. around 2500 m). Nevertheless, Adams and Welch 
(1980) reported H+ production was 2 nmol.l-1 greater at a lower level of acute hypoxia (1750 
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m) compared to normoxia in humans, despite exercise time to exhaustion being ~3min shorter 
(10 min at 55% VO2max, followed by 90% VO2max to exhaustion). A large portion of the exercise 
was at a low intensity however, therefore the application to high-intensity exercise is unclear. 
Nonetheless, Hogan et al. (1999) reported pH was 0.06 units lower at an FiO2 of 10% (5800 m 
equivalent) compared to normoxia following plantar flexion exercise to exhaustion (FiO2 = 
21%). Despite this, the level of altitude was extremely high and featured a small muscle mass, 
therefore the transfer to more moderate altitudes and whole-body exercise is unclear. Despite 
this mixed approach, these studies collectively demonstrate that H+ production under acute 
hypoxic conditions is accelerated and accumulates more greatly compared to normoxia.  
 
There is a paucity of literature investigating the effects of acute hypoxia on the SID. Compared 
to normoxia, the SID was significantly reduced in the hypoxic condition (12% FiO2, 4500 m) 
during an incremental cycling task to exhaustion, both in the latter stages of exercise (-16.4%; 
42.8 ± 1.5 vs. 35.8 ± 1.2 mmol.l-1) and post-exercise (-5.8%; 34.5 ± 2.8 vs. 32.5 ± 2.0 mmol.l-
1) (Lühker et al., 2017). Furthermore, a reduction in peak power at exhaustion was observed in 
the hypoxic condition by 26%, which is likely due to the known effects a reduced SID has on 
action potentials and muscle excitability (sections 2.1.2 and 2.2). Unfortunately, this is the only 
study to date exploring this mechanism, and at a FiO2 that reflects severe to ultra-levels of 
altitude and untrained participants, the application to typical training altitude levels and trained 
athletes is unclear. As a result, it is unknown whether these effects would be observed at more 
moderate altitudes (i.e. 3000 m) and the associated impact this would have on exercise 
performance. Based on this exacerbated H+ accumulation and greater decrements in the SID 
within a hypoxic environment during high-intensity exercise, interventions to dampen this 




2.7.3 Time trial performance at hypoxia 
It is important for practitioners to be able to predict the decline in performance at acute hypoxia 
to allow prescription of an optimal elevation for either training camps (i.e. IHT) or a sojourn. 
This is due to the risk of employing an elevation too high that may reduce both the intensity 
and volume of training, consequently leading to a reduction in the efficacy of hypoxic training 
schedules (Sinex and Chapman, 2015, Nakamoto et al., 2016). Hereafter, in relation to the 
current aims of this thesis, only the effects of acute hypoxia on TT performance will be 
reviewed. 
 
Short distance/duration TT performance displays ergolytic effects at acute hypoxia (Gore et 
al., 1997, Amann et al., 2006, Clark et al., 2007, Simpson et al., 2014, Weavil et al., 2015, 
Shearman et al., 2016). This is only for exercise over 2 min however, as no ergolytic effects 
from hypoxia have been reported for exercise of less than this duration (Deb et al., 2018b). 
This is explained by the predominant energy source of substrate level phosphorylation and non-
oxidative production of ATP being sufficient to meet the demand of the exercise (di Prampero, 
2003). Over this time point however a clear decrement in performance can be expected, 
primarily due to the greater dependence on energy contribution via oxidative sources. In a 
recent meta-analysis, Deb et al. (2018b) reported a curvilinear decline in performance with 
increasing elevations. Indeed, in TT’s using a fixed linear resistance (3 min all-out critical 
power test), decrements ranging between 7.7% and 14.8% at simulated altitudes of between 
2500 m and 3800 m have been reported (Shearman et al., 2016, Simpson et al., 2014, Deb et 
al., 2018b). Due to this test being against a fixed linear resistance however, this does not 
provide the expected effects on self-paced performance. Nonetheless, 5 min self-paced cycling 
TT’s have also reported ergolytic effects at acute hypoxia (Gore et al., 1997, Clark et al., 2007). 
These decrements are evident from 580 m, as Gore et al. (1997) reported a 3.9% reduction in 
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5 min TT performance compared to normoxia. Whilst, Clark et al. (2007) also reported 5 min 
TT performance showed a step-wise decline in performance with increasing elevations (200, 
1200, 2200, and 3200 m), ranging from 5.8% at 1200 m to 19.8% at 3200 m. This evidence 
clearly displays the progressive ergolytic effects on cycling TT performance as the level of 
hypoxia increases. 
 
Despite the guaranteed decline in TT performance, the magnitude of reduction in performance 
is highly inter-individual. Of note, current data suggests trained individuals display greater 
performance decrements compared to untrained individuals, despite the same level of hypoxia 
(Chapman et al., 1998, Chapman, 2013). Martin and O’Kroy (1993) reported at an FiO2 of 13% 
(3800 m), the decline in VO2max was significantly greater (26 ± 2.3% vs. 14.9 ± 5.1%) within 
a group of eight trained individuals (VO2max 67.2 ± 4.0 ml
.kg-1.min-1), compared to their 
untrained counterparts (VO2max 45.4 ± 5.5 ml
.kg-1.min-1). Interestingly, post-exercise SpO2 was 
more severely hampered in the trained individuals (67.0 ± 7.1% vs. 77.5 ± 9.0%), which 
seemed to explain the greater VO2max decrement. Deb et al. (2018b) supports this notion, 
reporting a significant moderating effect of SaO2 in trained subjects (-2.8 ± 0.5% per 1% fall 
in performance), whilst no such effects appear to be apparent in healthy untrained individuals. 
This difference is commonly attributed to the insufficient time available for the red blood cells 
to saturate with O2 in trained individuals, which occurs due to a reduction in transit time within 
the pulmonary capillary (Dempsey, Hanson and Henderson, 1984). Such greater decrements in 
performance are concerning for trained individuals, considering they are more likely to 
consider hypoxic training compared to their untrained counterparts. Therefore, based on TT 
performance being more severely hampered in trained individuals, it is plausible to suggest 
interventions to mitigate the decline in performance and sustain training intensity in this 
population are needed. 
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2.7.4 Ergogenic aids at hypoxia: the role of sodium bicarbonate 
Investigations assessing the effectiveness of ergogenic aids to mitigate the ergolytic effects at 
acute hypoxic conditions is a contemporary theme of research with investigations including 
supplementation of dietary nitrates (Shannon et al., 2017) and NaHCO3 (Flinn et al., 2014, 
Saunders et al., 2014b, Deb et al., 2017, 2018a). The latter is proposed to reinforce blood 
buffering during anaerobic work, subsequently protecting acid base balance. Furthermore, 
early work reported NaHCO3 ingestion provides a protective effect of SaO2, as the decline in 
SaO2 during a 2 km rowing TT was reduced (NaHCO3 95% vs. saline infusion 85%) (Nielsen 
et al., 2002). Both mechanisms are suggested to result in a performance benefit to exercise in 
acute hypoxia, however, research to date is equivocal. 
 
Since the early findings of Nielsen et al. (2002), studies have failed to corroborate this outcome. 
Indeed, Flinn et al. (2014) reported SpO2 was not significantly different between NaHCO3 
conditions at both normoxic and acute hypoxic conditions (2800 m altitude equivalent). 
Whereas, Deb et al. (2017) reported post-exercise SpO2 between the NaHCO3 and placebo 
conditions was similar (84.4 ± 3.9% vs. 83.5 ± 7.1%). A caveat to this may be the frequency 
of sampling however, as Nielsen et al. (2002) continuously measured SaO2 throughout 
exercise, whereas, both Flinn et al. (2014) and Deb et al. (2018a) recorded pre to post-exercise 
SpO2 only. Nielsen et al. (2002) reported the main significant differences were during the 
exercise between the NaHCO3 and saline control condition, whilst post-exercise, SaO2 was 
similar. Consequently, the lack of continuous measurements may explain why no protective 
effect was observed by Flinn et al. (2014) and Deb et al., (2018a). Nonetheless, Nielsen et al. 
(2002) used saline as a placebo, which can cause acidosis, and therefore it is unknown if this 
effect would have still occurred if an appropriate sodium chloride placebo or a control was 
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chosen. Therefore, a protective effect O2 delivery at acute hypoxia from NaHCO3 ingestion 
cannot be discounted, however further research is required. 
 
Deb et al. (2017) reported following NaHCO3 ingestion at a pre-determined individual peak 
pH, H+ accumulation was dampened, HCO3
- displayed a greater change from pre to post-
exercise and post-exercise blood lactate was greater in acute hypoxia during a 3 min all-out 
critical power test (FiO2 14.5%; 3000 m). These changes indicate enhanced buffering activity 
occurred, which infer enhanced glycolytic flux and better maintenance of pH within the 
intramuscular compartments (section 2.3). As a result, W’, defined as the amount of anaerobic 
work/energy an individual can perform above critical power, was improved by 2.7 kJ (+17.7%) 
following NaHCO3 ingestion compared to the placebo (15.2 ± 4.9 vs. 17.9 ± 5.2 kJ, p <0.001). 
This same group has also reported ergogenic effects of NaHCO3 ingestion at a pre-determined 
individual peak HCO3
- during intermittent severe-intensity exercise to exhaustion at hypoxia 
(FiO2 14.5%; 3000 m altitude equivalent) (Deb et al., 2018a). Before these contemporary 
studies however, no ergogenic effects following NaHCO3 ingestion had been reported at 
similar levels of acute hypoxia (Flinn et al., 2014, Saunders et al., 2014b). Briefly, during 
intermittent high-intensity cycling to exhaustion (120% peak power for 30 s interspersed with 
30 s active recovery), no significant ergogenic effects were reported (Flinn et al., 2014). In 
addition, Saunders et al. (2014b) reported NaHCO3 ingestion had no effect on repeated sprint 
performance prior to, at half-time, or post a 90 min football simulation. Unlike the studies 
individualising NaHCO3 ingestion to a time to peak pH or HCO3
- however (Deb et al., 2017, 
2018a), these studies employed a standardised time frame of ingestion of 90 min and 240 min, 
respectively. Consequently, this would have failed to elicit peak buffering capacity in all 
individuals based on the commonly observed inter-individual time to peak alkalosis, 
subsequently reducing the effects of NaHCO3 (Miller et al., 2016, Jones et al., 2016, Deb et al., 
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2017, 2018a). A further explanation may be the exercise intensity or the length of the protocol 
employed by Flinn et al. (2014) and Saunders et al. (2014b). Flinn et al. (2014) selected a 
supramaximal intensity, whereby the effect of NaHCO3 ingestion on this intensity has generally 
been inconsistent (McNaughton et al. 2016). Furthermore, Saunders et al. (2014b) selected a 
90 min protocol, which is outside of the 1-10 min window that NaHCO3 ingestion has displayed 
its most potent effects on performance (Carr et al., 2011a). Despite these other factors, the 
research to date highlights the potential importance of individualising NaHCO3 to peak 
alkalosis, particularly in acute hypoxic conditions where the acidic stress is heightened. 
 
2.7.5 Sodium bicarbonate: implications for recovery at hypoxia 
The recovery from repeated bouts of exercise is vital to ensure subsequent performance is not 
significantly hampered, particularly if more than one high-intensity bout of exercise is to be 
completed in a short time frame. These time frames might typically vary between 20 and 120 
min, with examples such as the time difference between heat and the subsequent events (i.e. 
semi-final, final) in track cycling, swimming and cross-country skiing all falling within this 
category (Barnett, 2006). Athletes therefore face a unique challenge to sufficiently recover in 
time for the subsequent bout of exercise, which importantly is the bout that is classically vital 
for competition success. Based on the trend of most national, Olympic, and world records being 
achieved in preliminary rounds of competition and not in finals however, it is plausible that 
recovery is inadequate (Al-Nawaiseh, Pritchett and Bishop, 2016). There is a requirement 
therefore to elucidate short-term recovery interventions that can mitigate the decline in 
subsequent exercise performance. 
 
A considerable amount of research exists on various short-term recovery methods with 
common approaches including cold-water immersion (Leeder et al., 2012), use of nonsteroidal 
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anti-inflammatory drugs (NSAIDs) (Schoenfeld, 2012), and active and passive recovery 
methods (Bangsbo et al., 1993, Fairchild et al., 2003). Despite common in-field practices, the 
above methods are largely unsubstantiated to provide beneficial effects to subsequent exercise 
within the same day. Cold-water immersion for instance, has reported no overall effect in 
multiple meta-analyses studies (Costello et al., 2015, Hohenauer et al., 2015), or reported 
benefits only ≥24 hours post-exercise (Leeder et al., 2012). Similarly, NSAIDs are contentious 
given their reported impairment of satellite cell activity, lack of ergogenic effects on 
performance, and potential health risks with long-term supplementation (Schoenfeld, 2012). 
Lastly, active recovery has been demonstrated to be effective to reverse metabolic disturbances 
through the elimination of metabolites (i.e. lactate, H+ and Pi), however this has only been 
reported in type I muscle fibers and also concomitantly reduces muscle glycogen resynthesis 
and therefore could compromise subsequent performance (depending on intensity and 
duration) (Bangsbo et al., 1994, Fairchild et al., 2003). In short, these common recovery 
methods do not result in the sufficient recovery of performance when a small amount of time 
is available, therefore further intervention is required. 
 
A key factor often overlooked when planning short-term recovery from high-intensity exercise 
is limiting the post-exercise acid base balance disturbances and accelerating the recovery back 
to baseline prior to the second bout. This is despite the large post-exercise metabolic 
perturbation reported by multiple studies (Ward et al., 2016, Callaghan et al., 2017, Oliveira et 
al., 2017). Ward et al. (2016) for instance reported pH declined from 7.42 ± 0.01 to 7.16 ± 0.01 
(-3.5% change) and HCO3
- from 25.2 ± 1.6 to 11.9 ± 2.3 mmol.l-1 (-52% change) during a 4 
km cycling TT. Importantly, the recovery of these analytes can take over 90 min with a passive 
rest (Robergs et al., 2005, Gough et al., 2017, Callaghan et al., 2017). Indeed, Callaghan et al. 
(2017) reported that pH had recovered back to baseline, however HCO3
- was still markedly 
61 
 
below baseline 75 min following the same 4 km TT used by Ward et al. (2016). Consequently, 
if the subsequent bout begins within this time frame, an existing acid base balance perturbation 
will be present. In turn, this might explain why subsequent exercise performance is commonly 
hampered in competition. These findings suggest that interventions to mitigate post-exercise 
acid base perturbation may therefore be worthwhile to subsequent exercise performance.  
 
One strategy that accelerates the recovery of acid base balance following high-intensity 
exercise is the ingestion of NaHCO3. Indeed, Pruscino et al. (2008) reported 25 min following 
a 200 m swimming TT, both pH and HCO3
- were increased following NaHCO3 ingestion, such 
that HCO3
- was greater by 10.5 mmol.l-1 compared to placebo (30 ± 1.5 vs. 19.5 ± 1.4 mmol.l-
1). Furthermore, the level of HCO3
- was also greater than baseline following NaHCO3 
ingestion, despite the initial fatiguing bout (vs. 25.7 ± 1 mmol.l-1). These findings suggest that 
NaHCO3 ingestion mitigates post-exercise acid base balance disturbance and subsequently 
avoids this carrying over into the subsequent bout. This might therefore improve subsequent 
exercise performance, considering the suggested effects of acid base balance on fatigue (Allen 
et al., 2008a, 2008b, section 2.2.2). Despite this, the translation of such enhanced post-exercise 
recovery of acid base balance into an improved subsequent performance is equivocal. 
 
In studies employing a short time frame of recovery (≤30 min), little to no effects of NaHCO3 
have been observed (Pierce et al., 1992, Zabala et al., 2008, 2011). Indeed, Zabala et al. (2008, 
2011) reported three repeated 30 s Wingate tests interspersed with between 15 min and 30 min 
passive recovery were unaffected by NaHCO3. This may be explained by the exercise protocol 
employed however, as NaHCO3 has been shown to have limited effects on exercise of less than 
one minute (Parry-Billings and MacLaren, 1986, McNaughton, 1992b, Douroudos et al., 2006). 
A study with a 20 min passive recovery and a longer exercise duration however, also reported 
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no ergogenic effects following NaHCO3 on three repeated swims (1 x 100 yard; 2 x 200 yard) 
(Pierce et al., 1992). Nonetheless, as 0.2 g.kg-1 BM NaHCO3 was ingested, it is unlikely this 
amount was sufficiently accelerated the recovery of acid base balance; although no blood acid 
base balance data is available to confirm this. Based on these findings, it is unclear whether 
NaHCO3 can improve subsequent exercise performance when under 30 min recovery is 
available. With limitations in the research to date such as the exercise protocol and dose of 
NaHCO3 however, further research is required.  
 
In studies utilising a longer recovery window (≥30 min) promising effects of NaHCO3 have 
been demonstrated (Verbitsky et al., 1997, Pruscino et al., 2010, Gough et al., 2017). 
Specifically, Pruscino et al. (2010) demonstrated a ‘trivial’ to ‘moderate’ benefit in magnitude 
based inferences analysis following 0.3 g.kg-1 BM NaHCO3 on two repeated 200 m swimming 
TT’s interspersed with a 30 min passive recovery. These findings suggest a benefit from 
NaHCO3 may be realised if the exercise test employed is appropriate, the recovery time frame 
is of sufficient duration, and 0.3 g.kg-1 BM is ingested. It is important to note however, the 
positive effects on performance did not reach statistical significance in parametric statistical 
analysis, which subsequently questions the efficacy of NaHCO3 ingestion. Verbitsky et al. 
(1997) nonetheless, has reported statistically significant increases in post-exercise quad torque 
following NaHCO3 ingestion at 10, 20, 30, and 40 min recovery compared to a placebo. This 
exercise was not dynamic however, and therefore the translation to whole-body exercise is 
unclear. Contemporary work by Gough et al. (2017) has reported a significant 35 s (16.6%) 
increase in subsequent cycling capacity (100% Wpeak) following NaHCO3 ingestion however, 
when ingested 30 min into a 90 min passive recovery compared to a placebo. These findings 
suggest a minimum of 30 min is required for NaHCO3 to elicit ergogenic effects on subsequent 
exercise performance, which is likely due to the greater recovery of acid base balance.  
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Despite ample research in normoxia, the ingestion of NaHCO3 to improve subsequent exercise 
performance has never been applied to acute hypoxia. This is despite this supplement arguably 
being more suited to this environment, considering the acid base balance perturbation is 
increased in acute hypoxia compared to the same absolute exercise in normoxia (section 2.6.1). 
Likewise, during hypoxic training schedules, athletes might complete multiple bouts of high-
intensity exercise to induce favourable metabolic and physiological adaptations. Despite this, 
only one study has profiled the post-exercise acid base balance recovery kinetics in acute 
hypoxic conditions following an alkalotic supplement (Robergs et al., 2005). The authors 
reported that following a cycling bout at 110% workload at VO2max to exhaustion, the co-
ingestion of NaHCO3 and sodium citrate achieved full recovery of pH and HCO3
- back to 
baseline in around 45 min at a terrestrial altitude of 1570 m. Conversely, the placebo condition 
failed to recover to baseline within the 60 min blood sampling period. This suggests a 
subsequent bout of exercise may be improved, as the acid base balance disturbance without 
supplementation of NaHCO3 is mitigated. This study did not feature a subsequent bout of 
exercise however, and it is also unclear if the participants in this study had an acclimatisation 
period at the terrestrial altitude location. Therefore, further research is required investigating 
the effects on NaHCO3 ingestion on post-exercise acid base balance recovery, and subsequent 
exercise performance in acute hypoxia. This will allow athletes to plan hypoxic training 
schedules with optimal recovery between bouts, whilst also assessing if they can gain ergogenic 
benefits from NaHCO3 ingestion.  
 
2.8 Summary and aims of research 
 
The extensive investigations that have evaluated NaHCO3 as an ergogenic practice to enhance 
high-intensity exercise performance have been presented in this review. Most research has 
employed 0.3 g.kg-1 BM NaHCO3 in view of early work suggesting this to be the optimal 
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amount for performance benefits (McNaughton, 1992a). Considering this study featured 
untrained participants, one exercise duration, and the difference between other NaHCO3 doses 
were non-significant however, further work is required to investigate dose-response 
relationship for performance enhancements. A further issue with this dose is the associated 
negative GI discomfort, which could plausibly affect the ability for exercise (Carr et al., 2011b, 
Saunders et al., 2014a, Gough et al., 2017). This suggests a smaller amount may alleviate GI 
discomfort and therefore reduce the tolerability issues from NaHCO3 ingestion. Despite this, 
no research has determined the GI discomfort responses from various amounts of NaHCO3.  
 
Individualising the timing of NaHCO3 to a pre-determined time to peak pH or HCO3
- may be 
important to maximise buffering capacity and the resulting ergogenic benefit (McNaughton et 
al., 2016). To enhance this approach however, the most appropriate analyte to determine the 
individualised NaHCO3 strategy requires investigation. Furthermore, the reproducibility of 
such a time to peak alkalosis is unknown. Elucidating this will allow athletes to appropriately 
elicit peak individual buffering capacity in training and competition and subsequently heighten 
the chance of an ergogenic benefit. Therefore, the first aim of this thesis is to determine the 
reproducibility of the time to peak pH and HCO3
- following two doses of NaHCO3 (0.2 g
.kg-1 
BM and 0.3 g.kg-1 BM NaHCO3).  
 
Following identification of the most appropriate analyte to elicit consistent time to peak 
alkalosis following NaHCO3, the next aim of this thesis is to assess the reproducibility of the 
performance responses. This will allow athletes to appropriately evaluate the effectiveness of 
the individualised NaHCO3 ingestion strategy to elicit consistent performances upon repeated 
use. Whilst this has been investigated previously (Bird et al., 1995, Carr et al., 2012, Dias et 
al., 2015), unsuitable statistical procedures were employed, and NaHCO3 ingestion was not 
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individualised to time to peak pH or HCO3
-. Further research investigating the reproducibility 
of the performance effects following an individualised NaHCO3 dose is therefore required. 
Moreover, ingestion of 0.2 g.kg-1 BM NaHCO3 may increase performance and lower the 
severity and instances of GI discomfort. The second aim of this thesis is twofold therefore; 
firstly, to investigate the reproducibility of 4 km cycling TT performance following 0.2 g.kg-1 
BM and 0.3 g.kg-1 BM NaHCO3 when supplemented at a pre-determined time to peak alkalosis. 
Whilst secondly, also compare this to a placebo. The analyte used to determine the time to peak 
alkalosis strategy (i.e. pH or HCO3
-) shall be the one that is the most reproducible in study one 
(Chapter 4). 
 
During bouts of high-intensity exercise at acute hypoxia, exacerbated accumulation of 
metabolites arises compared to the same absolute exercise in normoxia (Adams and Welch, 
1980, Hogan et al., 1999, Romer et al., 2007). In response, athletes may wish to supplement 
NaHCO3 to support the buffering mechanisms that are further stressed in this environment. 
Nonetheless, a paucity of research has been conducted to date with conflicting results (section 
2.6.4). Furthermore, no research to date has investigated the effects of NaHCO3 ingestion on a 
self-paced exercise bout, such as a 4 km TT in acute hypoxia. The third aim of this thesis 
therefore, is to investigate the effects of NaHCO3 supplemented at a pre-determined individual 
time to peak alkalosis on 4 km TT performance in moderate acute hypoxia. In addition, the 
post-exercise recovery profile of acid base balance to baseline following NaHCO3 will be 
determined in this study and applied in the subsequent one. 
 
The fourth aim of this thesis is to investigate the use of pre-exercise NaHCO3 ingestion to 
improve acid base balance recovery and subsequent high-intensity exercise performance at 
acute hypoxia. This is due to the common practice of athletes performing repeated bouts of 
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high-intensity exercise with a limited recovery in between training and/or competition. 
Following a bout of high-intensity exercise, a large perturbation to acid base balance occurs 
that can take over 75 mins to recover (Callaghan et al., 2017). As a result, existing acid base 
balance perturbation is present during the subsequent bout of exercise, which might explain 
why performance is normally hampered in this bout. The ingestion of NaHCO3 can mitigate 
this perturbation by accelerating the speed, and magnitude of acid base balance recovery 
including pH, HCO3
-, and the SID (section 2.6.5). In turn, this could mitigate the typical 






















































3.1 General Project Methods 
3.1.1 Ethical Considerations 
All experimental studies were approved by the Departmental Research Ethics Committee 
(Sport and Physical Activity; DREC), and where appropriate, the University’s Research Ethics 
Sub-Committee (URESC). A full description of each study was provided to each participant 
prior to the informed consent form. Each participant verbally agreed to take part and then 
signed the consent form to acknowledge they understood the aims of the research. Additionally, 
participants completed a departmental general health screening questionnaire and medical 
screening form prior to the first trial.   
 
3.1.2 Participants 
In Chapter 4, male team sport players were recruited with backgrounds in rugby, football and 
running. This participant cohort was recruited on the premise that H+ accumulation during 
repeated sprint tasks contribute to fatigue, and therefore they may benefit from enhancing their 
buffering capacity through NaHCO3 ingestion (Bishop, Girard and Mendez-Villanueva, 2011). 
Participants habitually completed 4 (± 1) exercise bouts per week lasting 2 (± 0) h per session 
and had 10 (± 3) years training experience within their respective sports. A more detailed 
description is provided in the specific chapter.  
 
In subsequent Chapters (5a, 5b, 6, and 7), male and female competitive cyclists were recruited. 
Each cyclist had a minimum weekly training frequency of ≥3 times, for a total of ≥5 hours per 
week, and for a minimum of 2 years in cycling. Participants in Chapters 5a and 5b met the 
criteria of a ‘trained’ cyclist as outlined by De Pauw et al. (2013), however in Chapters 6 and 
7, participants could not be compared with these guidelines as these studies were conducted at 
69 
 
hypoxia, in line with the study aims (Table 3.1). A more detailed description can be found in 
each specific chapter. 
 




















<45 45.0 – 54.9 55.0 – 64.9 65 – 71 >71 
VO2max l.min
-1 <3.7 3.4 – 4.2 4.2 – 4.9 4.5 – 5.3 5.2 ± 0.2, >5 
PPO W <280 280 – 319 320 – 379 380 – 440 >350 
PPO w.kg-1 <4.0 3.6 – 4.5 4.6 – 5.5 4.9 – 6.4 >5.5 
Cycling status      
Training 
frequency 
-  -  ≥3 >3 >5 
Training h/week <2-3 4 ≥5 ≥10 ≥10 
Training distance, 
km/week 
-  <60 60 – 290 >250 >500 
Cycling 
experience 
-  -  -  ≥3 ≥5 
Abbreviations: VO2max = maximal rate of oxygen consumption; PPO = peak power output; PL 
= participation level. 
 
3.1.3 Experimental design 
All experimental trials were conducted in the same physiology laboratory at Edge Hill 
University. For all studies, a repeated measures experimental design was employed, and the 
order of experimental trials was counterbalanced and randomised utilising a block 
randomisation method. Treatments were also double blinded from both the researcher and the 
participant in each experimental chapter, apart from in Chapter 4. Each trial was performed at 
the same time of day (±2 hours) and participants arrived four hours fasted to limit any 
confounding effects of nutritional intake. Likewise, trials were separated by a minimum of 




3.1.4 Pre-experiment screening and procedures 
Participants were specifically asked to maintain consistent nutritional intake throughout the 
study durations. Participants also avoided any strenuous activity and alcohol consumption 24 
hours prior to all trials, whilst caffeine and spicy foods were avoided 12 hours prior as they 
may influence metabolic regulation (Westerterp-Plantenga et al., 2006). To confirm adherence 
to the above procedures, a written nutrition log was requested from each participant detailing 
intake for the 24 hours prior to each trial. The first nutrition log was sent back to the participant 
to be replicated as closely as possible for all subsequent trials. Verbal screening of prior and 
current supplement use was also completed, whereby participants were asked to confirm they 
had not ingested beta alanine within the previous 6 months, to account for the long wash-out 
period of muscular carnosine (Stellingwerff et al., 2012). This screening procedure was also 
carried out for other nutritional buffers such as sodium citrate and NaHCO3, to ensure 
supplementation was not taking place outside of the experimental trials. On experimental days, 
participants were encouraged to ingest 500 ml of water a minimum of 2 hours prior to achieve 
euhydration. Experimental trials were separated by three days to allow for washout of NaHCO3 
(Siegler et al., 2010). 
 
3.2 General experimental procedures  
3.2.1 Anthropometric measurements 
Body mass (BM) and body fat percentage (%) was measured using an Air Displacement 
Plethysmograph device (BODPOD, Cosmed, Italy) and reported to the nearest 0.1 kg/%. 
Calibration was carried out prior to each measurement, as per the manufacturer’s guidelines. 
This method of assessing body composition has been shown to be both valid against other body 
composition techniques (skinfolds and hydrostatic weighing) and display high test-retest 
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reliability (Tseh, Caputo and Keefer, 2010). Height was measured in centimetres (cm) using a 
stadiometer (Holtain, UK) and reported in metres to the nearest 0.1 metres.  
 
3.2.2 Heart rate  
Continuous measures for heart rate (HR) using a telemetric HR monitor were obtained during 
each experimental trial and were recorded at several time-points throughout each individual 
study chapter for analysis (Garmin, Forerunner 15, UK). Further description can be found in 
each study chapter. 
 
3.2.3 Cycle ergometer 
All cycling TT’s were conducted on a Velotron cycle ergometer (Velotron, RacerMate., USA) 
interfaced with 3D visual Velotron coaching software (RacerMate Inc., USA). This ergometer 
has displayed excellent test-retest reliability in previous studies of between r = 0.90 to 0.96 (p 
= <0.01) for mean power (Sporer and McKenzie, 2007, Astorino and Cottrell, 2012). Whilst, 
it has also been shown to provide valid measurements against other laboratory-based cycle 
ergometers such as the Monark and SRM (Abbiss et al., 2009, Astorino and Cottrell, 2012). 
Furthermore, in respect of the 4 km TT the current thesis employed, Stone et al. (2011) reported 
a TE of 0.9% for completion time for this distance in participants of similar characteristics to 
those used in the thesis, and on the Velotron cycle ergometer. Lastly, within the laboratory a 
high test-retest reliability of the completion time of the 4 km TT protocol was observed between 
the familiarisation trial and control trial in Chapter 5a (ICC r = 0.96, p = <0.001; TE = 0.5%). 
Preferred frame geometry (i.e. handlebar and saddle position) was selected by the participant 
on the first use of the Velotron and was replicated for all subsequent experimental trials. 




3.2.4 Normobaric hypoxia chamber 
The normobaric hypoxic chamber (TISS, UK) was used in Chapter 6 and 7. Configuration was 
conducted approximately 2 hours prior to any trial, which entailed adjusting the fraction of 
inspired oxygen (FiO2) from 20.9% (sea level) to 14.5% to represent approximately 3000 m 
(Flinn et al., 2014). Temperature was also continuously regulated at 20 °C and humidity was 
set at 40%. This level of altitude was selected as it is considered relevant to elicit greater 
accumulation of H+ compared to normoxic conditions (Adam and Welch, 1980, Hogan et al., 
1999). The researcher was always present within the chamber as the participant exercised, with 
a second individual present outside the chamber in case of any difficulties. Once the participant 
entered the chamber, a 10 min seated rest was conducted to allow equilibrium between 
atmospheric and body O2 stores (Andreassen and Rees, 2005). Furthermore, blood oxygen 
saturation (SpO2) level was measured continually throughout hypoxic exposure and recorded 
at multiple time points using pulse oximetry from the forefinger (Nissei, BO-600, Japan). If 
SpO2 dropped below 75% during experimental trials, then the participant was withdrawn from 
the chamber. 
 
3.2.5 Gas Analysis 
Expired gas samples were analysed using an online breath-by-breath metabolic gas analyser 
(Metamax 3b, Cortex, Germany) for minute ventilation (VE), oxygen consumption (VO2), 
carbon dioxide production (VCO2), and respiratory exchange ratio (RER). This device was 
used for all VO2max tests throughout the experimental chapters. Following a 40 min warm-up 
period, calibration was carried out prior to each trial as per the manufacturer’s instructions 
using known gas concentrations of 4.96% CO2, 14.97% O2, and balance N2 ± 0.02%. The flow 
turbine and volume calibration were conducted using a Hans Rudolph 3 litre calibration syringe 
(5530 series, Hans Rudolph, Inc., USA) using the manufacturers’ on-screen instructions. This 
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metabolic gas analyser has reported reliable outputs with a typical error of measure of between 
0.8 and 1.4% for VO2 and VCO2 (Macfarlane and Wong, 2012), which is lower than the 
recommended 3% typical error or measure of the Australian Sports Commission (Gore, 2000). 
In addition, this device has shown to be valid compared to other commercially available gas 
analysers, including the Oxycon and Douglas Bag method (MacFarlane and Wong, 2012).   
 
3.2.6 Blood metabolites  
Blood samples were collected from a fingertip capillary using a disposable lancing device 
(AccuCheck Safe-T-Pro, Indianapolis, USA). In Chapter 4, these samples were arterialised by 
warming the hand with a heated blanket (45°C) for 5 min prior to each individual sample 
(Johnston, Vickers and Mapleson, 1996). In subsequent chapters this was not completed, as it 
was not logistically possible in the exercising trials. Each sample was drawn into a 100-
microliter (µl) sodium heparinized clinitube and then inserted into a blood gas analyser 
(ABL800 Basic, Radiometer Medical ltd., Denmark) for analysis of pH, blood bicarbonate 
concentration [HCO3], base excess (BE), partial pressure of oxygen (PO2), and the partial 
pressure of carbon dioxide (PCO2). The concentration of electrolytes including potassium [K
+], 
sodium [Na+], chloride [Cl-] and calcium [Ca2+] were also analysed. The blood gas analyser 
used in this thesis has been shown to be reliable for the above parameters and valid against 
other commercially available devices (Radiometer medical, 2015; Stadlbauer et al., 2011). A 5 
µl sample was also collected for analysis of blood lactate using a reliable device (Lactate Pro 
2, LT-1730, Arkray, Japan) (Pyne et al., 2000). The collection of the electrolytes determined 
the apparent strong ion difference (SID) by the following calculation: [K+] + [Na+] + [Ca2+] + 
[Na+] - [Cl-] - [Lac-] using a freely available spreadsheet (Lloyd, 2004). This method has been 
shown to be valid in previous research (Figge, Rossing and Fencl, 1991) displaying a mean 
bias of 5% (95% confidence limit = -7.1%, +3.4%) and correlation of r2 = 0.98 for predicted 
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SID versus the observed SID. Moreover, the blood gas analyser used in this thesis has displayed 
a low bias in limit of agreement (LOA) analysis for pH, PCO2 and Na
+ (Radiometer Medical, 
2015). Furthermore, a small pilot study (n = 8) in our laboratory revealed high test-retest 
reliability for both HCO3
- at rest and following NaHCO3 (Table 3.1). Lastly, a Pearson 
correlation coefficient of between 0.95 and 0.99 has been reported for HCO3
- and pH against 
other commercially available blood gas analysers (Stadlbauer et al., 2011).  
 
Table 3.2 – Reliability summary for the Radiometer ABL800 Basic following 0.3 g.kg-1 BM 
NaHCO3 (n = 8). 
T1 = trial 1, T2 = trial 2, HCO3
- = blood bicarbonate 
ICC Pre-Supp pH Pre-Supp HCO3
- Post-Supp pH Post-Supp HCO3
- 
p value 0.001 0.001 0.001 0.003 
r value 0.94 0.94 0.97 0.97 
LB 0.71 0.76 0.86 0.21 
UB 0.99 0.86 0.99 0.95 








































1 7.404 7.402 23.4 23.6 7.479 7.481 30.6 30.5 
2 7.413 7.411 23.2 23.5 7.486 7.482 31.2 31.0 
3 7.411 7.410 24.4 24.5 7.482 7.486 30.5 30.8 
4 7.410 7.409 22.4 23.4 7.513 7.504 31.0 30.0 
5 7.442 7.443 26.6 27 7.512 7.509 33.2 32.8 
6 7.410 7.411 24.4 24.5 7.547 7.540 32.3 32.5 
7 7.397 7.390 23.3 22.9 7.496 7.504 32.1 30.6 
8 7.410 7.398 24.2 24.0 7.478 7.479 30.4 29.4 
Mean 7.412 7.409 24.0 24.2 7.499 7.498 31.4 31.0 
SD 0.012 0.015 1.2 1.2 0.022 0.019 0.9 1.1 
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3.3 Perceptual measures  
3.3.1 Ratings of perceived exertion  
During exercise, ratings of perceived exertion (RPE) were recorded as a subjective measure of 
effort using the 15-point Borg (1982) 6-20 scale, where 6 represents ‘no exertion’, and 20 
represents ‘maximal exertion’. For the graded incremental test (section 3.4.2), RPE was 
recorded every 2 min and at the end of exercise. From this point forward, including the 
familiarisation trial, overall RPE (RPEo) and leg RPE (RPEL) was recorded at every 500 m 
segment of the 4 km TT. A localised measure was used to separate for overall cardiovascular 
strain (i.e. RPEO) and fatigue feelings specific to the leg musculature (i.e. RPEL), as RPE from 
specific exercising muscles is suggested to be positively related to blood H+, and therefore 
sensitive to changes elicited by NaHCO3 ingestion (Robertson et al., 1986).  
 
3.3.2 Gastrointestinal discomfort 
In each experimental chapter, subjective feelings of nausea, flatulence, stomach cramp, bowel 
urgency, diarrhoea, vomiting, and stomach bloating were measured at various time points. To 
do this, a visual analogue scale (VAS) was used, with the scale anchored at each end of a 20 
cm line with ‘no symptom’ to the left and ‘severe symptom’ to the right (Appendix 1). The use 
of VAS scales have been shown to be reliable to determine symptoms of pain such as stomach 
discomfort/abdominal pain, displaying ICC scores of between 0.98 – 0.99 (Gallagher et al., 
2002; Bahreini et al., 2015). Similarly, VAS scales have been shown to be valid against an 
alternative common method of assessment of gastrointestinal discomfort, the Likert 11 point 
scale (0-10) (Hawker et al., 2011).  
 
If any symptom was scored, this was measured to the nearest millimetre and then subsequently 
divided by two, meaning ‘0’ represented ‘no symptoms’ and 10 represented ‘severe 
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symptoms’. Each experimental chapter describes the time intervals when this questionnaire 
was completed. Questionnaires were blinded from the researcher in an attempt to maintain the 
double blind study design. In the subsequent analysis the time to peak GI, and the highest point 
of severity in Chapters 4, 5a, and 5b was reported. Whilst in Chapters 6 and 7, the aggregated 
score of GI discomfort was also calculated and reported. The aggregated score was calculated 
by adding all of the symptoms suffered together throughout the ingestion period. If participants 
suffered a substantial amount of GI disturbance during any point of the study, they were 
permitted to voluntarily withdraw from the study.  
 
3.4 Exercise protocols  
3.4.1 Warm up 
Except for Chapter 6, participants completed a self-selected warm-up of between 5 and 10 min. 
This warm-up was then recorded and subsequently repeated in all further trials. The warm-up 
was standardised to 60% of the peak power output achieved at VO2max in Chapter 6, to quantify 
anaerobic/aerobic contributions during the 4 km TT. Due to technical/validity issues with the 
gas analyser operating at hypoxia however, this data does not feature within the thesis. 
Nonetheless, this standardised warm-up was used to quantify the effects of a warm-up on the 
corresponding changes in HCO3
- following NaHCO3 supplementation.  
 
3.4.2 Graded incremental exercise test 
Each participant initially completed a maximal rate of oxygen uptake (VO2max) test prior to 
experimental testing as a marker of fitness level. This was completed on an electromagnetically 
braked cycle ergometer (Excalibur Sport, Lode, Netherlands), which also allowed for the 
determination of peak power output (PPO). Following a self-selected warm up, the exercise 
test began at 75 W for 1 min. Thereafter, this increased by 1 W every 2 s (30 W.min-1) until the 
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point of volitional exhaustion. This exhaustion point was determined by the inability of the 
participant to maintain their self-selected cadence (range = 70 – 100 rev.min-1) for longer than 
5 s on two occasions, whereby in the first instance, the participant was given a warning, and 
the test was then terminated on the subsequent occurrence. This load was selected to ensure the 
participant finished between 7 and 26 min, which is considered valid for a VO2max test (Midgley 
et al., 2008). All participants achieved the set criteria for achievement of a valid maximal test 
as outlined by Bird and Davison (1997). Specifically, participants reached within 10 b.min-1 of 
age predicted maximal HR (220 b.min-1 – age), a blood lactate of >8 mmol.l-1, a respiratory 
exchange ratio (RER) ≥1.15, and an RPE of between 19 and 20 at the end of exercise. The PPO 
output was determined by the power at the end of the test, whilst VO2max was determined as 
the highest 30 s rolling average of VO2 (l
.min-1). 
 
3.4.3 Cycling time trial  
Using the cycle ergometer described previously, participants were required to complete a 4 km 
TT (section 3.2.3). Participants were asked to mimic a competition scenario, where they were 
required to complete the distance in the fastest time possible. Equally, participants were given 
strong, consistent verbal encouragement throughout the task. This consisted of a verbal cue 
every 0.1 km until the last 1 km, where cues were provided throughout with feedback on 
distance left every 100 m. In both Chapters 5a and 5b, participants were provided with feedback 
on distance covered, power (W), cadence (rev.min-1) and current gear via a digital display 
(Thomas et al., 2015). This feedback was provided as cyclists used in this study were not 
habitually completing 4 km TT distances in competition. Whereas, in Chapters 6 and 7, 
participants were provided with the same feedback, with the exclusion of power (W) (Stone et 
al., 2011). This was due to the participant’s greater familiarity with 4 km TT’s compared to 
those in Chapters 5a and 5b, and these studies were also conducted at hypoxia. During exercise, 
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measures for both RPEO and RPEL were recorded every 1 km, while HR and time splits were 
recorded every 500 m in all experimental chapters, excluding Chapter 4. 
 
3.4.4 Ingestion of sodium bicarbonate and sodium chloride 
Treatments were administered with either 0.2 g.kg-1 BM, 0.3 g.kg-1 BM NaHCO3, or a taste-
matched placebo containing 0.07 g.kg-1 BM NaCl. Treatments were mixed with 400 ml water 
and 50 ml no added sugar, double-strength squash (blackcurrant squash, Herritage, UK). In 
contrast to previous research utilising a placebo containing 0.21 g.kg-1 BM NaCl, pilot testing 
suggested this could not be taste-matched against either of the NaHCO3 treatments. Participants 
were requested to complete ingestion within a 10 min window, and drinks were refrigerated 
prior to ingestion to increase the palatability and administered in black bottles (Price and Singh, 
2008, Higgins et al., 2013). Each specific chapter describes the method utilised to determine 
time to peak HCO3
-.  
 
A supplement belief questionnaire was administered in Chapters 6 and 7, to confirm the 
supplement was successfully taste-matched. Participants were asked at individual time to peak 
alkalosis, and at the end of each trial how confidently they could determine the supplement 
they had ingested using a 1-5 Likert scale with 1 representing ‘not confident at all’, and 5 
representing ‘extremely confident’. If participants scored above a 3, they were then asked 
which supplement they perceived they had ingested.  
 
3.5 Statistical analysis 
3.5.1 Power calculations 
Researchers are strongly encouraged to determine the estimated sample size required to achieve 
‘acceptable’ statistical power. This is typically set at a threshold of 80% (McCrum-Gardner, 
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2010), which suggests if the study was repeated 1000 times statistical significance would be 
observed 80% of the time. Where appropriate, prior power calculations were used to determine 
the appropriate sample sizes required (Chapters 4, 5a, and 5b). A variance explained model 
was used for Chapter 4 as this was a reliability study, while, a difference in means approach 
was used for Chapters 5a and 5b. The difference in means was determined using unstandardised 
measures, which is based on historical data and is considered a valid approach to determine an 
appropriate sample size (Jones, Carley and Harrison, 2003, McCrum-Gardner, 2010). Power 
calculations were not conducted for Chapters 6 and 7, due to the lack of historical data available 
to estimate the required change in performance required in acute hypoxia. Rather, post-hoc 
analysis of observed power from the analysis of variance test (ANOVA) was checked in SPSS 
to ensure an appropriate sample was included. All power calculation analysis was conducted 
using SPSS Sample Power 3 (IBM, USA).  
 
3.5.2 General statistical procedures  
3.5.2.1 Differences procedures 
Initially, all data was analysed for normality and homogeneity of variance/sphericity using 
Shapiro-Wilk and Mauchly tests. If data was normally distributed, the appropriate parametric 
test was conducted. This was primarily a t-test, or a repeated measure ANOVA with a 
Bonferroni correction applied. Degrees of freedom and p values were corrected if sphericity 
was violated by using the appropriate corrections of Huyn-Feldt (epsilon value >0.75) or 
Greenhouse-Geiser (epsilon value <0.75). A violation was identified at the statistical level of 
p <0.05 from the Mauchly test. In Chapter 4, Tukey’s honestly significant difference (HSD) 
post hoc analysis was used to determine the minimal difference between means required to 
confirm significance at the alpha (α) level of .05 or .01 (Vincent and Weir, 2012). In all other 
Chapters (5a, 5b, 6, and 7), post hoc pairwise comparisons were determined by the Bonferroni 
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correction. Partial eta squared (Pη2) effect size is reported where main effects or interactions 
are observed, and are interpreted as small (<0.01), medium (0.01 – 0.06), and large (≥0.14) 
(Cohen, 1988). Between treatment effect sizes (g) were calculated where appropriate using the 
difference in means divided by the pooled SD of the compared trials (Nagakawa and Cuthill, 
2007), with the addition of a Hedge’s g bias correction to account for the bias in Cohen’s d 
effect size with sample sizes of less than 20 (Lakens, 2013). Between treatment effect sizes are 
considered trivial (<0.20), small (0.20-0.49), medium (0.50-0.79) and large (≥0.80), in 
accordance with conventional Cohen’s d interpretations (Cohen, 1988). If normality of data 
was violated, the appropriate non-parametric test was used (i.e. Wilcoxon, Mann-Whitney U 
Test or Friedman rank test). Between treatments effect sizes for these tests were calculated by 
Z/√n and interpreted as small (0.10), medium (0.24), or large (>0.37) (Ivarsson et al., 2013). 
Further frequentist inferences included the 95% confidence interval (CI), which were assessed 
against the mean difference between trials. Variances that do not cross the zero-boundary are 
treated as significant. 
 
In Chapters 6 and 7, a magnitude based inferences (MBI) approach was used as a method to 
detect the practical outcome of the interventions. These were calculated using a widely 
available spreadsheet (Batterham and Hopkins, 2006) and interpreted using the thresholds of 
<1% almost certainly not; 1-5% very unlikely; 5-25% unlikely; 25-75% possibly; 75-95% 
likely; 95-99% very likely; >99% almost certainly. The threshold values for benefit or harm 
were determined by the calculated typical error (TE) of the 4 km TT in each chapter, whereby 
this TE percentage was converted into an absolute value and then placed in the spreadsheet. 
The TE was selected as the threshold for improvement, as the Cohen d small effect size (0.2) 
is in many cases smaller than the meaningful change required to display a meaningful 
performance improvement. This contemporary statistical procedure substantiates inferences 
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from null hypothesis testing and effect sizes, whilst also reducing error rates (Hopkins and 
Batterham, 2016). Data is presented as mean ± SD with 95% confidence intervals (CI) unless 
otherwise stated. Statistical significance was set at p <0.05 and analysis was completed using 
a statistical software package (SPSS, V. 22, IBM, USA). 
 
3.5.2.2 Intra and inter-individual reliability procedures  
To determine test-retest reliability (intra-individual variation), Intraclass correlation coefficient 
(ICC) analysis was undertaken. A two-way mixed effects model was utilised to determine the 
absolute agreement between measures (i.e. time to peak HCO3
-), in accordance with the 
guidelines of Koo and Li (2016). Significance value (p value) and r value is reported, and 
categories of reliability are consistent with those of (Cicchetti, 1994) of poor (<0.40), fair (0.40-
0.59), good (0.60-0.74) or excellent (>0.75). This test is a widely used reliability index in Sport 
and Exercise Science (Hallgren, 2012), and considered stronger than the Pearson’s product-
moment correlation coefficient (Pearson’s r). Unlike Pearson’s r, an ICC can assess more than 
one retest, and it is sensitive to large intra-individual variation by accounting for both 
consistency of performances as well as the change in average performances over time (i.e. the 
change in the mean). Finally, this test can assess the complete agreement between sets, and not 
just the rank order (Atkinson and Nevill, 1998, Bland and Altman, 2003).  
 
Further tests of reliability included limits of agreement (LOA) with bland altman plots (Bland 
and Altman, 2003) and TE (Hopkins, 2000). The use of LOA provides an absolute value for 
bias within the variable being assessed, and limits where the individual differences between 
measures should fall for the test-retest to be acceptable. Assessed variables were initially 
checked to ensure data was not heteroscedastic, and thereafter, were analysed using 
calculations for bias (mean of differences between measures), standard deviation (SD of 
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differences between measures), lower limits (bias -1.96 x SD) and upper limits (bias + 1.96 x 
SD), as recommended by Bland and Altman (1986). A criticism of LOA analysis however, is 
that when the participant cohort is <25 subjects the resulting degrees of freedom can create 
greater bias than the 5% accepted limit (Hopkins, 2000). Therefore, accounting for the sample 
size in the individual study chapters, typical error (TE) is also reported where appropriate which 
is a measure of the average deviation from the mean between repeated experiments (Hopkins, 
2000). The benefit of this procedure is that TE is not sensitive to degrees of freedom, instead 
having an expected value independent of sample size. Furthermore, TE is viewed as a more 
sports performance measure compared to LOA analysis, and is commonly used to depict 
boundaries of variation in performance bouts. This was calculated as per the latest update of 
the Hopkins (2015) spreadsheet where typical error is displayed as a percentage and calculated 
by dividing the standard deviation of the differences between trials by √2. Thresholds were 
then subsequently interpreted as small (0.2), moderate (0.6), large (1.2), very large (2.0) and 
extremely large (4.0) (Hopkins, 2015). It is important to note, considerable debate on both LOA 
and TE as measures of reliability exist between Hopkins (supporter of TE analysis) and 
Atkinson and Nevill (supporters of LOA analysis). Considering the purpose of this thesis is not 
statistical in nature however, both were therefore considered throughout the thesis. The reader 
is directed to more pertinent literature on these topics (Atkinson and Nevill, 1998, 2000, 
Hopkins, 2000).  
 
3.5.2.3 Missing data 
In the scenario of missing data, either through equipment or operator malfunction, hot deck 
imputation (HDI) was used to estimate the missing value, which is considered a valid approach 
when only 1 to 5% of data is missing following an experiment (Myers, 2011). Estimation of 
missing values were determined using an adapted version of Schafer and Graham (2002), 
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whereby data from observations from other similar participants were used, or where possible, 











































Chapter 4 – The Reproducibility of Blood Acid Base 




















Exogenous enhancement of the bicarbonate buffering systems is thought to have an important 
role in offsetting metabolic fatigue, by dampening critical rises in hydrogen ions (H+) (Sahlin, 
1978, Fitts, 2016). In response, ingestion of sodium bicarbonate (NaHCO3), a known alkalotic 
buffer, has been widely investigated (McNaughton et al., 2016). This can attain an increase of 
blood bicarbonate concentration (HCO3
-) within the extracellular fluid by around 4 to 8 mmol.l-
1 following ingestion of between 0.2 and 0.3 g.kg-1 BM NaHCO3 (Jones et al., 2016). Lower 
amounts are considered insufficient to induce a level of peak alkalosis that would improve 
performance (Carr et al., 2011a), whilst doses above this exacerbate the incidence and severity 
of gastrointestinal (GI) discomfort (McNaughton, 1992a).  
 
Studies have previously investigated the dose-response to NaHCO3 and the resulting increases 
of pH and HCO3
- following ingestion, however have reported a high inter-individual variation 
to determine when peak changes in these analytes occur. Indeed, Siegler et al. (2010) 
previously reported following both 0.2 and 0.3 g.kg-1 BM NaHCO3, peak HCO3
- occurred at 
40 and 60 min, respectively. Other studies however, have observed peaks at 90 (Renfree, 2007, 
Price and Singh, 2008), 120 (Carr et al., 2011a) and 180 min (Siegler et al., 2010). Whilst these 
differences might be due to infrequent sampling rates and different ingestion protocols, it is 
more likely there is a large degree of inter-individual variability in blood responses. Equally, a 
mean group analysis approach has been used, which may subsequently overlook some 
important individual acid base balance changes NaHCO3 ingestion elicits. Consequently, this 
may explain, in part, the common inter-individual performance responses following NaHCO3 




Several contemporary studies have addressed these previous limitations by supplementing 
NaHCO3 at a pre-determined individual time to peak pH or HCO3
- (Miller et al., 2016, Jones 
et al., 2016, Deb et al., 2017, 2018a). This is in response to the high inter-individual variation 
reported to achieve time to peak alkalosis, as Miller et al. (2016) reported time to peak pH 
ranged between 10 and 90 min following fluid ingestion of 0.3 g.kg-1 BM NaHCO3. Whereas, 
Jones et al. (2016) reported time to peak HCO3
- ranged between 40 and 165 min following 0.2 
g.kg-1 BM NaHCO3 and 75 to 180 min following 0.3 g
.kg-1 BM NaHCO3 in capsules. Clearly, 
these findings challenge the conclusions of the studies analysing time to peak alkalosis on mean 
group responses. Furthermore, a number of studies (Miller et al., 2016, Deb et al., 2017, 2018a) 
have reported ergogenic effects on performance following NaHCO3 ingestion at either 
individual time to peak pH or HCO3
-. These improvements have been found despite previous 
studies using a standardised time frame of NaHCO3 reporting a reduced, or no effect at all on 
performance in similar exercise protocols (Bishop et al., 2004, Vanhatalo et al., 2010). 
Nonetheless, whilst this is promising, no research to date has investigated the reproducibility 
of the time to peak and absolute changes in blood acid base balance analytes following 
NaHCO3 ingestion.  
 
A better understanding of the reproducibility of individual time to peak alkalosis following 
NaHCO3 is required. In the current research to date, the approach to determine individual time 
to peak has varied with some opting for pH (Miller et al., 2016, Deb et al., 2017) and others 
HCO3
- (Deb et al., 2018a). Consequently, it is unknown which analyte is the most appropriate 
to determine the individual NaHCO3 ingestion strategy to elicit consistent increases of the acid 
base balance prior to exercise. Furthermore, it is unknown to what degree daily biological 
variation and nutritional practices may affect the bioavailability of pH and HCO3
- following 
NaHCO3 ingestion, which may in turn, compromise the reliability of the individual time to 
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peak pH and/or HCO3
- (Remer and Manz, 1995, Remer, 2001, Poupin et al., 2012). Quantifying 
how these factors affect the time to peak pH and HCO3
- will allow athletes to appropriately 
evaluate if using an individualised NaHCO3 ingestion strategy can elicit consistent blood 
responses, and hence, performance responses. The aim of the study therefore, was to assess the 
reproducibility of individual blood pH, HCO3
- and Na+ responses following acute ingestion of 
0.2 or 0.3 g.kg-1 BM NaHCO3. The hypothesis of this study was that the blood and GI 
discomfort would display at least a good level of reproducibility irrespective of the dose.  
 
4.2 Materials and Methods 
4.2.1 Participants 
Participants were recruited on the basis they may gain a performance benefit from enhancing 
their buffering capacity (Bishop et al., 2011). As a result, sixteen team and individual sports 
participants with backgrounds in rugby, football and running volunteered for this single blind, 
randomised, crossover designed study. One participant withdrew from the study due to GI 
discomfort (vomiting) from NaHCO3 (0.3 g
.kg-1 BM dose; first session), therefore 15 male 
participants (n = 5 rugby, n = 7 football, n = 3 sprinting) completed the study (height 1.81 ± 
0.06 m, body mass 84 ± 8 kg, age 21 ± 2 years, VO2max 52.1 ± 2.2 ml
.kg-1.min-1). Participants 
habitually completed four exercise bouts per week (4 ± 1 p.wk-1), lasting two hours per session 
(2 ± 0 hr) and had ten years training experience (10 ± 3 years) within their respective sports. 
Ethical approval was obtained from Departmental Research Ethics Committee (SPA-REC-
2015-325) and each participant provided written informed consent and completed a health 






4.2.2 Pre-experiment procedures 
Participants visited the laboratory on seven occasions at the same time of day to minimise the 
effects of circadian rhythms (Reilly, 1990) and 4 hr postprandial. Participants followed the 
procedures detailed in section 3.1.4.  
 
4.2.3 Main experimental procedures  
Initially, an incremental ramp maximal oxygen uptake (VO2max) test on an electromagnetically 
braked cycle ergometer was conducted (Lode Excalibur, Germany). The procedure for this is 
detailed in section 3.4.2. Thereafter, administered in a block randomised method, the 
subsequent six visits entailed two treatments of 0.2 g.kg-1 BM (SBC2a, SBC2b), two with 0.3 
g.kg-1 BM NaHCO3 (SBC3a, SBCC3b), and two control treatments (CONa, CONb). 
Treatments were single blinded from participants. 
 
An arterialised finger prick capillary blood sample was obtained from the finger whilst in a 
rested and seated state, prior to NaHCO3 ingestion. Arterialisation was achieved by warming 
the hand with a heated blanket (45°C) for 5 min prior to each individual sample (Johnston et 
al., 1996). After NaHCO3 ingestion, a further 15 blood samples were obtained over a 180 min 
period in each treatment to obtain time to peak pH, HCO3
-, and Na+, whilst GI discomfort was 
monitored every 10 min. The peak value was determined by the largest value for each blood 
analyte. If two values were the same during the ingestion period, the earlier value was recorded 
as the peak. Participants remained seated throughout, with only toilet breaks permitted. No 
food could be consumed during this period, and water was consumed ab libitum, with total 





4.2.4 Statistical analysis 
A priori power calculation was conducted, which was based upon the expected population 
correlation of r = 0.80 between both NaHCO3 conditions (SBC2 and SBC3). A minimum of 
11 participants were required to achieve 80% power (p <0.05).  
 
Assessed variables were initially analysed for normality (Shapiro-Wilks and Q-Q plots) and 
homogeneity of variance/sphericity (Mauchly), respectively. To assess the differences between 
conditions for time to peak and absolute changes from baseline in blood analytes, t tests were 
used. For non-normally distributed data, a Mann-Whitney U test was used with Z score and 
significance reported (e.g. GI discomfort). Likewise, for violations of sphericity the appropriate 
correction was applied (Greenhouse Geisser). Both one (treatment) and two (treatment * time) 
way repeated measures ANOVA were used to analyse differences in blood parameters across 
the ingestion period with Bonferroni-corrections applied. Tukeys honestly significance 
difference (HSD) post-hoc analysis was carried out to assess interactions, by calculating the 
minimal difference required between means to identify significance had been achieved (section 
3.5.2, Vincent and Weir, 2012). Statistical significance was set a p >0.05. 
 
To assess within-subject variance and to determine if data was heteroscedastic, limits of 
agreement (LOA) were used (Bland and Altman, 1986) was used for pH, HCO3
- and Na+. In 
addition, Intraclass correlation coefficient (ICC) analysis was conducted to assess intra-
individual variation (Koo and Li, 2016). Coefficient of variation (CV) is reported using 
SD/mean*100. Correlation between HCO3
- and pH time to peak was calculated using Pearson 
correlation, from an online spreadsheet (Hopkins, 2000). A more detailed description of the 





4.3.1 Nutritional intake 
Total daily calorie intake was highly reproducible for all treatments (r = 0.78, p <0.001; Mean 
± SD = 2283 ± 75), as was carbohydrate (r = 0.97 p <0.001; 253 ± 4 g), protein (r = 0.98, p 
<0.001; 85 ± 2 g) and fat (r = 0.97, p <0.001; 126 ± 3 g) intake. 
 
4.3.2 Reproducibility of blood pH, bicarbonate and sodium 
Baseline measures for both HCO3
- (r = 0.83, p <0.001) and Na+ (Na+ r = 0.86, p <0.001) 
displayed excellent reproducibility, whereas pH displayed good reproducibility (r = 0.66, p = 
0.002). Values for ICC across the three hour sampling period ranged from fair to excellent (r 
= 0.53-0.91) for pH in SBC2, and good to excellent (r = 0.76-0.92) in SBC3 upon excluding 
two poor values at 80 (r = 0.05) and 85 min (r = 0.01). Higher reproducibility for HCO3
- was 
observed compared to pH however, such that SBC2 demonstrated excellent reproducibility (r 
= 0.76-0.87), whereas SBC3 displayed good to excellent (r = 0.65-0.87) reproducibility across 
all time points (Table 4.1).  
 
Greater reproducibility of the time to peak HCO3
- was demonstrated for SBC3 (ICC: r = 0.94, 
p < 0.001; LOA: B 2.3, -15.9 +20.5) compared to SBC2 (ICC: r = 0.77, p = 0.003; LOA: B -6, 
-36, +24). Likewise, time to peak pH demonstrated a greater reproducibility for SBC3 (ICC: r 
= 0.71, p = 0.016; LOA: B 2.3, -37.3, +42) than for SBC2 (ICC: r = 0.62, p = 0.044; LOA: B 
2.3, -39.3, +42). The correlation between time to peak pH and HCO3
- was greater in SBC2 (r 
= 0.61 and r = 0.66, respectively) than in SBC3 (r = 0.26 and r = 0.17, respectively). The 
reproducibility of time to peak Na+ was greater for SBC2 (ICC: r = 0.75, p = 0.838; LOA: B 





- change from baseline to peak displayed high reproducibility for SBC2 
(ICC: r = 0.90, p <0.001; LOA: B 0.1, -0.9, +1.1) compared to SBC3 (ICC: r = 0.76, p = 0.008; 
LOA: B 0.1, -1.9, +2.0). The absolute change in pH was more reproducible in SBC2 (ICC: r = 
0.84, p = 0.001; LOA: B -0.1, -0.04, +0.03) compared with SBC3 (ICC: r = 0.62, p = 0.04; 
LOA: B 0.01, -0.04, +0.05), however not as reproducible as the absolute change from baseline 
to peak HCO3
-. In contrast, the absolute change in Na+ displayed poor reproducibility in both 
SBC2 (ICC: r = 0.10, p = 0.56; LOA: B 0.1, -4.9, +5.1) and SBC3 (ICC: r = 0.10, p = 0.43; 
LOA: B 1.3, -6.2, +8.7).  
 
4.3.3 Differences between treatments  
Time to peak HCO3
- was not significantly different between SBC2 and SBC3 (all p >0.05) 
(Table 4.2). Whereas, time to peak pH occurred significantly later in SBC3a compared to 
SBC2a (+17 min; p = 0.03). In SBC3b versus SBC2b however, time to peak pH was non-
significantly different (+8 min; p = 0.392) (Table 4.2). Time to peak Na+ occurred significantly 
later in SBC3a compared to SBC2a (+32 min; p = 0.03) and 25 min later for SBC3b compared 
to SBC2b (p = 0.06). A large inter-individual variation in time to peak pH, HCO3
- and Na+ was 
observed following both SBC treatments (Table 4.2).  
 
The absolute change from baseline to peak in pH, HCO3
- and Na+ are depicted in Table 2, 
which all displayed a high inter-individual variation. The absolute change in HCO3
- was greater 
for SBC3 compared to SBC2 (p <0.001; Table 4.2). The absolute change in pH was greater for 
SBC3a compared to SBC2a (+0.2; p = 0.02), however, not different between SBC3b and 
SBC2b (+0.1; p = 0.24; Table 4.2). Absolute change in Na+ was significantly greater in SBC3 
than in SBC2 (p >0.05; Figure 4.1). Lastly, pH and HCO3
- were not significantly different up 
to 60 min between SBC treatments (p >0.05; Figure 4.1). 
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Figure 4.1 Mean blood analyte responses for blood bicarbonate (HCO3
-), pH and sodium (Na+) 
following CON, SBC2 and SBC3. Some error bars and time points (5 min interval samples) 
are omitted for clarity.
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Table 4.1 Statistical summary table of limit of agreement analysis (LOA) and coefficient of variation (CV) of both blood pH (A) and bicarbonate 
(HCO3
-) (B) following SBC2 and SBC3. Time points included cover the respective time taken to achieve peak time to peak pH or HCO3
-.  
A (pH)             
             
SBC2                         
   Time Point 40 60 80 85 90 95 100 120 125 130 135 140 
LOA                         
    Bias -0.001 -0.007 0.001 0.004 -0.002 -0.001 -0.001 0.000 -0.008 -0.007 -0.004 0.001 
    SD 0.020 0.020 0.010 0.020 0.020 0.020 0.020 0.020 0.020 0.030 0.020 0.010 
     - -0.040 -0.050 -0.020 -0.040 -0.030 -0.030 -0.030 -0.030 -0.050 -0.060 -0.030 -0.030 
    + 0.040 0.040 0.030 0.050 0.030 0.030 0.030 0.030 0.030 0.040 0.020 0.030 
 
CV 0.4 0.3 0.3 0.2 0.2 0.3 0.3 0.3 0.3 0.3 0.4 0.3 
Interpretation Excellent Excellent Excellent Excellent Excellent Excellent Excellent Excellent Excellent Excellent Excellent Excellent 
 
SBC3             
   Time Point 40 60 80 85 90 95 100 120 125 130 135 140 
LOA             
   Bias -0.001 0.005 0.003 0.002 0.007 -0.002 0.002 0.006 0.005 0.001 0.005 0.005 
   SD 0.010 0.020 0.030 0.020 0.010 0.020 0.020 0.020 0.020 0.020 0.020 0.020 
   - -0.030 -0.020 -0.050 -0.030 -0.020 -0.040 -0.040 -0.030 -0.030 -0.030 -0.030 -0.030 
   + 0.030 0.040 0.060 0.030 0.030 0.040 0.040 0.040 0.040 0.030 0.040 0.040 
 
CV 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.3 





SBC2          
   Time Point 40 60 80 85 90 95 100 120 125 
LOA          
   Bias 0.1 0.4 0.4 0.3 0.5 0.2 0.3 0.3 0.0 
   SD 1.4 1.2 1.1 1.2 1.1 1.2 1.0 1.1 0.9 
    - -2.7 -2.0 -1.9 -2.0 -1.7 -2.1 -1.7 -1.8 -1.8 
   + 2.8 2.7 2.6 2.6 2.7 2.5 2.2 2.4 1.8 
 
CV 6.2 5.4 5.2 4.2 4.6 5.1 4.5 4.8 4.6 
Interpretation Good Good Good Excellent Excellent Good Excellent Excellent Excellent 
 
SBC3          
   Time Point 40 60 80 85 90 95 100 120 125 
LOA          
   Bias -0.1 0.0 0.0 0.1 0.0 0.1 -0.1 0.3 0.3 
   SD 1.0 1.1 1.2 1.2 1.2 1.2 1.2 1.5 1.1 
    - -2.2 -2.3 -2.4 -2.3 -2.4 -2.3 -2.4 -2.6 -1.7 
   + 1.9 2.2 2.4 2.4 2.4 2.4 2.2 3.2 2.4 
 
CV 3.6 3.8 4.6 4.7 5.1 5.5 5.5 5.6 4.7 
Interpretation Excellent Excellent Excellent Excellent Good Good Good Good Excellent 




Table 4.2 Individual data displaying time to peak (TTP) and absolute change (peak change from baseline) in both blood pH and bicarbonate 
(HCO3
-) (mmol.l-1) following SBC treatments. CV = coefficient of variation, SEM = standard error of measure. Numbers in bold represent where 
TTP occurred ±10 min of the group mean. 
* TTP = time to peak, CV = coefficient of variation, SEM = standard error of mean. 
pH 
(TTP)     
HCO3
- 
(TTP)    
pH 
(Abs. ∆)     
HCO3
- 
























1 80 85 125 95 80 85 125 100 0.08 0.05 0.08 0.07 6.8 5.6 6.9 5.6 
2 85 120 80 85 85 80 80 80 0.03 0.06 0.07 0.08 5.0 4.8 6 5.4 
3 80 40 125 100 60 60 90 90 0.07 0.08 0.13 0.08 6.0 7.2 6.5 6.3 
4 40 40 60 60 60 60 95 95 0.07 0.07 0.14 0.13 4.8 4.9 7.9 8.0 
5 60 60 90 90 60 60 85 85 0.06 0.10 0.14 0.07 7.1 7.2 9.3 7.1 
6 60 125 80 140 80 125 100 120 0.10 0.12 0.09 0.09 7.1 7.3 8.3 8.4 
7 140 135 130 130 85 85 60 60 0.10 0.10 0.08 0.07 5.3 5.0 6.5 6.6 
8 100 130 100 90 85 95 100 90 0.11 0.10 0.10 0.09 7.2 7.2 7.5 9.3 
9 40 60 100 100 60 85 95 95 0.11 0.14 0.12 0.12 5.2 5.4 7.3 7.0 
10 40 130 80 80 95 85 80 80 0.06 0.06 0.08 0.10 5.2 5.0 6.2 6.2 
11 120 135 135 120 85 85 120 120 0.10 0.10 0.10 0.09 4.8 4.3 4.9 6.1 
12 60 40 90 100 60 40 40 40 0.05 0.04 0.05 0.08 5.0 4.9 5.9 6.2 
13 140 95 125 120 100 125 95 80 0.07 0.06 0.10 0.10 4.8 4.6 8.8 7.7 
14 95 100 120 95 85 95 85 80 0.07 0.07 0.10 0.11 5.4 4.7 6.6 8.1 
15 130 85 90 90 80 85 90 90 0.07 0.10 0.09 0.10 6.1 6.1 7.8 7.6 
Mean 85 92 102 100 77 83 89 87 0.08 0.08 0.10 0.09 5.7 5.6 7.1 7.0 
SD 35 37 23 20 14 23 21 20 0.02 0.03 0.02 0.02 0.9 1.1 1.2 1.1 
CV 41 39 22 20 17 26 23 22 29 31 25 23 16 18 14 17 
SEM 9.2 9.5 6.0 5.3 3.6 5.9 5.4 5.2 0.01 0.01 0.01 0.00 0.2 0.3 0.3 0.3 
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Table 4.3 The most severe individual symptom of GI upset suffered following SBC treatments. 
P.no SBC2a SBC2b SBC3a SBC3b  
1 None None None None 
2 Flatulence None None None 
3 Flatulence None Bowel Urgency Bowel Urgency 
4 Stomach Cramp Belching Belching Stomach Ache 
5 None None None None 
6 None None None None 
7 Stomach Bloating Stomach Cramp Bowel Urgency Stomach Ache 
8 Stomach ache Nausea Stomach cramp Diarrhoea 
9 Bowel urgency Bowel urgency None Stomach bloating 
10 Stomach Bloating Stomach Bloating Stomach Ache Stomach Ache 
11 Diarrhoea Diarrhoea Diarrhoea Diarrhoea 
12 None None Bowel Urgency None 
13 Nausea Nausea Nausea Nausea 
14 None None None None 
15 None None None None 
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4.3.4 Gastrointestinal discomfort 
Both the severity, and time to peak GI discomfort displayed excellent reproducibility in SBC2 
and SBC3 (severity SBC2 r = 0.92, p <0.001; LOA: B -0.5, -3.1, +2.2; time to peak SBC2 r = 
0.91, p <0.001; LOA: B 5, -38, +47 vs. severity SBC3 r = 0.90, p <0.001; LOA: B -0.4, -4.7, 
+3.8; time to peak SBC3 r = 0.78, p = 0.005; LOA: B 7, -64, 77). In total 10 of the 15 
participants reported symptoms of GI discomfort following NaHCO3 (Table 4.3). The severity 
of GI discomfort was decreased in SBC2 compared to SBC3 (mean = 2.0 vs. 3.6), however not 
significantly (z = 0.92, p = 0.36). In SBC2 the time to peak GI discomfort was established 
earlier compared to SBC3 (mean = 29 vs. 36 min), but this was also not significant (z = 0.44, 
p = 0.66). 
 
4.4 Discussion 
This is the first study to investigate the reproducibility of pH, HCO3
- and Na+ following acute 
NaHCO3 ingestion. The current study shows the reproducibility of both the time to peak and 
the absolute changes from baseline in both pH and HCO3
- following NaHCO3 are generally 
excellent, whilst Na+ displays poor reproducibility. The time to peak and absolute change from 
baseline in HCO3
- displayed the greatest level of reproducibility following both NaHCO3 doses 
however, suggesting athletes and practitioners should develop their respective NaHCO3 dosing 
strategies based on time to peak HCO3
-. Lastly, based on both NaHCO3 doses increasing acid 
base balance to the 5 mmol.l-1 threshold suggested to elicit ergogenic effects on performance  
(SBC2 = 12/15, SBC3 = 15/15; Carr et al., 2011a), future research should compare the effects 
of these two doses on performance.  
 
In the current study, greater reproducibility was observed for the time to peak HCO3
- following 
both NaHCO3 doses compared to pH. Inconsistencies in pH reproducibility could be explained 
98 
 
by the breadth of factors that affect pH, including contributions from intracellular buffering 
such as carnosine, phosphocreatine and phosphates (Goel and Calvert, 2012). Moreover, as 
ingestion of a NaHCO3 bolus will initially and directly increase HCO3
- concentration the effect 
on pH is secondary, and therefore may lead to increased variability (Goel and Calvert, 2012). 
A more variable pH has also been observed in a previous study, such that the change in pH 
from baseline to peak displayed a CV of 18%, compared to 3% for the change in HCO3
- (Dias 
et al., 2015). No reproducibility statistics were used in this study however, and these 
observations are also based on group mean data. Nonetheless, a study by Carr et al. (2012) has 
also reported a large TE of 2.4% (CV 7.3%) for HCO3
- following NaHCO3 on two separate 
occasions. This study analysed the absolute HCO3
- value 120 min post-ingestion however, and 
not the absolute changes from baseline, which would have been a better marker of 
reproducibility. The present study therefore, for the first time, has assessed the changes in blood 
analytes using appropriate statistical tests. As such, the results suggest that the time to peak and 
absolute changes in HCO3
- are more reproducible compared to pH, and therefore a time to 
individual HCO3
- peak should be employed. Further work is required investigating the 
performance responses following this strategy.   
 
In some participants, the absolute HCO3
- change lacked reproducibility (SBC3 n = 6; SBC2 n 
= 2), with differences of over the standard error of measurement (0.2 – 0.3 mmol.l-1) in each 
NaHCO3 treatment, respectively. Participant 1 for example elicited a 6.9 mmol.l
-1 change in 
HCO3
- from baseline to peak in SCB3a, compared with a 5.6 mmol.l-1 change in SBC3b. 
Furthermore, eight participants failed to reproduce a similar time to peak HCO3
-, with 
differences between peaks over the standard error of measurement (>5min) after repeated 
NaHCO3 ingestion (both SBC2 and SBC3). It is unclear why this occurred given that 
participants replicated nutritional intake. Nonetheless, these findings suggest some individuals 
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may require a test-retest to evaluate the reproducibility of the absolute change in HCO3
-. 
Clearly, this presents a logistical limitation to the practitioner/athlete. Whether such 
discrepancies would translate to a lack of consistency in the performance responses is 
unknown, however, McNaughton (1992a) has previously demonstrated that differences of 
around 1 mmol.l-1 in HCO3
- elicited different performance responses. Future work should 
therefore assess whether such discrepancies in either time to peak or the absolute HCO3
- change 
from baseline following NaHCO3 ingestion affects the reproducibility of the performance 
response. 
 
In four of the participants in the current study, the absolute change in HCO3
- following SBC2 
was not enhanced further following SBC3. For instance, participant 1 displayed a minimal 
improvement of 0.1 mmol.l-1 between SBC2 and SBC3. In comparison, participant 13 
increased nearly two-fold between SBC2 (+4.8 mmol.l-1) and SBC3 (+8.8 mmol.l-1). This 
indicates that ingestion of 0.2 g.kg-1 BM NaHCO3 may be a physiologically optimal dose to 
heighten buffering capacity in some individuals, suggesting doses above this threshold are not 
warranted. In turn, identification of the absolute HCO3
- change between different doses of 
NaHCO3 is required, as some do not display any further increase in HCO3
- from NaHCO3 doses 
over 0.2 g.kg-1 BM. This finding could be of practical significance to individuals who 
experience severe GI discomfort from 0.3 g.kg-1 BM, given that the same acid base balance 
response can be elicited from a smaller dose. Further research could evaluate whether both 
doses improve performance to a similar extent in individuals who respond this way. 
 
The time to peak HCO3
- ranged between 40 and 125 min in both SBC2 and SBC3. This large 
inter-individual variation is in in agreement with the growing body of research reporting a 
similar inter-individual variation to achieve peak alkalosis (Miller et al., 2016, Jones et al., 
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2016, Deb et al., 2017, Deb et al., 2018a). As a result, these findings challenge the previously 
recommended timing of NaHCO3 ingestion of between 60 and 90 min (Renfree, 2007, Price 
and Singh, 2008), suggesting this is not optimal to heighten individual buffering capacity. This 
could be important for the resulting performance effect from NaHCO3, and in part, reduce the 
large inter-individual performance responses commonly observed (McNaughton et al., 2016). 
In addition, the increases in HCO3
- from baseline to peak following NaHCO3 ingestion were 
large using an individualised ingestion strategy (SBC2 5.7 mmol.l-1, SBC3 7.0 mmol.l-1), and 
greater than some employing a standardised time frame of ingestion (Dias et al., 2015, Siegler 
et al., 2012). Combined, it is recommended to heighten the level of alkalosis prior to exercise 
and therefore heighten the chance of an ergogenic benefit, a NaHCO3 ingestion strategy based 
on the individual time to peak HCO3
- should be employed. It is important to note however, this 
may be logistically challenging to individuals who do not have access to a blood gas analyser 
and laboratory.  
 
A novel finding of this study was that HCO3
- and pH did not significantly differ between SBC2 
and SBC3 up to 60 min, which supports previous findings (Jones et al., 2016). This suggests it 
may be possible for individuals to ingest a smaller dose if a limited time (60 min) is available 
before exercise, or if the individual does not have access to a blood gas analyser. This may be 
of significance to individuals who participate in two bouts of exercise with a small recovery 
time, such as the time between a heat and final in track cycling, swimming, and running 
(Monedero and Donne, 2000). In addition, this may be beneficial for athletes who experience 
GI discomfort, as lower doses have been shown to reduce the severity and incidence of such 




The Na+ response displayed high intra-individual variability following NaHCO3. In this study, 
participants replicated nutritional practices prior to experiments, and analysis revealed this was 
highly reproducible but not specifically for Na+ ingestion. Therefore, small changes in total 
Na+ ingested may explain these findings. Moreover, whilst the volume of water was controlled 
during experimental treatments, a limitation of this study is that the frequency of ingestion was 
not measured, which may have affected Na+ concentrations (Nose et al., 1987). Nonetheless, 
whether small differences in pre-trial Na+ ingestion or frequency of water consumption would 
account for a meaningful change is unclear. An alternative, but speculative factor may be 
gastric emptying, as previous research has reported a large intra-individual variability 
(Paintaud et al., 1998, Barnett et al., 1999, Tougas et al., 2000). Clearly, the analysis in the 
current study focused on blood Na+, and therefore potentially different quantities may have 
reached the bloodstream on the second intake of NaHCO3, and consequently produced varied 
responses. Future research may wish to investigate the impact of pre-exercise nutrition on Na+ 
and acid base balance following NaHCO3 ingestion.  
 
It is suggested the residual Na+ load through the neutralisation of the NaHCO3 bolus in the 
stomach can cause the onset of GI discomfort, as upon reaching the ileum and colon, can irritate 
the intestinal mucosa and cause osmotic fluctuations (Jones et al., 2016). When considering 
participants who experienced GI discomfort in this study, time to peak GI discomfort broadly 
corresponded with peak Na+ in SBC2 (peak GI discomfort ~30 min, peak Na+ ~41 min), but 
not as strongly in SBC3 (peak GI discomfort ~35 min, peak Na+ ~70 min). Moreover, the 
absolute change in Na+ was significantly higher in SBC3 than in SBC2 (~2 vs. ~6 mmol.l-1), 
however, the incidence and severity of GI discomfort did not differ significantly. As a result, 
whether the magnitude of change in blood Na+ is a good prediction of stomach Na+ movements 
is unclear, and therefore it is unlikely to predict the onset of GI discomfort. Interestingly, the 
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same severity of nausea in SBC2 and diarrhoea in SBC3 was observed in participant 8, with 
this theme apparent for seven participants in total. Furthemore, one participant withdrew from 
the study following ingestion of SBC3 due to vomiting. Clearly, the symptom suffered 
following SBC3 is more likely to affect the ability to perform exercise and therefore it is 
important to evaluate the severity of the specific symptom experienced and make judgements 
on the cost: benefit of NaHCO3 ingestion. 
 
4.5 Conclusion 
The increase in blood acid base balance following NaHCO3 ingestion is highly reproducible. 
The time to peak and absolute change from baseline was more reproducible for HCO3
- 
compared to pH however, and therefore athletes and practitioners should determine their 
individual strategy based on these responses. Caution should be taken however with individuals 
who display a large variability in blood responses, such that multiple trials may be required to 
establish their respective time to peak. Furthermore, as some individuals displayed marginal 
differences in blood acid base balance between NaHCO3 doses, it is worthwhile to monitor the 
responses from both doses. This will be of practical significance to individuals who suffer from 
GI discomfort, as they may opt for a lower dose. Similarly, both SBC2 and SBC3 elicited an 
absolute change in HCO3
- that suggests a performance improvement would be observed, 






















Chapter 5a – The Reproducibility of 4 km Time 
Trial Performance Following Individualised Sodium 



















5a.1 Introduction  
Athletes and coaches are continuously seeking to maximise the outcome of nutritional 
interventions to potentially improve or reduce the physiological adaptation from an 
intervention, or to improve competitive performance (Jeukendrup, 2017). This typically 
involves personalising a nutrition strategy to maximise both the bioavailability and bio-efficacy 
of the intervention within an individual (Kussmann and Fay, 2008). This concept can also be 
applied to the use of nutritional ergogenic aids aimed at enhancing human physiology and 
exercise performance. This is seldom considered in ergogenic aids research however, as 
commonly only the mean responses between groups and trials from a single treatment are 
determined (Hecksteden et al., 2015). Consequently, both the inter- and intra-individual 
responses are not evaluated. To solve this, repeated administration of the experimental 
treatment allows the reproducibility of nutritional ergogenic aids to be quantified (Hopkins, 
2000, Burke, 2017). The outcomes of such investigations allow athletes to appropriately assess 
if an ergogenic aid can provide consistent benefits to exercise performance upon repeated use 
during training and/or competition (Burke, 2017).  
 
The use of sodium bicarbonate (NaHCO3) is one example of a nutritional ergogenic aid that 
allows for repeated administration by representing a low cost and easy digestion. Primarily, 
NaHCO3 is used as an ergogenic aid to mitigate the effects of metabolic acidosis, by increasing 
blood bicarbonate (HCO3
-) buffering capacity (Bishop and Claudius, 2005). This has been 
shown to improve performance during short distance/duration high-intensity exercise of 
between 1 and 10 min (Carr et al., 2011a, McNaughton et al., 2016). Traditionally, NaHCO3 is 
standardised within studies to a single dose of 0.3 g.kg-1 BM NaHCO3 between 1 and 4 hours 
prior to exercise (McNaughton, 1992a, Saunders et al., 2014a, Siegler et al., 2010). Recent 
work has displayed the time to peak alkalosis displays a large inter-individual variation 
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however, with ranges of between 10 and 140 min to achieve either peak pH or HCO3
- (Miller 
et al., 2016, Jones et al., 2016, Deb et al., 2017, Chapter 4). Consequently, some athletes may 
not be ingesting this supplement at a time that corresponds to their peak buffering capacity, 
which might limit the resulting ergogenic effect. 
 
To account for the common inter-individual variation to achieve time to peak alkalosis, it is 
recommended NaHCO3 is administered at time point that corresponds with each individual’s 
time to peak pH or HCO3
- (Chapter 4, McNaughton et al., 2016, Jones et al., 2016, Deb et al., 
2017, 2018a). By doing so, this ensures that HCO3
- buffering capacity is maximised in all 
individuals. This, in turn, may therefore account for some of the equivocal performance data 
which has been observed using NaHCO3 (Higgins et al., 2013, Saunders et al., 2014a, Dias et 
al., 2015). This individualised strategy also suggests that 0.2 g.kg-1 BM NaHCO3 may be a 
physiologically optimal dose to improve performance. Specifically, Chapter 4 of this thesis 
displayed that the mean increase in HCO3
- from baseline to peak was +5.7 mmol.l-1 following 
this dose, and 12/15 participanted were within the 5 mmol.l-1 change suggested to heighten the 
potential of an ergogenic effect (Carr et al., 2011a). Furthermore, Chapter 4 also showed the 
reproducibility of these blood acid base balance responses were highly repeatable in Intraclass 
correlation coefficient (ICC) analysis (r = 0.77 to 0.94). Combined, this suggests through 
personalising the NaHCO3 ingestion strategy this may produce consistent, and ergogenic 
responses. To date however, the reproducibility of the performance responses using 
individualised doses of NaHCO3 have not been investigated.  
 
Previous research employing a standardised time frame of NaHCO3 ingestion has reported 
equivocal responses in terms of the reproducibility of performance (Carr et al., 2012, Dias et 
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al., 2015). Dias et al. (2015) reported a CV of 7.4% in performance responses following 
NaHCO3 in four separate repeated cycling bouts at 110% peak power output until exhaustion.  
Likewise, a lack of consistency in the ergogenic responses compared to a placebo was also 
observed, such that ten participants improved in at least one trial, however only one improved 
in all trials. Nonetheless, a factor contributing to this variation may be the exercise test 
employed, as this has displayed a high variation in previous research using untrained 
participants (Higgins et al., 2013). This lack of consistency might therefore be due to the 
exercise protocol, and not necessarily the failure of the NaHCO3 buffering mechanism. Carr et 
al. (2012) supports this, such that a low CV of 2.1% for mean power was reported between two 
repeated 2000 m rowing TT’s following 0.3 g.kg-1 BM NaHCO3. Of concern however, is the 
lack of ergogenic effect following NaHCO3 compared to the placebo. The authors did report 
variability in the blood responses however, whereby the HCO3
- value following NaHCO3 
ingestion displayed a very large typical error (TE) (2.5%) and CV (7%), which might explain 
why no performance effect was observed. Interestingly, only the peak absolute HCO3
- value 
was analysed however, whereas, the absolute change from baseline to peak would have 
arguably been a better representation of the reproducibility of the blood responses. 
Furthermore, both Dias et al. (2015) and Carr et al. (2012) employed a standardised NaHCO3 
ingestion strategy and only reported mean blood responses, which may have adversely effected 
the blood responses and thus, the interpretation of the data. Consequently, further research is 
warranted.   
 
A factor that may hamper the use of NaHCO3 in a practical sense is the onset of gastrointestinal 
(GI) discomfort. It is suggested that such instances have resulted in a fear of supplementation 
amongst athletes (Carr et al., 2011b), particularly considering it may negate the ergogenic 
effects (Saunders et al., 2014a). Therefore, whilst it is important to initially heighten the level 
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of peak alkalosis, it is equally important to mitigate GI discomfort. One strategy to reduce the 
severity of GI discomfort is a lower dose (0.2 g.kg-1 BM NaHCO3), which has been shown to 
reduce both the instances and the severity of the symptom suffered compared to 0.3 g.kg-1 BM 
(McNaughton, 1992a, Jones et al., 2016). This dose might not have been used as widely in 
previous research due to the previous standardised times of ingestion revealing increases in 
HCO3
- that are unlikely to improve performance. Or alternatively, due to the early findings of 
McNaughton (1992a) reporting 0.3 g.kg-1 BM produced greater ergogenic benefits compared 
to 0.2 g kg-1 BM NaHCO3. Nonetheless, considering with an individualised ingestion strategy 
an increase in HCO3
- (~5 mmol.l-1) should be reached with 0.2 g.kg-1 BM NaHCO3, this may 
lead to a performance enhancement. The purpose of this study therefore, was to investigate the 
reproducibility of blood acid base balance, performance and GI discomfort responses following 
two individualised NaHCO3 doses. The hypothesis of this study was that both NaHCO3 doses 
would produce a good level of reproducibility in respect of performances and blood responses. 
 
5a.2 Methods  
5a.2.1 Participants 
Eleven trained male club-level cyclists volunteered for a randomised, double-blind, crossover 
design study (height 182 ± 8 cm, body mass 86.4 ± 12.9 kg, age 32 ± 9 years, maximal oxygen 
consumption (VO2max) 58.0 ± 3.8 ml kg min
-1, peak power 4.5 ± 0.5 W kg-1). The participant 
inclusion required individuals to meet the criteria of a ‘trained cyclist’ as outlined by De Pauw 
et al. (2013). Ethical approval was obtained from the Departmental Research Ethics Committee 






5a.2.2 Experimental procedures 
Participants visited the laboratory a total of nine occasions. A VO2max test was conducted on 
the first visit to obtain a marker of fitness. This was then followed by two visits to identify time 
to peak HCO3
- following 0.2 g.kg-1 BM and 0.3 g.kg-1 BM NaHCO3. The time to peak HCO3
- 
was employed as this was more reproducible in Chapter 4. This procedure required participants 
to ingest NaHCO3 (within 10 min) and then remain in a seated position quietly resting whilst 
blood samples were taken every 10 min for a period of 180 min. Gastrointestinal (GI) 
discomfort was measured using a visual analogue scale (VAS) every 10 min during the 
ingestion period. 
 
On a separate occasion, participants then performed a 4 km TT familiarisation trial. The 
procedure for the 4 km TT are described in Chapter 3 (section 3.4.3). This was followed by a 
further five separate visits requiring completion of the same exercise following ingestion of 
either 0.2 g.kg-1 BM NaHCO3 twice (SBC2a and SBC2b), 0.3 g
.kg-1 BM NaHCO3 twice 
(SBC3a and SBC3b) or a control treatment entailing no supplementation in a block randomised 
order. A control trial was conducted to obtain a reference point measure of performance. 
Treatments were administered in a double blind manner and in black bottles to disguise the 
colour differences between SBC treatments. Blood samples were taken at rest, at time to peak 
HCO3
-, and post-exercise to analyse blood pH and HCO3
-, with the addition of a 5-μl sample 
for blood lactate (Lactate Pro 2, Arkray, Japan). Ingestion of either SBC2 or SBC3 was 
completed within 10 min, and participants remained seated and rested until their respective 
time to peak. Gastrointestinal (GI) discomfort was also measured during the ingestion time 






5a.2.3 Statistical analysis  
Shapiro-Wilk test and standard graphical methods (Q-Q plots) were used to assess normality 
of the data, and the Mauchly test was used for homogeneity and variance. Both the severity 
and time to peak GI discomfort were considered non-normally distributed by the respective 
normality tests. As a result, a Friedman rank test was used as an alternative and is reported with 
z score (significance) and effect size (d) calculated by Z/√n. Interpretation was then considered 
as small (0.10), medium (0.24) and large (>0.37) (Ivarsson et al., 2013). Mean speed, power 
and time to complete were compared between treatments using a repeated measures ANOVA. 
Haematological data such as blood pH, HCO3
- and lactate were analysed using a two-way 
(treatment x time) repeated measures ANOVA. Post hoc comparisons were determined by 
Bonferroni correction. Effect size is reported as partial eta squared (Pη2) where main effects 
or interactions were observed. Interpretations for effect sizes were interpreted as per the 
thresholds described in Chapter 3 (section 3.5.2.1). 
 
Limits of agreement (LOA) with 95% percent limits and Bland-Altman plots were initially 
used to determine if data was heteroscedastic (Bland and Altman, 1986). The repeatability of 
both blood acid base balance and performance responses to SBC2 and SBC3 was determined 
using Intraclass correlation coefficients (ICC) with r value and significance level (i.e. p value), 
as per previous recommendations (Atkinson and Nevill, 1998, Vincent and Weir, 2012). 
Typical error (TE) is reported and calculated using the method of Hopkins (Hopkins, 2000). 
Interpretation of reproducibility statistics were determined as per the thresholds in Chapter 3 
(section 3.5.2.2). Coefficient of variation (CV) was reported using SD/mean x 100. Statistical 
procedures were completed using SPSS version 22 (IBM, Chicago, USA), and calculations 
were carried out using Microsoft Excel 2013 (Microsoft Inc., USA). All data are presented as 




5a.3.1 Reliability of treatments 
The blood responses following SBC treatments were largely reproducible (Tables 5.1a and 
5.2a). Individual blood responses displaying absolute changes from baseline to peak pH and 
HCO3
- are depicted in Table 5.3a. The only inconsistency observed was the absolute change in 
pH from baseline to peak in SBC3, revealing a poor ICC during cycling trails. Excluding that 
case, blood responses pre-, during and post-exercise ranged from good to excellent for all SBC 
treatments (ICC range r = 0.68 to 0.95).  
 
Excellent reproducibility of time to complete the 4 km TT was observed in both SBC2 (r = 
0.97, p <0.001) and SBC3 (r = 0.99, p <0.001), with a low TE (range = 0.3 to 0.5%, 1.2 to 1.9 
s; Table 5.4a). Mean power displayed excellent reproducibility in both SBC2 (r = 0.96, p 
<0.001; TE = 0.6%) and SBC3 (r = 0.98, p <0.001; TE = 0.4%). Mean speed also displayed 
excellent reproducibility in SBC2 (r = 0.97, p <0.001; TE = 0.6%) and SBC3 (r = 0.98, p 
<0.001; TE = 0.4%). Eight participants reported symptoms of GI discomfort (Table 5.5a). The 
severity of GI discomfort displayed good reproducibility in SBC2 (r = 0.72, p = 0.023; TE = 
1.3%) in comparison to excellent in SBC3 (r = 0.76, p = 0.017; TE = 1.3%). The time to peak 
GI discomfort displayed excellent reproducibility in both SBC2 (r = 0.99, p <0.001; TE = 





Table 5a.1 – Overview of Intraclass correlation coefficient (ICC) and typical error (TE) statistical analysis following sodium bicarbonate 
(NaHCO3) treatments (SBC2 and SBC3) on pre-, during and post-exercise blood pH, bicarbonate (HCO3
-) and lactate.  
Absolute change from baseline to peak (including initial time to peak trial) 
HCO3
- SBC2 SBC3  pH SBC2 SBC3     
           
ICC    ICC       
r value 0.79 0.69  r value 0.79 0.17     
P value <0.001 0.006  P value <0.001 0.326     
Typical error % 1.2 1.4  Typical error % 1.4 1.7     
Interpretation Excellent Good  Interpretation Excellent Poor     
           
During Exercise           
Decline in HCO3
-  SBC2 SBC3         
           
ICC           
r value 0.69 0.95         
P value 0.026 <0.001         
Typical error % 1.3 0.6         
Interpretation Good Excellent         
           
Post Exercise           
Blood lactate SBC2 SBC3  HCO3
- SBC2 SBC3  pH SBC2 SBC3 
           
ICC    ICC    ICC   
r value 0.91 0.92  r value 0.89 0.95  r value 0.92 0.95 
P value <0.001 <0.001  P value <0.001 <0.001  P value <0.001 <0.001 
Typical error % 0.7 0.8  Typical error % 0.8 0.6  Typical error % 0.6 0.6 
Interpretation Excellent Excellent  Interpretation Excellent Excellent  Interpretation Excellent Excellent 
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Table 5a.2 – Mean (± SD) blood pH, bicarbonate (HCO3
-) and lactate responses following 
sodium bicarbonate.  
Baseline to pre-

















5.5 ±  
0.7 
4.9 ±  
0.8 
5.2 ±  
1.1 
6.5 ±  
1.3 
5.6 ±  
1.0 
5.7 ±  
1.1 























* = changes from baseline to peak values within the individual time to peak trial  
 
5a.3.2 Differences between treatments 
Following NaHCO3 ingestion, HCO3
- was greater compared to baseline in both SBC2 and 
SBC3, revealing a main [time] effect (p <0.001, Pη2 = 0.932); however, no difference between 
treatments was observed (p = 0.184, Pη2 = 0.010; Table 5.2a). This trend was similar for pH, 
as a main [time] effect was observed (p <0.001, Pη2 = 0.983), with no difference between SBC 
treatments (p = 0.512, Pη2 = 0.003). During exercise, the decline in HCO3
- was similar between 
SBC2 and SBC3 (p = 0.251, Pη2 = 0.129). Post-exercise blood lactate also displayed no 
difference between SBC treatments (p = 0.494, Pη2 = 0.076; Table 5.2a). The time to complete 
the 4 km distance was similar for both SBC2 (combined mean = 373.6 ± 13.3 s) and SBC3 
(373.5 ± 13.1 s) (mean diff = 0.01 s; p = 0.929, Pη2 = 0.015; Table 5.4a). Compared to the 
control treatment, both SBC2 and SBC3 produced faster completion times (mean difference 
SBC2 = -8.0, p <0.001 and 8.8 s, p = 0.006; SBC3 = -8.2, p = 0.005 and 8.6 s, p = 0.006). There 
was no difference between SBC2 and SBC3 for either mean power (p = 0.966, Pη2 = 0.009) or 
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mean speed (p = 0.746, Pη2 = 0.040). Severity of GI discomfort in SBC3 was marginally greater 
(3.4 ± 3.0 and 4.6 ± 3.6) compared to SBC2 (2.8 ± 3.4 and 1.4 ± 1.5), however not significantly 
(z = 0.268, d = 0.08) (Table 5.5a). Likewise, time to peak GI discomfort was around 20 min 
later in SBC3 (41 ± 27 and 43 ± 31 min) compared to SBC2 (23 ± 25 and 20 ± 24 min), although 
again not significantly (z = 0.197, d = 0.06; Table 5.5a). 
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Table 5a.3 – Individual blood responses for both blood pH and bicarbonate (HCO3
-) following sodium bicarbonate (NaHCO3). 
Blood 
HCO3
- Absolute change in mmol.l-1 
Blood 




Dose. SBC2 SBC2 
Ind. 
Dose. SBC3 SBC3 CON 
Ind. 
Dose. SBC2 SBC2 
Ind. 
Dose. SBC3 SBC3 CON 
1 5.5 5.4 5.7 4.9 4.1 4.8 0.0 0.06 0.07 0.04 0.09 0.09 0.08 0.00 
2 6.8 5.6 5.1 5.6 4.1 4.9 0.1 0.08 0.08 0.07 0.05 0.04 0.05 0.00 
3 5.6 4.7 7.2 5.0 6.2 6.9 -0.5 0.07 0.05 0.06 0.07 0.05 0.08 0.00 
4 6.2 4.5 5.0 8.1 7.2 7.2 0.0 0.05 0.03 0.08 0.10 0.02 0.03 0.01 
5 5.8 5.5 6.3 8.1 5.8 4.9 0.0 0.09 0.05 0.06 0.06 0.08 0.07 0.00 
6 5.3 5.4 5.0 6.5 5.4 6.9 0.0 0.09 0.08 0.11 0.16 0.05 0.04 0.00 
7 4.7 3.3 2.9 7.6 6.5 4.2 0.1 0.07 0.06 0.06 0.10 0.07 0.08 0.00 
8 3.8 3.8 4.3 7.8 6.4 6.1 -0.1 0.06 0.05 0.05 0.09 0.06 0.06 0.00 
9 5.3 5.6 5.2 4.6 4.8 4.8 0.3 0.05 0.06 0.06 0.06 0.09 0.09 0.00 
10 5.4 5.8 6.0 7.0 6.0 6.9 0.0 0.05 0.04 0.04 0.09 0.05 0.04 0.00 
11 5.9 4.9 5.2 6.4 5.6 5.7 0.0 0.11 0.07 0.12 0.09 0.10 0.11 0.01 
Mean  5.5 5.0 5.3 6.5 5.6 5.8 0.0 0.07 0.06 0.07 0.09 0.06 0.07 0.00 




Table 5a.4 – Individual 4 km TT performance differences between sodium bicarbonate (NaHCO3) treatments (SBC2 and SBC3). 
 Participant number Difference in seconds between treatments  % difference between treatments 
  SBC2 vs. SBC2   SBC3 vs. SBC3   SBC2 vs. SBC2   SBC3 vs. SBC3 
1 1.4  2.3  0.4  0.6 
2 2.5  1.1  0.7  0.3 
3 0.5  3.0  0.1  0.9 
4 11.2  4.3  2.9  1.1 
5 0.2  0.4  0.1  0.1 
6 4.6  0.4  1.2  0.1 
7 5.6  1.9  1.5  0.5 
8 7.8  2.5  2.1  0.7 
9 3.0  5.2  0.8  1.3 
10 1.6  2.4  0.4  0.7 
11 2.7  1.7  0.7  0.4 
Mean 3.7    2.3   1.0   0.6 
SD 3.2   1.4   0.8   0.4 




Table 5a.5 – Individual severity and time to peak gastrointestinal (GI) responses in participants who reported symptoms (n = 8).  
 




















1 6 30 
Diarrhoea/bowel 
urgency 
2 30 Belching 4 50 Belching 3 60 Belching 
2 3 30 Belching 3.5 20 Belching 0 0 None 0 0 None 
3 10 50 
Diarrhoea/bowel 
urgency 
3 40 Belching 5 60 Belching 0 0 None 









5 0 0 None 0 0 None 3 80 Stomach cramp 10 80 
Diarrhoea/bowel 
urgency 
6 0 0 None 0 0 None 3 40 Nausea/bloating 4 40 
Diarrhoea/bowel 
urgency 
7 0 0 None 0 0 None 2 40 Bloating 5.5 30 Bloating/belching 
8 0 0 None 0 0 None 0 0 None 4 40 Stomach cramp 
Mean 2.8 23   1.4 20   3.4 41   4.6 43   




The aim of this study was to investigate the reproducibility of both blood acid base balance 
analytes and performance responses following repeated NaHCO3 ingestion. The present study 
is the first to demonstrate that both the physiological and performance responses are 
reproducible when the ingestion time for NaHCO3 is determined by an individual time to peak 
HCO3
-. As a result, this provides a legitimate and workable strategy to elicit consistent 
performance responses on exercise of this duration and intensity. The primary findings contrast 
with previous research, which has reported large inter- and intra-individual variability in both 
performance responses (Dias et al., 2015) and blood acid base balance responses (Carr et al., 
2012) following a standardised NaHCO3 ingestion strategy. It would therefore appear that an 
individual time to peak HCO3
- ingestion strategy is more effective at eliciting consistent 
responses. 
 
Performance following NaHCO3 displayed excellent reproducibility within the trained cyclist 
cohort used in this study. The TE values for the time to complete the 4 km cycling TT in the 
present study are consistent with a previous investigation of the reliability of TT cycling of the 
same distance without NaHCO3 ingestion. Briefly, Stone et al. (2011) reported a TE of <1% 
for both completion time and mean speed, which is similar to both SBC treatments in the 
present study (TE <0.6%). These consistent values may be evident due to the combined high 
training status of the cyclists used in each respective study, and the well reported reliability of 
4 km TT cycling performance under laboratory conditions (Altareki et al., 2009, Thomas et al., 
2015). The present study data suggests the inclusion of NaHCO3 did not compromise the 
reliability of the performance responses, and therefore, it can be recommended to elicit 
consistent performance responses during this type of exercise. The present study also displays 
the intra-individual variation between conditions (i.e. SBC2 vs. SBC2), which was larger in 
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SBC2 compared to SBC3. This was largely due to participant 4 however, who displayed an 11 
s difference between the two SBC2 treatments. Nonetheless, with participant 4 removed from 
the analysis, a 3 s change would have occurred which is more akin to SBC3. In contrast, four 
of the sample reported a difference of <1 s between the same SBC treatments. Athletes should 
therefore be aware of this variation and monitor their performance if they are going to consider 
using NaHCO3 on a consistent basis. 
 
The primary findings of this study agree with Carr et al. (2012) who reported a low TE (2.1%) 
for 2000 m rowing ergometry following NaHCO3. In contrast, a lack of repeatability was 
observed in a later study (Dias et al., 2015) reporting a mean CV of 7.4 ± 3.2% (range = 2.5 to 
14.8%) and large intra-individual variation following NaHCO3. This is considerably higher 
than the CV of Carr et al. (2012) (1.6%) and the present study (3.5%), which is likely due to 
the lower training status of the participants used by Dias et al. (2015). Equally, both the study 
by Carr et al. (2012) and the present study used TT simulation compared to a cycling TTE 
protocol at 110% peak power output (Dias et al., 2015). It is suggested the ‘open-ended’ nature, 
the lack of control over power output and motivational differences during a TTE test explain 
the greater variation compared to TT simulation (laursen et al., 2007). In a study by Saunders 
et al. (2013), however, an identical protocol to that used by Dias et al. (2015) displayed 
excellent test-retest reliability in ICC analysis (r = 0.88), suggesting the exercise protocol did 
not negate the reliability of responses following NaHCO3. It is more likely therefore, that the 
training status of participants may have caused the greater variation in responses compared to 
that of Carr et al.’s (2012) and the present study, as a trained athlete is likely to be able to 





The present study reports similar reproducibility of blood acid base balance analytes following 
NaHCO3 in previous research (Carr et al., 2012, Dias et al., 2015). Carr et al. (2012) reported 
a high inter-individual variation in HCO3
- post-supplementation (TE = 2.4%), whilst Dias et 
al. (2015) reported an 18% CV for change in pH from baseline between two NaHCO3 
treatments. Likewise, the present study reported similar inconsistencies, such as a 0.03 pH unit 
discrepancy and a poor ICC between the SBC3 individual time to peak trial and subsequent 
cycling trial, and a 0.9 mmol.l-1 discrepancy in HCO3
- following the same treatment. Whether 
such small discrepancies are practically meaningful however, is unknown. Nonetheless, 
individual analysis revealed a small number of inconsistencies in blood acid base balance, as 
participant 4’s absolute HCO3
- change from baseline to peak was +4.7 mmol.l-1 in SBC2a, 
compared to a +7.2 mmol.l-1 change in SBC2b. Likewise, the change from baseline to peak for 
participant 8 was +2.3 mmol.l-1 different in SBC3 (SBC3a +6.5 vs. SBC3b +4.2 mmol.l-1). 
Some degree of inconsistency was subsequently evident in performance times, particularly 
with participant 4, who was around 11 s slower in SBC2a than in SBC2b. This suggests the 
larger HCO3
- increase in SBC2b led to a greater effect on performance. Participant 8 however, 
was slower in SBC3a by around 3 s, despite the greater change in HCO3
-, compared to SBC3b. 
These inconsistencies add to previous findings in Chapter 4 that reported whilst most of blood 
responses were reproducible, some individuals display large variability following NaHCO3. It 
is also unknown whether such greater increases in HCO3
- necessarily lead to a greater 
performance effect. Given these inconsistencies, individuals should monitor the performance 
effects following NaHCO3 ingestion across multiple trials to ensure similar responses are 
elicited. 
 
The physiological responses pre, during and post the TT’s displayed good to excellent 




- was highly repeatable for all SBC conditions and the values were reflective of a recent 
study following NaHCO3 during a 3-min ‘all-out’ cycling test compared to a placebo (Deb et 
al., 2017). Of particular interest is the lack of a difference in blood responses during 
experimental trials between the NaHCO3 doses used in the present study. The absolute HCO3
- 
change from baseline was similar for both SBC conditions, such that SBC3 was only 0.5 
mmol.l-1 greater compared to SBC2. Likewise, the increases in pH following NaHCO3 
ingestion were similar between the SBC conditions. This may explain why no dose-dependent 
performance effects were observed in this study, as buffering capacity would have been 




In respect of blood lactate, a low TE range of 0.7 to 0.8% was displayed along with excellent 
ICC’s (r = 0.91 to 0.92). This is in contrast to previous research displaying a TE of ~7% (Carr 
et al., 2012). The analysis by Carr et al. (2012) seemed to be based on group mean responses, 
and not individual data, which would have potentially negatively affected results. Nonetheless, 
some small inconsistencies were apparent as participants 6, 8 and 10 reported values with at 
least 2 mmol.l-1 difference in SBC2, whilst participants 3 and 9 displayed this effect in SBC3. 
The reasons for this are unclear, although it may be partly due to the technical error associated 
with the lactate analyser used in this study (Tanner, Fuller and Ross, 2010). Nonetheless, the 
present study displays that the physiological responses are generally consistent, suggesting the 
primary acting mechanisms for performance enhancement should be in place with repeated use 
of NaHCO3. 
 
A unique finding of the present study is that the performance responses following NaHCO3 
were not dose dependent, akin to previous research (McKenzie et al., 1986). The fastest 4 km 
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TT completion time was observed in SBC2b, although the other SBC treatments were not 
significantly slower (range + 0.2 to 0.9 s; % diff < 0.5%). This suggests a smaller dose of 
NaHCO3 may be physiologically optimal when supplemented at a pre-determined individual 
time to peak HCO3
- to prompt similar biochemical and performance responses. A consideration 
of this study however, is that no placebo treatment was utilised to identify if these responses 
were ergogenic. As a result, it is difficult to determine the if the improvements in performance 
were due to a physiological or psychological placebo effect or due to the ergogenic mechanisms 
of NaHCO3 ingestion. The central aim of the study nonetheless, was to quantify the 
reproducibility of performance following repeated NaHCO3 ingestion; therefore, this 
comparison was not included. Of note, a control trial was conducted and the SBC conditions 
were significantly faster by between 2.1 and 2.3% for SBC2 and between 2.2 and 2.3% faster 
for SBC3 (both p <0.05). This infers an ergogenic effect was apparent, in agreement with other 
studies using a time to peak alkalosis NaHCO3 ingestion strategy (Miller et al., 2016, Deb et 
al., 2017, 2018a). Yet, further research should address this by comparing such performance 
responses to a placebo. 
 
A practical benefit of utilising smaller doses of NaHCO3 is to minimise GI discomfort, as 
smaller doses have been shown to reduce the severity of symptoms (Chapter 4, McNaughton, 
1992a). McNaughton (1992a) reported anecdotally as the amount of NaHCO3 ingested 
increased from 0.1 to 0.5 g.kg-1 BM, the severity of GI discomfort increased. Since this study 
however, dose comparisons have been sparse. Indeed, both the severity and time to peak GI 
discomfort was reproducible in the present study using ICC analysis (ICC range r = 0.72 to 
0.99); however, in some cases, the symptom suffered varied despite a similar rating of GI 
discomfort. Participant 8 for instance suffered from nausea and bloating in SBC3a, but then 
suffered diarrhoea and bowel urgency in SBC3b. The reasons for the discrepancies in 
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symptoms remain inconclusive, as previous research seemed to suggest it was not linked to 
pre-exercise nutrition (carbohydrate, protein, fat and sodium intake) or the change in Na+ 
following NaHCO3 ingestion (Chapter 4, Jones et al., 2016); although further research is 
warranted. Nonetheless, this provides a challenge to the individual considering routine use of 
NaHCO3 as the symptom suffered may change with no clear pattern, which subsequently could 
impact the ability or desire to perform exercise. The time to peak GI discomfort does seem to 
occur at the same time point however, suggesting athletes could at least avoid ingestion at the 
time to peak GI discomfort (if possible). This influence of GI discomfort should therefore be 
monitored during training prior to use in competition. 
 
5a.5 Conclusion  
This study is the first to display consistent performance responses from NaHCO3 ingestion 
when exercise begins at the individual time of peak HCO3
-. This supports the use of 
individualised NaHCO3 supplementation strategies prior to performance to elicit reproducible 
physiological and performance responses. As a result, this study shows through the use of 
personalised nutrition to maximise the bioavailability of HCO3
-, reliable responses can be 
elicited and this approach is therefore recommended. Accompanying this finding, both 0.2 and 
0.3 g.kg-1 BM NaHCO3 produced similar blood acid base balance and performance reliability, 
with no difference between doses. This suggests both amounts can be used as an ergogenic 
strategy. Lastly, the use of NaHCO3, irrespective of dose and repeated ingestion, appears to 
have a varied response on GI discomfort. Athletes should therefore monitor these responses, in 












Chapter 5b – Sodium Bicarbonate Improves 4 km 
Time Trial Cycling Performance when 
Individualised to Time to Peak Blood Bicarbonate in 

















Competitive track cycling is reflective of high-intensity exercise, particularly in events such as 
the individual and team pursuit, which entail completion of a 4 km time trial (TT). The typical 
duration of this event ranges from between 4 min (elite) and 7 min (recreational), and because 
of this, a large energy supply is derived from anaerobic glycolysis (Gastin, 2001). With such a 
demand, an exponential accumulation of metabolites including inorganic phosphate, hydrogen 
ions (H+), and lactate occurs (Westerblad et al., 2002). Of concern is the large rises in H+, which 
causes metabolic acidosis leading to a decline in both muscle and blood pH (Allen et al., 
2008a). Whilst there is no singular mechanism of peripheral fatigue, perturbations to acid base 
balance have been implicated to inhibit enzyme activity (e.g. glycogen phosphorylase) and 
calcium ion (Ca2+) cross-bridge binding (Fitts, 2008, 2016). Preventative strategies such as the 
ingestion of nutritional ergogenic aids may therefore be beneficial to mitigate such local acid-
base disturbances in active musculature. 
 
Ingestion of sodium bicarbonate (NaHCO3), a known buffering agent, can reinforce acid base 
balance by producing a state of metabolic alkalosis (increased pH and HCO3
-) (McNamara and 
Worthley, 2001). Increases in pH result in a greater efflux of H+ and lactate from active 
musculature into extracellular compartments due to a greater intra-extracellular gradient, whilst 
elevated HCO3
- can be utilised to buffer against H+ within extracellular compartments (Bishop 
et al., 2004). The resulting effect is more work completed during exercise of high intensities, 
which in turn, may improve performance (Bishop et al., 2004, Marx et al., 2002). It is therefore 
important to heighten the level of blood alkalosis via changes in pH and HCO3
- prior to exercise 
(McNaughton et al., 2016, Jones et al., 2016). Common practice is to prescribe NaHCO3 
between a set time of between 60 and 90 min for all participants (Carr et al., 2011b, Price & 
Singh, 2008, Siegler et al., 2009). Chapter 4 revealed that the time to peak alkalosis varied 
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between 40 and 140 min within individuals however, whilst a similar variation has been 
observed in other dose-response studies (Jones et al., 2016, Miller et al., 2016). This means 
participants may not achieve peak alkalosis at the start of exercise, which subsequently might 
explain, the lack of ergogenic effects from NaHCO3 supplementation 100 min (Oliveira et al., 
2017) and 150 min (Callahan et al., 2017) prior to a 4 km TT. 
 
In response to such variation to achieve time to peak alkalosis, it is recommended that either 
time to peak pH or HCO3
- is predetermined prior to use for an exercise bout. This is to account 
for the high inter-individual variation commonly observed (Jones et al., 2016, McNaughton et 
al., 2016, Miller et al., 2016). Indeed, preliminary studies to date have displayed ergogenic 
benefits of NaHCO3 individualised to a predetermined time to peak pH in cycling performance 
(Miller et al., 2016, Deb et al., 2017). Chapter 4 however, demonstrated greater reliability of 
time to peak HCO3
- compared to time to peak pH with Intraclass correlation coefficient (ICC) 
analysis (r = 0.94 vs. 0.71). It may therefore be more appropriate to determine the effects of 
NaHCO3 on HCO3
- responses, particularly if the athlete wishes to achieve peak alkalosis 
consistently. Nonetheless, only one study to date has employed this strategy, which also 
observed an improvement in high-intensity intermittent exercise using fixed workloads in 
hypoxic conditions of 3000 m (Deb et al., 2018a). This strategy however, is yet to be applied 
to exercise in normoxia or on an exercise protocol with a self-paced strategy, such as a 4 km 
TT.  
 
A further concern of a 0.3 g.kg-1 BM NaHCO3 ingestion strategy is the commonly reported 
gastrointestinal (GI) discomfort symptoms such as stomach cramp, diarrhoea, and in extreme 
cases, vomiting, which can have major negative implications for exercise performance 
(Chapter 4, Saunders et al., 2014a, Gough et al., 2017). It is therefore important to maximise 
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the potential ergogenic effect through attaining peak buffering capacity, whilst also managing 
the severity of GI discomfort. Given that smaller amounts of NaHCO3 (i.e. 0.2 g
.kg-1 BM) are 
associated with lower instances and severity of GI discomfort (Chapters 4 and 5a), it may be 
prudent to suggest this amount is a better practical option to the athlete. This will only be 
worthwhile, however, if a lower dose of NaHCO3 still improves performance to at least a 
similar extent. In response, Chapter 5a suggested this is the case, as no dose-dependent 
differences were observed between 0.2 g.kg-1 BM and 0.3 g.kg-1 BM NaHCO3 on 4 km TT 
performance, such that the mean difference ranged between 0.2 to 0.9 s. Nonetheless, a 
comparison with a placebo was not conducted, which limits the interpretation of NaHCO3 
providing a true effect on performance. The purpose of this study therefore, was to investigate 
the effects of both 0.2 g.kg-1 BM (SBC2) and 0.3 g.kg-1 BM (SBC3) NaHCO3 individualised to 
a predetermined time to peak HCO3
- on 4 km TT performance, and against a placebo. The 
hypothesis of this study was that both NaHCO3 doses would create a more alkaline 
physiological environment, however SBC3 would produce a greater performance effect 




A priori power calculation displayed a sample size of 11 would allow detection of a 3 s change 
with high statistical power (β = 0.80; 0.05 = α level). This set criterion was used to detect a 
difference between NaHCO3 treatments (i.e. SBC2 vs. SBC3) and between SBC treatments 
and the placebo. This difference was used as this is the typical difference required to determine 
medal positions for the men’s individual pursuit and similar events at Olympic Games 
(Christensen et al., 2017). Eleven male trained club-level cyclists therefore volunteered for this 
study (height 1.82 ± 0.8 m, body mass 86.4 ± 12.9 kg, age 32 ± 9 years, peak power output 
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(PPO) 382 ± 22 W), as described by De Pauw et al. (2013). This group of participants also 
volunteered for Chapter 5a. Ethical approval was obtained from the Departmental Research 
Ethics Committee (SPA-REC-2015-366) and each participant provided written informed 
consent prior to experimental testing. 
 
5b.2.2 Experimental overview 
Following an initial VO2max test, participants visited the laboratory on a further six occasions 
in a randomised, crossover and double blind designed study (2 x identification of peak blood 
HCO3
-, 4 x cycling TT’s). Participants followed the same pre-experimental procedures as stated 
in Chapter 3 (section 3.1.4).  
 
5b.2.3 Determination of maximal rate of oxygen consumption and time to peak blood 
bicarbonate  
The procedures to determine VO2max were conducted as described in Chapter 3 (section 3.4.2). 
Time to peak HCO3
- following NaHCO3 was determined using the same procedures detailed 
in Chapter 5a. Gastrointestinal (GI) discomfort was measured using a visual analogue scale 
(VAS) every 10 min during the ingestion period, as described in Chapter 3 (section 3.3.2). 
 
5b.2.4 Four-kilometre cycling protocol, blood measures and perceptual measures 
Participants initially completed a familiarisation trial of the 4 km cycling TT, replicating the 
procedures described in Chapter 3 (section 3.4.3). Time to complete, mean power and mean 
speed was recorded for both the total distance and 0.5 km splits, along with heart rate (HR) 
every 0.5 km (Polar, T31, Finland). This procedure was then repeated another three times, with 
the exception that either 0.2 g.kg-1 BM NaHCO3 (SBC2), 0.3 g
.kg-1 BM NaHCO3 (SBC3) or a 
taste matched placebo (PLA) containing 0.07 g.kg-1 BM sodium chloride (NaCl) was ingested, 
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after baseline blood measures were taken. Participants then sat quietly resting until their 
respective predetermined time to peak HCO3
-, at which point a further blood sample was taken. 
Gastrointestinal (GI) discomfort was measured using a visual analogue scale (VAS) every 10 
min until each individual’s time to peak. A self-selected warm-up was then completed by the 
participants, and this was repeated for each trial prior to the beginning of the TT. A further 
blood sample was taken post-exercise. Measured analytes were pH, HCO3
- and lactate as per 
previous chapters (Chapters 3 and 5a). 
 
5b.2.5 Statistical analysis  
A paired sampled t test was used to assess the severity and time to peak GI discomfort between 
SBC treatments. Both mean power and speed were analysed using a repeated measures 
ANOVA. Otherwise, a two-way repeated measures ANOVA (e.g. condition x each 0.5 km 
segment/time point) was used and where either interactions or main effects were observed, 
Bonferroni corrected posthoc pairwise comparisons were carried out. Partial eta squared (Pη2) 
effect size is reported with interactions and main effects. Between treatment effect sizes (g) 
were calculated using the difference in means divided by the pooled SD of the compared trials 
(Nakagawa and Cuthill, 2007), however with a Hedge’s g bias correction to account for the 
sample size in this study (Lakens, 2013). Intraclass correlation coefficients (ICC) were used to 
determine the reproducibility of blood metabolites (i.e. time to peak HCO3
- and pH) following 
SBC conditions and are reported with r value and significance value (p value). Interpretation 
thresholds for effect sizes and reliability statistics are described in Chapter 3 (section 3.5). Data 
are presented as mean ± SD with 95% confidence intervals (CI) unless otherwise stated. 








Faster mean completion times (Figure 5b.1) by 8.3 ± 3.4 s were observed following SBC2 (p 
<0.001, CI = 12.0, 4.7, g = 0.64) and by 8.6 s ± 5.2 s following SBC3 compared to PLA, 
respectively (p = 0.003, CI = 14.2, 3.0, g = 0.66). There was no difference between SBC2 and 
SBC3 (374.0 ± 13.3 vs. 373.7 ± 13.3 s, p = 0.87, CI = -3.0, 3.7, g = 0.02; Figure 5b.1). 
 
A 16 ± 13 W (+5.7%) increase in mean power was observed following SBC2 (304 ± 28 W, p 
= 0.02, CI = 2.6, 30.3, g = 0.62), while in SBC3, an increase of 16 ± 15 W (+5.9%) was 
observed (304 ± 31 W, p = 0.03, CI = 1.1, 32.9, g = 0.58; Figure 5b.2) compared to PLA (287 
± 25 W). There was no difference between SBC2 and SBC3 (p = 0.90, CI = -10.2, 9.1, g = 
0.01). Following SBC2, a 0.9 ± 0.6 km.h-1 (+2.4%) increase in mean speed was observed 
compared to PLA (38.6 ± 1.4 vs. 37.7 ± 1.1 km.h-1, p = 0.008, CI = 0.2, 1.6, g = 0.69). Similarly, 
a 0.8 ± 0.6 km.h-1 (+2.0%) increase in mean speed was observed following SBC3 (38.4 ± 1.3, 
p = 0.02, CI = 0.1, 1.4, g = 0.56), whilst there was no difference between SBC conditions (p = 
0.42, CI = −0.3, 0.6, g = 0.14; Figure 5b.2). 
 
5b.3.2 Performance responses for participants who suffered gastrointestinal discomfort (n = 
8) 
Despite the occurrence of GI discomfort, SBC2 improved performance by 9.0 ± 3.8 s in SBC2 
(p = 0.001, CI = 4.5, 13.5, g = 0.68) and 8.9 ± 6.1 s in SBC3 (p = 0.02, CI = 1.7, 16.2, g = 0.68) 
compared to PLA. Only one participant failed to improve performance following SBC3 (0.1 s 
difference vs. PLA), whilst three participants improved by less than the 3 s threshold from 
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Figure 5b.1 Mean (± SD) 4 km time trial responses following sodium bicarbonate (NaHCO3). 
Horizontal dotted lines represent individual responses. * Denotes significantly different from 











Figure 5b.2 Mean (± SD) cycling power (A) and speed (B) during each 0.5 km segment of the 





5b.3.3 Blood metabolite responses  
Absolute peak change in HCO3
- from baseline was 5.5 ± 0.7 in SBC2 and 6.5 ± 1.3 mmol.l-1 in 
SBC3, which was not significantly different (p = 0.07; g = 0.92). Peak HCO3
- occurred within 
a range of between 40 to 110 min in SBC2 (mean 62 ± 20 min, CV: 33%), and between 40 to 
100 min in SBC3 (mean 73 ± 20 min, CV: 27%; Figure 5b.3). 
Figure 5b.3 Individual time to peak blood bicarbonate (HCO3
-) following SBC2 and SBC3. 
 
The change from baseline to the peak pH was not significantly different between SBC 
conditions (p = 0.13, g = 0.75; SBC2 = 0.07 ± 0.02, SBC3 = 0.09 ± 0.03). In the subsequent 
cycling trials, good reproducibility was observed for the absolute mean change from baseline 
in pH following both SBC2 (+0.06; ICC r = 0.67, p = 0.03) and SBC3 (+0.06; r = 0.65, p = 
0.04). Greater reproducibility was observed for absolute mean change in HCO3
- however, 
displaying excellent reliability in both SBC2 (+4.9 mmol.l-1; r = 0.86, p = 0.002) and SBC3 




In the cycling trials a [time x treatment] interaction was observed for pH (p = 0.048, Pη2 = 
0.285), whereby pH was +0.07 ± 0.02 (+0.9%) greater at time to peak (Figure 5b.4) for SBC2 
(7.46 ± 0.03; p <0.001, CI = 0.09, 0.04, g = 2.64) and 0.08 ± 0.02 (+1%) greater for SBC3 (7.47 
± 0.02; p <0.001, CI = 0.09, 0.05, g = 3.85) compared to PLA (7.39 ± 0.02). There was no 
difference between SBC2 and SBC3 (p = 0.69, CI = -0.3, 0.1; g = 0.38). A [time x treatment] 
interaction was observed for HCO3
- (p <0.001, Pη2 = 0.796), with values greater following 
supplementation of NaHCO3 (Figure 5b.4). At time to peak HCO3
-, SBC2 was 5.0 mmol.l-1 ± 
1.0 mmol.l-1 (+17.6%) (28.6 ± 1.1 mmol.l-1; p <0.001, CI = 6.0, 4.1, g = 5.22) and SBC3 was 
5.9 ± 1.1 mmol.l-1 (+20.0%) (29.5 ± 1.0 mmol.1-1; p <0.001, CI = 6.9, 5.0, g = 6.58) greater 
than PLA (23.6 ± 0.7 mmol.l-1). There was no difference between SBC2 and SBC3 (p = 0.34, 
CI = -2.3, 0.6, g = 0.82). 
 
Post-exercise HCO3
- was +1.8 ± 1.3 mmol.l-1 (+12.3%) greater for SBC2 (16.0 ± 2.2 mmol.l-1; 
p = 0.004, CI = 2.9, 0.6, g = 0.79) and +1.5 ± 1.3 mmol.l-1 (+10.9%) greater for SBC3 (15.8 ± 
2.7 mmol.l-1; p = 0.01, CI = 2.7, 0.4, g = 0.62), compared to PLA (14.2 ± 2.2 mmol.l-1). There 
was a [treatment] effect for HCO3
- change during exercise (p <0.001, Pη2 = 0.714), whereby 
the change in HCO3
- was 3.3 ± 1.8 mmol.l-1 (+25.9%) greater following SBC2 (12.7 ± 2.6 
mmol.l-1; p = 0.001, CI = 4.9, 1.6, g = 1.37) and 4.4 ± 1.7 mmol.l-1 (+31.7%) greater in SBC3 
(13.8 ± 2.7 mmol.l-1; p <0.001, CI = 5.9, 2.8, g = 1.78) compared to PLA (9.4 ± 2.0 mmol.l-1). 
There was no difference between SBC conditions (p = 0.59, CI = -1.2, 3.3; g = 0.40). Post-
exercise, a [time x treatment] interaction was observed for blood lactate (p <0.001, Pη2 = 
0.577) as SBC2 was +3.7 ± 2.8 mmol.l-1 (+22.5%) greater than PLA (16.1 ± 3.4 vs. 12.5 ± 2.7 
mmol.l-1, p = 0.006, CI = 1.1, 5.8, g = 1.13; Figure 5b.4), with SBC3 greater by +3.7 ± 2.4 
mmol.l-1 (+22.7%) (16.1 ± 3.4 mmol.l-1; p = 0.002, CI = 1.5, 5.8, g = 1.13). No differences 

























Figure 5b.4 Mean (± SD) blood pH (A), bicarbonate (HCO3
-) (B), and lactate (C) responses 
following sodium bicarbonate (NaHCO3). Significantly different (p <0.05) in SBC2 = # and 







5b.3.4 Gastrointestinal discomfort  
Four participants reported symptoms of belching and stomach bloating in SBC2, compared to 
seven participants reporting symptoms of belching, stomach cramp, bowel urgency and 
diarrhoea in SBC3. There was no significant difference in severity of GI discomfort between 
SBC treatments (SBC2 = 1.4 ± 1.5 vs. SBC3 = 4.6 ± 3.6; p = 0.10), although a large effect size 
was evident (g = 0.88). Similarly, time to peak GI discomfort was not significantly different 
between SBC treatments (SBC2 = 20 ± 24 vs. SBC = 43 ± 31 min, p = 0.13), although a large 
effect size was determined (g = 0.80). 
 
5b.3.5 Heart rate, ratings of perceived exertion and affective perceptions of work rate scale  
Heart rate was unaffected by NaHCO3 ingestion (p = 0.56, Pη
2 = 0.055). There was a main 
effect for [time] (p <0.001, Pη2 = 0.977) however, such that mean data combined from all 
treatments displayed HR at 500m was 144 ± 3 b.min-1, compared to 171 ± 2 b.min-1 at 4 km, 
respectively. A main effect for time was observed for RPEO (p <0.001, Pη
2 = 0.849), as at 1 
km, RPEO was 14 ± 1 compared to 17 ± 1 at 4 km, although no [time x treatment] interaction 
was apparent (p = 0.31, Pη2 = 0.109). Similarly, a main effect for [time] was observed for RPEL 
(p <0.001, Pη2 = 0.657), as at 1 km, RPEL was 15 ± 1 compared to 18 ± 0 at 4 km, although no 
[time x treatment] interaction was evident (p = 0.73, Pη2 = 0.085). Affective perceptions of 
work rate revealed no [time x treatment] interaction (p = 0.38, Pη2 = 0.099) or main effect for 
time (p = 0.92, Pη2 = 0.020). 
 
5b.4 Discussion  
This study reports that both 0.2 g.kg-1 (SBC2) and 0.3 g.kg-1 BM (SBC3) NaHCO3 improves 4 
km TT cycling performance in trained cyclists when the ingestion point is individualised to a 
predetermined time to peak HCO3
-. Time to complete the time trial was 2.2% faster in SBC2 
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and 2.3% in SBC3 compared to PLA, whilst there was also no statistical difference between 
SBC conditions. This suggests both amounts are appropriate to enhance this type of exercise 
performance. Combining such performance effects with the reduced instances and severity of 
GI discomfort following 0.2 g.kg-1 BM NaHCO3, the present study findings suggest this amount 
may be more attractive to the athlete in a practical setting. 
 
The findings of the present study contrast that of two recent studies reporting no effect of 
NaHCO3 on 4 km TT performance (Callahan et al., 2017, Oliveira et al., 2017). Indeed, 
Callahan et al. (2017) reported a ‘possibly trivial’ effect and Oliveira (2017) reported no 
significant supplement interaction in ANOVA analysis following 0.3 g.kg-1 BM NaHCO3. In 
comparison, the present study displayed a statistically significant effect and a moderate effect 
size for both SBC2 and SBC3. This ergogenic effect was likely realised due to supplementing 
NaHCO3 to a predetermined time to peak HCO3
-, as this would have ensured peak 
bioavailability of HCO3
- at the commencement of exercise. In particular, the increase in HCO3
- 
from baseline to peak following the SBC2 treatment of the present study was similar, whilst 
the SBC3 treatment was superior, to the values reported in the aforementioned studies with 0.3 
g.kg-1 BM NaHCO3 (SBC2 = 4.9 to 5.5 mmol.l
-1, SBC3 = 5.6 to 6.5 mmol.l-1 vs. Callaghan et 
al. = +3 mmol.l-1 vs. Oliveira et al. = +5mmol.l-1). Based on this evidence, it is therefore more 
appropriate to identify time to peak HCO3
- prior to the use in exercise to elicit ergogenic effects 
on performance. Research is needed to further support this concept however, as no study to 
date has directly compared beginning exercise at individual time to peak to times outside of 
individual time to peak on exercise performance, following NaHCO3 ingestion. A further 
consideration is that identifying time to peak HCO3
- presents a logistical challenge, as this 




A unique finding of the present study was the lack of a dose-dependent effect on exercise 
performance, with SBC2 improving performance to a similar magnitude as SBC3. These 
findings contrast with McNaughton (1992a) reporting 0.3 g.kg-1 BM NaHCO3 improved TWD 
greater than 0.2 g.kg-1 BM NaHCO3 during 60 s of maximal cycling, compared to a placebo. 
The negligible 0.1% difference observed between SBC2 and SBC3 are more in agreement with 
the findings of McKenzie et al. (1986), whereby a negligible 0.3% difference between 0.15 
g.kg-1 BM and 0.3 g.kg-1 BM NaHCO3 was observed. Based on the 3 s cut off from the priori 
power calculation, three participants improved more greatly in SBC2 compared to SBC3, 
whilst two participants improved more greatly in SBC3 compared to SBC2. These data 
combined suggest a lower dose of NaHCO3 is plausibly a physiologically optimal for some 
individuals to enhance exercise of this duration and intensity. Although, athletes should still 
trial each dose prior to use in competition to evaluate which amount of NaHCO3 provides a 
larger ergogenic benefit. Considering the potential for the onset of GI discomfort however, 
athletes who are susceptible to such symptoms may select the lower dose knowing this may 
still improve performance. Future work should continue to explore the dose-dependent effects 
of NaHCO3 on exercise of different intensities and durations.  
 
It is purported that mitigating the severity of GI discomfort is important to obtain a performance 
benefit following NaHCO3 supplementation. This is based on findings by Saunders et al. 
(2014a), who reported a significant effect on performance only upon the removal of 
participants who suffered from GI discomfort. The present study findings contrast this 
however, by reporting a significant 2.3% improvement following both SBC2 and SBC3, 
despite the occurrence of mild to moderate GI discomfort. Reasons for this may be due to the 
good tolerance of NaHCO3 in the participant cohort of the current study compared to Saunders 
et al. (2014a), although it is difficult to compare as no explicit statistical analysis on GI 
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discomfort is available in the latter study. Nonetheless, there may still be a relationship between 
GI discomfort and performance, as for instance, participant 8 in the present study suffered from 
moderate diarrhoea and bowel urgency in SBC3 and no improvement in performance was 
observed as a result (0.1 s). This occurred despite performance in SBC2 improving by 8.9 s in 
the same participant, where no instances of GI discomfort occurred. Combining this finding 
with other investigations where participants have self-withdrawn or have been withdrawn by 
the research team due to the severity of GI discomfort, the responses from NaHCO3 still warrant 
observation in training prior to use in competition (Chapters 4 and 5a, Jones et al., 2016). 
Nonetheless, smaller amounts of NaHCO3 may be an attractive solution to the athlete to reduce 
the severity of GI discomfort symptoms, whilst still providing ergogenic effects to exercise 
performance. 
 
The increases in pH and HCO3
- following NaHCO3 are the most likely mechanism for an 
improved performance in the present study, as both SBC treatments raised HCO3
- and pH 
significantly compared PLA. An increase in extracellular HCO3
- is suggested to increase H+ 
efflux during exercise due to the upregulation of the lactate/H+ cotransporter, leading to an 
increased energy contribution from anaerobic processes (Marx et al., 2002). Specifically, the 
change in HCO3
- was superior in both SBC2 (+25.9% vs. PLA) and SBC3 (+31.7% vs. PLA), 
whilst post-exercise blood lactate was also significantly higher (~15%) in the SBC conditions. 
These combined changes in blood acid base balance and lactate following NaHCO3 ingestion 
are therefore indicative of exercise at higher exercise intensities in the SBC conditions and 
hence, improved performance. Furthermore, between SBC conditions there were minimal 
differences in respect of blood acid base balance prior to, or during exercise. This provides a 





Ingestion of NaHCO3 individualised to time to peak HCO3
- improves 4 km TT cycling 
performance in trained cyclists. Both 0.2 g.kg-1 BM and 0.3 g.kg-1 BM NaHCO3 equally 
increased buffering capacity and subsequently provided ergogenic benefits to exercise 
performance. No difference was observed between SBC conditions; therefore, athletes can 
plausibly use the lower dose of NaHCO3, particularly if they are susceptible to the onset GI 
discomfort. Future research should investigate the dose-dependent effects of both 0.2 g.kg-1 






























Chapter 6 – The Effects of Sodium Bicarbonate 
Ingestion in Two Separate Doses on 4 km Time Trial 
















Exercise and training programmes with a hypoxic stimulus have been of interest to both 
exercise physiologists and athletes, primarily due to the potential for augmented exercise 
performance upon a return to sea level (Holliss et al., 2013, Sinex and Chapman, 2015). One 
common issue with incorporating a hypoxic stimulus however, is the ability of the athlete to 
sustain overall training intensity and volume, as exercise performance represents a curvilinear 
decline with increasing elevations (Deb et al., 2018b). In cycling time trial (TT) performance, 
Amann et al. (2006) displayed a 5.4% (25 s) reduction in 5 km TT completion time in acute 
moderate hypoxic conditions (FiO2 15%; 2700 m). Consequently, this reduction in volume and 
intensity can potentially limit the efficacy of hypoxic training schedules, such as intermittent 
hypoxic training (IHT) (Hoppeler, Klossner and Vogt, 2008, Sinex and Chapman, 2015, 
Nakamoto et al., 2016). Athletes and coaches may therefore consider interventions that mitigate 
the decline in performance observed at acute hypoxia, to sustain overall training intensity and 
volume.  
 
To identify plausible interventions to limit the decline in performance at hypoxia, the key 
mediators of fatigue need to be addressed. It is well researched that the aetiology of fatigue 
comprises of an interplay of both afferent/efferent feedback to the central nervous system (i.e. 
central fatigue), and biochemical alterations in the intramuscular regions (i.e. peripheral 
fatigue) (Davis, 1995, Ament and Verkerke, 2009). The contribution from each task is 
dependent on the exercise intensity and duration (Enoka and Duchateau, 2008). Decreases in 
performance shown in acute moderate (i.e. 2000 to 3000 m) hypoxia are attributed to the 
reduction in the partial pressure of oxygen (PO2), which hampers O2 delivery and supply to the 
active musculature (Bassett and Howley, 2000, Amann and Calbet, 2008). This reduction in 
convective O2 transport places a greater reliance on non-oxidative energy pathways, owing to 
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the higher relative intensity (i.e. % of maximal rate of oxygen consumption; VO2max) required 
at hypoxia compared to a given absolute workload in normoxia (Wolfel et al., 1991, Amann et 
al., 2007, Romer et al., 2007, Chapter 2.6).  
 
A concern is that such greater reliance on non-oxidative energy systems will increase metabolic 
perturbation, and in turn, increase the peripheral drive of fatigue compared to normoxia 
(Amann et al., 2007, Romer et al., 2007). This includes a potential further impairment of 
calcium (Ca2+) ion release from the sarcoplasmic reticulum (SR) (Duhamel et al., 2004a, 
Duhamel et al., 2004b), more rapid accumulation of energy metabolites such as hydrogen ions 
(H+) (Adam and Welch, 1980) and inorganic phosphate (Pi) (Hogan et al., 1999), and greater 
decrements in the strong ion difference (SID) (Lühker et al., 2017); all of which have been 
linked to fatigue (Allen et al., 2008a, 2008b, Cairns and Lindinger, 2008). Adams and Welch 
(1980) reported a reduction in pH and an increased H+ production at acute hypoxia compared 
to normoxia, despite a 3 min shorter cycling time to exhaustion at 90% VO2max in the hypoxic 
condition. These biochemical changes show H+ accumulation is more rapid in hypoxia, which 
may also explain why performance is hampered. The importance of a decline in pH and the 
associated increase in H+ accumulation on fatigue during exercise are controversial however, 
with suggestions that such reductions offer minimal explanation to the decrements in force 
production observed during fatiguing exercise (Fitts, 2016, Westerblad, 2016). Considering 
these controversies, further research investigating strategies to mitigate the acid base balance 
perturbation, such as ingestion of alkalotic supplements, may offer a greater insight into the 
determinants of fatigue during high-intensity exercise in acute hypoxic conditions. 
  
Ingestion of sodium bicarbonate (NaHCO3) may help alleviate the heightened acid base 
balance perturbation in hypoxic conditions, by significantly increasing blood pH and increasing 
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the availability of bicarbonate (HCO3
-) ions. This has been shown to facilitate an increased 
efflux of H+ from intramuscular to extracellular compartments, thereby protecting 
intramuscular acid base balance (Bishop et al., 2004, Carr et al., 2011a). Previous chapters in 
this thesis (Chapters 4, 5a and 5b) showed that ingestion of 0.2 g.kg-1 BM and 0.3 g.kg-1 BM 
NaHCO3 are physiologically optimal doses to increase acid base balance, by increasing HCO3
- 
above the 5 mmol.l-1 threshold suggested to lead to ergogenic effects on performance (Carr et 
al., 2011a). As a result, both amounts increased performance during a 4 km cycling TT 
compared to a placebo. More importantly however, little difference between NaHCO3 
treatments was observed (0.1%). This finding is potentially important for coaches aiming to 
mitigate the onset of gastrointestinal (GI) discomfort following NaHCO3 within their athletes, 
particularly if the smaller dose still leads to similar ergogenic effects. Despite this, the dose-
dependent effects of NaHCO3 are untested in acute hypoxic conditions to date, as only 0.3 g
.kg-
1 BM has been investigated (Saunders et al., 2014b, Flinn et al., 2014, Deb et al., 2017, 2018a).  
 
Flinn et al. (2014) reported no significant effects of 0.3 g.kg-1 BM NaHCO3 on intermittent 
high-intensity exercise consisting of cycling at 120% peak power output for 30 s, followed by 
a 30 s active recovery repeated to exhaustion at a FiO2 of 14.7% (2800m). Moreover, in a sport-
specific study no effect of NaHCO3 ingestion was observed on three sets of repeated sprints (5 
x 6 s) conducted pre, mid (half-time) and following a 90 min football simulation (Saunders et 
al., 2014b). Recently however, a 4.8% increase in total work done (TWD) during a 3-min ‘all-
out’ cycling test has been observed with NaHCO3 ingestion in similar acute hypoxic conditions 
(FiO2 14.5%) (Deb et al., 2017). Similarly, an improved exercise tolerance (+14%) has also 
been observed during an intermittent cycling test consisting of repeated 60 s work in the severe 
intensity domain and 30 s recovery at 20 W to exhaustion, at the same hypoxic level (Deb et 
al., 2018a). Interestingly, Deb et al. (2017 and 2018a) opted for a NaHCO3 ingestion strategy 
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individualised to a pre-determined time to peak alkalosis, whereas, Flinn et al. (2014) and 
Saunders et al. (2014b) employed a standardised ingestion strategy beginning at 90 and 240 
min prior to exercise, respectively. Considering recent literature suggests that accounting for 
the large inter-individual variation in time to peak alkalosis may heighten the likelihood of 
observing an ergogenic effect (Jones et al., 2016, McNaughton et al., 2016), this may explain 
why performance improvements were only observed by Deb et al. (2017, 2018a). Nonetheless, 
these studies were varied in their approach with differences including training status (trained 
vs. untrained), exercise type (continuous vs. intermittent), and mode (running vs. cycling), 
which may have affected results (Peart, Siegler and Vince, 2012, McNaughton et al., 2016). 
Likewise, the individual time to peak NaHCO3 ingestion strategy warrants further research, as 
no study to date has investigated the dose dependent effects on performance or during a self-
paced TT in moderate acute hypoxic conditions. 
 
During hypoxic training schedules some athletes may participate in multiple bouts of exercise, 
therefore the post-exercise recovery kinetics of acid base balance following NaHCO3 ingestion 
could be important. In the only study to date conducted at a terrestrial altitude of 1570 m, 
recovery of pH and HCO3
- occurred between 45 and 50 min following a high-intensity exercise 
bout, and pre-exercise co-ingestion of NaHCO3 and sodium citrate (0.2 g
.kg-1 BM each) 
(Robergs et al., 2005). Conversely, the placebo treatment failed to recover in the 60 min period 
of blood sampling (Robergs et al., 2005). This suggests that if a second bout of exercise is 
undertaken, NaHCO3 could alleviate the metabolic perturbation and potentially improve 
performance. Due to this study being conducted at terrestrial altitude however, and it is unclear 
if participants had an acclimatisation period. In addition, Robergs et al. (2005) employed a 
level of hypoxia lower than the typical moderate elevations of around 2000 to 3000 m 
suggested to be required to elicit significant physiological adaptions in hypoxic training 
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schedules (Sinex et al., 2015). Therefore, investigations evaluating acid base balance recovery 
in moderate hypoxic conditions following NaHCO3 would have greater application to hypoxic 
training models. The purpose of this study therefore, was to investigate the effects of 0.2 g.kg-
1 BM and 0.3 g.kg-1 BM NaHCO3 on 4 km cycling TT performance and post-exercise blood 
acid base balance recovery at acute moderate hypoxia. The hypothesis of this study was that 
both NaHCO3 doses would improve performance, however that 0.3 g
.kg-1 BM NaHCO3 would 
lead to a faster post-exercise recovery of acid base balance.  
 
6.2 Methods  
6.2.1 Participants  
Ten trained club-level cyclists (9 male, 1 female, age 29 ± 11 years, body mass 77 ± 13 kg, 
hypoxic maximal rate of oxygen consumption (VO2max) 51 ± 6 ml
.kg.min-1, hypoxic peak power 
output 334 ± 37 W), and Four male recreationally trained cyclists (age 24 ± 1 years, body mass 
81 ± 2 kg, hypoxic VO2max 44 ± 2 ml
.kg.min-1, hypoxic peak power output 289 ± 19 W) 
volunteered for this study. Ethical approval was granted from the University Research Ethics 
Committee (URESC16-LG01) and all participants provided written informed consent.  
 
6.2.2 Experimental overview 
After an initial VO2max test, participants visited the laboratory on a further seven occasions in 
a block randomised, crossover, and double blind designed study (2 x identification of peak 
blood HCO3
-, 5 x cycling TT’s). Participants followed the same pre-experimental procedures 




6.2.3 Determination of maximal oxygen consumption and time to peak blood bicarbonate 
These procedures to determine VO2max were conducted as described in section 3.4.2. Time to 
peak HCO3
- was determined using the same procedures detailed in Chapters 5a and 5b. 
 
6.2.4 Four-kilometre time trial cycling protocol, supplementation of sodium bicarbonate, 
and blood measures 
The cycling TT protocol was identical to the procedures described in previous chapters (section 
3.4.3, 5a and 5b), apart from each TT was completed in a normobaric hypoxic chamber (FiO2 
14.5%; ~3000 m). Similarly, the supplementation of either 0.2 g.kg-1 BM (SBC2), 0.3 g.kg-1 
BM NaHCO3 (SBC3) or 0.07 g
.kg-1 BM sodium chloride (NaCl) (PLA) was identical to the 
procedures described in previous chapters (5a and 5b). For the control (CON) trial, 
experimental procedures were mimicked apart from no ingestion of any supplement was 
completed. In each trial, from the ingestion point until individual time to peak HCO3
-, 
participants were outside of the chamber. Once individual time to peak HCO3
- was reached, 
the participants then entered the chamber to complete the TT. Blood sampling procedures and 
measured variables were consistent with previous chapters (section 3.2.6, Chapter 5a and 5b), 
apart from an additional blood sample was taken post warm-up to determine the effects on 
HCO3
-, and electrolyte data was also included for K+, Na+, Ca2+ and Cl-. The calculation for 
the SID was completed as per previously stated in section 3.2.6. Lastly, for a period of 40 min 
post-exercise, a blood sample was taken every 10 min to obtain the acid base recovery kinetics 
following each treatment. During this time frame, participants remained seated in the hypoxic 




6.2.5 Perceptual measures, heart rate, and oxygen saturation 
Ratings of perceived exertion for the legs (RPEL) and overall body exertion (RPEO) were 
recorded every 1 km during the TT, while, heart rate (HR) and oxygen saturation (SpO2) were 
measured at rest, every 500 m, and post-exercise. Both HR and SpO2 were also measured at 
every 10 min interval during recovery. Gastrointestinal discomfort (GI) was recorded using 
identical procedures detailed previously (Chapters 5a and 5b), with the addition that 
participants were also asked to rate their level of GI discomfort at 10 min intervals during the 
40 min recovery window. Participants were also asked to complete the supplement belief 
questionnaire at their respective time to peak HCO3
- (i.e. pre TT warm-up).   
 
6.2.6 Statistical analysis 
A paired t test was used to compare both the differences in blood responses (time to peak and 
absolute changes in pH and HCO3
-), and GI discomfort (severity and aggregate score) between 
SBC treatments. Performance data (time to complete the TT, mean power, and mean speed) 
and blood data (change in both pH and HCO3
- during exercise, and the absolute changes in 
these analytes from post-exercise to 40 min recovery) were assessed for differences using a 
repeated measures ANOVA. Magnitude based inferences (MBI) were also calculated (with 
90% CI) for performance data (time to complete, mean power and mean speed) and interpreted 
as described in section 3.5.2. Otherwise, a two-way [treatment x time] repeated measures 
ANOVA was employed, and where a significant main effect was observed, the Bonferroni 
post-hoc pairwise comparison was applied. The effect size of the interactions/main effects are 
reported as the partial eta squared (Pƞ2), and where appropriate, between treatment Hedge’s g 
effect sizes (g) are calculated and interpreted as per section 3.5.2. Confidence intervals (CI) are 
reported (± 95%) between experimental treatments for significant effects only. Intraclass 
correlation coefficients (ICC) were used with both the point value (r) and significance reported, 
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to assess the reproducibility of the absolute changes in pH and HCO3
- between the initial 
identification of time to peak blood bicarbonate trial and the subsequent cycling trials. Data are 
reported as mean ± standard deviation (SD) unless otherwise stated and statistical significance 
was set at p <0.05.  
 
6.3 Results 
6.3.1 Preliminary trials to determine time to peak blood bicarbonate 
Time to peak pH ranged between 30 and 100 min in SBC2 (mean: 64 ± 20 min; median: 60 
min; CV: 31%), compared to 40 and 120 min in SBC3 (mean: 75 ± 21 min; median: 80 min; 
CV: 28%; vs. SBC2 p = 0.07). Absolute pH change from baseline to peak was similar in SBC2 
and SBC3 (SBC2 0.08 ± 0.02, SBC3 0.09 ± 0.02; p = 0.30). In subsequent experimental trials, 
the absolute change in pH displayed a fair level of reproducibility in both SBC2 (r = 0.56, p = 
0.02) and SBC3 (r = 0.48, p = 0.11). Time to peak HCO3
- occurred at similar time frames to 
pH ranging from between 30 and 110 min in SBC2 (mean: 69 ± 22 min; median: 60; CV: 32%), 
and between 50 to 100 min in SBC3 (mean: 72 ± 17 min; median: 70; CV: 24%; vs. SBC2 p = 
0.91). The absolute change in HCO3
- from baseline to peak was greater with SBC3 by 1.2 
mmol.l-1 compared to SBC2 (6.9 ± 1.2 vs. 5.7 ± 0.9 mmol.l-1; p <0.05). The reproducibility of 
the absolute change in HCO3
- was greater compared to pH however, with good reproducibility 




Time to complete the TT following SBC2 was 1.1% ± 1.0% faster compared to CON (p = 
0.009; CI = 8.1, 1.0; g = 0.20) and 0.9% ± 1.1% faster compared to PLA (p = 0.04; CI = 6.8, 
0.3; g = 0.16). The performance effect was more pronounced in SBC3 however, reporting a 
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1.6% ± 1.3% improvement compared to CON (p = 0.002; CI = 11.1, 1.9; g = 0.28) and 1.4% ± 
1.0% improvement compared to PLA (p = 0.005; CI = 9.9, 1.1; g = 0.24; Figure 6.1). Using an 
MBI approach, a very likely beneficial effect was determined for both SBC2 and SBC3 
compared to PLA (Table 6.1). There was no significant difference between SBC3 and SBC2 
(p = 0.13; g = 0.10), however a mean 2 s (0.5% ± 0.8%) improvement was observed in the 
SBC3 treatment, which was determined as a likely benefit in MBI analysis (Table 6.1). 
 
Compared with PLA, mean power in both SBC2 (+4.6%, p = 0.34; g = 0.25) and SBC3 (+5.9%; 
p = 0.17; g = 0.33) was increased, although no interaction was observed (ƞ2 = 0.18, p = 0.09). 
Nonetheless, MBI analysis revealed a likely benefit for both SBC treatments (Table 6.1). Mean 
speed was significantly greater for SBC3 (+0.8%, p = 0.002; CI = 0.1, 0.5; g = 0.14), however 
not for SBC2 (+0.3%, p = 0.58; g = 0.05).  
Figure 6.1 Mean (± SD) and individual (solid horizontal lines) time to TT completion 





Table 6.1 Magnitude based inferences (MBI’s) overview of performance data. 
Condition Change in mean compared to placebo  
(± 90% CI) 
Non-clinical MBI 
Time to complete 
(seconds) 
  
SBC2 -3.7 ± 2.9 (403.6 ± 22.4 s)  Very likely beneficial 
SBC3 -5.6 ± 3.3 (401.6 ± 22.1) Very likely beneficial  
Change in mean between SBC2 and 
SBC3 (%, ± 90% CI) 
 
SBC3 vs. SBC2 2.0 ± 2.2 Likely beneficial 
Mean power (W) 
  
Condition Change in mean compared to placebo  
(± 90% CI) 
 
SBC2 +13 ± 21 Likely beneficial 
SBC3 +17 ± 19 Likely beneficial 
Mean speed (km.h-1) 
  
SBC2 +0.1 ± 0.3 Very likely trivial 
SBC3 +0.3 ± 0.1 Very likely trivial 
 
6.3.3 Blood responses 
During experimental trials a [treatment x time] interaction was observed for pH (Pƞ2 = 0.34, p 
<0.001), such that pH was greater post-supplementation of NaHCO3 in SBC2 compared to 
PLA (+0.06; p <0.001; CI = 0.6, 0.8, g = 3.7) and CON (+0.06; p <0.001; CI = 0.5, 0.9, g = 
3.7). The largest increases however were observed in SBC3 (vs. SBC2 +0.02; p <0.005; CI = 
0.1, 0.3; g = 1.9; vs. PLA and CON; p <0.001; Figure 6.2). Similarly, higher pH values were 
observed in both SBC treatments post-warm up and post-TT compared to PLA and CON (p 
<0.005; Figure 6.2), although SBC3 was significantly greater (+0.02) than SBC2 post-warm 
up (p = 0.04; CI = 0.01, 0.4, g = 0.7). Similarly, a [treatment x time] interaction was observed 
for HCO3
- (Pƞ2 = 0.60; p <0.001; Figure 6.2), as SBC3 elicited the greatest change in HCO3
- 
from baseline to post-supplement (+7 mmol.l-1) compared to SBC2 (+5.8 mmol.l-1, p = 0.01; 
CI = 0.3, 2.3; g = 1.4) and both PLA and CON (p <0.001). This was also evident post warm-
up where SBC3 was 1.8 mmol.l-1 greater than SBC2 (p = 0.02; CI = 0.3, 3.2; g = 1.0), however 
no differences between these two treatments were seen post-TT (p = 0.35). Whilst both 
treatments were greater than both PLA and CON at the post warm-up and post-TT stages (p 
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<0.005). A [treatment] effect was observed for the HCO3
- change during the TT (Pƞ2 = 0.70; p 
<0.001) where there were marginal differences between SBC2 and SBC3 (10.6 ± 3.0 vs. 11.4 
± 2.7 mmol.l-1; p = 0.72; g = 0.3), however greater changes compared to PLA and CON were 
evident (8.0 ± 2.4 and 8.1 ± 2.2 mmol.l-1; both p <0.001). Blood lactate was greater post-TT in 
SBC3 treatments compared to both PLA and CON (both p <0.002), with no differences 
between SBC treatments (p >0.05; Figure 6.2).   
 
Post-NaHCO3 supplementation, the SID was greater in SBC2 compared to PLA (+4 meq/L; p 
<0.001; CI = 1.7, 6.3, g = 1.5) and CON (+4 meq/L; p <0.001; CI = 2.0, 5.2; g = 1.5). Similarly, 
the SID was greater in SBC3 compared to PLA (+6 meq/L vs. CON p <0.001; CI = 3.1, 7.9; g 
= 3.7) and CON (+6 meq/L vs. PLA p <0.001; CI = 3.9, 8.1; g = 4.1; Figure 6.3). There was 
no difference between SBC conditions (p >0.05). Post-warm up, the SID was significantly 
greater to all other treatments in SBC3 (all p <0.05). Whereas, SBC2 was only significantly 
greater compared to PLA (+3 meq/L, p = 0.02, CI = 0.3, 6.2, g = 1.0), although did reveal a 
large effect size compared to CON (ES = 0.97; p = 0.63). Post-TT there was no difference in 
the SID between any treatment (p >0.05).   
 
6.3.4 Recovery  
From post-TT to 40 min recovery, pH was greater for SBC treatments at all time points 
compared to PLA and CON (p <0.05; Figure 6.2), with SBC3 only significantly higher than 
SBC2 at 20 min recovery (+0.02; p = 0.02; CI = 0.5, 0.01; g = 0.5). Compared to PLA and 
CON, both SBC treatments demonstrated greater HCO3
- across all recovery time points (all p 
<0.003; Figure 6.2). There were no differences in HCO3
- between SBC2 and SBC3 at any 
recovery time point (all p >0.05). A [treatment] effect (Pƞ2 = 0.49; p <0.001) was revealed for 
the change in HCO3
- during recovery, which was greater for both SBC2 (+2.2 mmol.l-1; p 
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<0.001 vs. PLA; +2.2 mmol.l-1; p = 0.05 vs. CON) and SBC3 (+2.4 mmol.l-1; p < 0.001 vs. 





















Figure 6.2 Mean (± SD) blood pH (A), bicarbonate (HCO3
-) (B) and lactate (C) following 
NaHCO3. ** SBC3 greater than (p <0.05) PLA and CON, ## SBC2 greater than PLA and CON, 






Blood lactate was greater at 10 and 20 min recovery in both SBC treatments compared to PLA 
and CON (p <0.05; Figure 6.2), however no differences were observed at any other time point 
during recovery (all p >0.05). Blood lactate did not return to baseline in any treatment following 
the TT. 
 
At 30 and 40 min recovery, the SID was greater in SBC3 compared to PLA and CON (both p 
<0.05), whereas SBC2 was only greater at 40 min recovery (p <0.05). There were no 
differences between SBC2 and SBC3 throughout recovery (all p >0.05; Figure 6.3). The change 
in SID from post-TT to 40 min recovery was greater for SBC2 compared to PLA only (+3 
meq/L; p = 0.008; CI = 0.9, 6.8; g = 1.1), whereas SBC3 was greater compared to PLA and 
CON (+5 meq/L; +4 meq/L; both p <0.01). The effects of NaHCO3 on singular ionic shifts 
including K+, Na+, Ca2+ and Cl- are depicted in figure 6.4.  
Figure 6.3 Mean (± SD) strong ion difference (SID) responses over time. SBC3 different to (p 
<0.05) CON (*) and PLA (**), SBC2 different to CON (#) and PLA (##), † SBC3 different to 


















Figure 6.4 Mean (± SD) potassium (A), sodium (B), calcium (C) and chloride (D) responses 
over time. SBC3 different to (p <0.05) CON (*) and PLA (**), SBC2 different to CON (#) and 









6.3.5 Rating of perceived exertion, heart rate, oxygen saturation, and gastrointestinal 
discomfort  
No effect of NaHCO3 was observed on RPEO (Pƞ
2 = 0.04, p = 0.66) or RPEL (Pƞ
2 = 0.04, p = 
0.47) during the TT. Similarly, HR (Pƞ2 = 0.08, p = 0.31) and SpO2 (Pƞ
2 = 0.03, p = 0.79; 
Figure 6.5) was unaffected by NaHCO3 at any 500 m segment of the TT (Table 6.2) or during 
recovery. More participants suffered from GI discomfort following SBC3 compared to SBC2 
from ingestion to time to peak HCO3
- (11/14 SBC3, 7/14 SBC2), however no GI discomfort 
was reported in the recovery period. The most common symptom of GI discomfort in SBC2 
was belching (2/14), compared to diarrhoea (5/14) in SBC3. Both the severity and aggregate 
score of GI discomfort was greater in SBC3 compared to SBC2 (severity: 7.6 ± 2.0 vs. 5.3 ± 
2.4; p = 0.002; g = 1.0) (aggregated score: 20 ± 14 vs. 9 ± 6; p = 0.005; g = 1.0). There was a 
significant positive moderate correlation for the absolute amount of NaHCO3 ingested and the 
resulting aggregated score of GI discomfort following SBC3 (r2 = 0.57; p <0.03). The 
supplement was correctly identified by the participant on 4/42 occasions.  




























SBC2 SBC3 PLA CON
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Table 6.2 Overview of the 4 km TT perceptual measures  
No significant differences throughout. RPEO = ratings of overall perceived exertion, RPEL = ratings of 
perceived leg exertion, HRpeak = heart rate peak, SpO2 = saturation of oxygen, PO2 = partial pressure of 
oxygen, PCO2 = partial pressure of carbon dioxide.  
 
6.4 Discussion 
The aim of this study was to investigate the effects of NaHCO3 on 4 km TT cycling 
performance, and the subsequent recovery of acid base balance in acute moderate hypoxic 
conditions. Accordingly, both SBC2 and SBC3 improved performance compared to PLA, 
revealing a ‘very likely’ beneficial effect. Furthermore, SBC3 displayed a greater magnitude 
of performance improvement compared to SBC2, showing a ‘likely’ beneficial effect, however, 
based on the inter-individual performance responses, both should be trialled. The selection of 
dose may be dependent on the GI discomfort responses from SBC3, as some individuals 
struggled to tolerate this amount in the present study compared to SBC2. These individuals 
may therefore benefit from a smaller dose, especially if they still obtain similar ergogenic 
effects as SBC3. This study also identifies that the recovery kinetics of acid base balance in 
moderate acute hypoxic conditions is accelerated following NaHCO3. Indeed, both SBC2 and 
Variable SBC2 SBC3 PLA CON 









RPEO  19 ± 2  19 ± 2  19 ± 1  19 ± 2 
         
RPEL  19 ± 2  19 ± 2  19 ± 1  19 ± 1 











         
SpO2 (%) 90 ± 3  80 ± 4 90 ± 2 80 ± 4  90 ± 3 81 ± 3 89 ± 2 79 ± 4 






































SBC3 displayed similar recovery kinetics and fully recovered acid base balance to baseline 
within 20 to 40 min, whereas in contrast, PLA and CON failed to recover. Considering the 
potential important role of acid base balance on fatigue, this enhanced recovery plausibly 
suggests that the ingestion of NaHCO3 may improve subsequent exercise performance, which 
future research should address.  
 
A clear performance effect following NaHCO3 was observed in the trained cyclist population 
employed in the current study. This contrasts with previous investigations reporting no effect 
of effect of NaHCO3 on performance in moderate hypoxic conditions equivalent to 3000 m 
(Saunders et al., 2014b, Flinn et al., 2014). The current study findings instead support recent 
investigations by Deb et al. (2017) who reported 0.3 g.kg-1 BM NaHCO3 improved performance 
during a 3 min all-out, and during intermittent high-intensity exercise to exhaustion (Deb et al., 
2018a); both at 3000 m acute hypoxia. Whilst there were differences between these studies that 
may explain some of the variation in outcomes that include the exercise type and mode, and 
training status of participants (Peart et al., 2012, McNaughton et al., 2016), the current study 
findings suggest the most plausible difference is the NaHCO3 ingestion strategy employed. 
Both Saunders et al. (2014b) and Flinn et al. (2014) employed a standardised NaHCO3 
ingestion strategy, which fails to account for the high inter-individual variation to achieve peak 
alkalosis (Jones et al., 2016, McNaughton et al., 2016). Therefore, buffering capacity may not 
have been maximised in some individuals, subsequently leading to a reduced effect of NaHCO3 
(Jones et al., 2016, Miller et al., 2016, Chapter 4, 5a and 5b). In contrast, both the present study 
and the investigations by Deb et al. (2017, 2018a) accounted for such inter-individual variation 
by supplementing NaHCO3 at a pre-determined individual time to peak pH or HCO3
-, which in 




- following NaHCO3 should be determined prior to use in training or competition, 
to heighten the chances of an ergogenic effect.  
 
An interesting finding of this study was that SBC3 was ‘likely’ beneficial to performance 
compared to SBC2 in magnitude based inferences analysis. This contrasts with previous 
chapters of this thesis (5a and 5b) reporting no dose-dependent differences on performance in 
normoxic conditions. In the current study, the TE between the familiarisation and the CON 
trial was 3.3 seconds, and in using this cut off, three participants displayed improvements in 
SBC3 versus SBC2. This more pronounced effect in hypoxia from SBC3 vs. SBC2 may be 
explained by the exacerbated acidic stress in hypoxic conditions, as a normoxic study displayed 
minimal differences in normoxia using the same exercise protocol as the current study (Gough 
et al., 2018). Nonetheless, eleven participants displayed minimal differences between SBC2 
and SBC3 (<3.3 seconds), and SBC2 also still significantly improved performance compared 
to PLA. This suggests there is large inter-individual responses to the NaHCO3 dose in acute 
hypoxic conditions, and for most, 0.2 g.kg-1 BM NaHCO3 may be physiologically optimal. 
Individuals should therefore trial both SBC2 and SBC3 to identify which is the most ergogenic, 
and opt for SBC3 if this provides an additive ergogenic effect.  
 
The changes in both blood acid base balance and lactate following NaHCO3 in the present 
study offer mechanistic insight to explain the enhanced performance. The change in HCO3
- 
during exercise was enhanced by 25% in SBC2 and 30% in SBC3 compared to PLA, whilst 
greater post-TT blood lactate was also observed in both SBC conditions (SBC +22%, SBC3 
+23% vs. PLA). Indeed, these changes infer a greater amount of extracellular H+ buffering 
occurred during exercise following NaHCO3, thereby protecting the pH gradient between the 
intramuscular and extracellular compartments. Alternatively, evidence has suggested that the 
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post-exercise increase in lactate following NaHCO3 ingestion may lead to upregulation of 
glycolytic flux and utilisation by preventing the inhibition of key glycolytic enzymes (i.e. 
phosphorylase and phosphofructokinase) (Hollidge-Horvat et al., 2000, Percival et al., 2015). 
These indirect markers cited in the present study are contested in literature however suggesting 
acidosis does not hinder anaerobic exercise performance, and that increases in post-exercise 
lactate actually infer a reduction of lactate uptake into inactive muscle tissue (Granier et al. 
1996; Westerblad, 2016). Nonetheless, a recent study reported a 34% significantly greater 
estimated glycolytic energy contribution during taekwondo exercise following NaHCO3 
ingestion (Lopes-silva et al., 2018). Therefore, the findings of the current study support that 
the mechanism of action following NaHCO3 may augment glycolytic contribution.  
 
The SID was significantly enhanced following NaHCO3 prior to exercise in the current study, 
primarily due to increases in Na+, and reductions in Cl- from baseline to pre-exercise. These 
changes may have better preserved the action potentials within the T-system by eliciting a 
greater ionic charge and thus, sustaining muscle excitability (Worthley, 1999, Allen et al., 
2008a, Gehlert, Bloch and Suhr, 2015). Subsequently, these changes offer an alternative site of 
action for NaHCO3’s ergogenic effects, rather than the traditional pH and HCO3
- mediated 
mechanisms often discussed, yet contested. Only Sostaric et al. (2006) has previously reported 
increases in the SID following NaHCO3, who also reported a 25% increase in finger flexion 
exercise to exhaustion. The use of such a small muscle mass however would have induced 
more extreme localised ionic fluxes compared to those experienced during whole-body 
exercise (Sejersted and Sjogaard, 2000). Therefore, by eliciting ionic fluxes consistent with 
whole-body exercise using a 4 km TT, the current study findings are more pertinent to support 
this mechanism of action. Nonetheless, such findings are restricted to extracellular ionic fluxes, 
and therefore further work is required investigating the intracellular ionic charges following 
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NaHCO3. These investigations may also include the assessment of muscle fibre conduction 
velocity or rapid generation force (RFD) following NaHCO3, as these are markers of membrane 
potential and sarcolemma excitability (Lowery, Nolan and O’Malley, 2002, Cairns and 
Lindinger, 2008). This would quantify the effects of the SID on performance more 
appropriately.  
 
The present study shows that pH and HCO3
- recovery do not display similar patterns. In short, 
from 20 min recovery onwards pH was beginning to plateau, whereas, HCO3
- was continuing 
to rise in a linear fashion. This suggest that practitioners should be aware that recovery of one 
of these analytes does not inform full recovery of the other, or acid base balance per se. It is 
also conceivable that the recovery of HCO3
- is more important compared to pH, as firstly, this 
is the predominant buffer during exercise. Secondly, in the PLA and CON conditions pH was 
close to baseline after the 40 min recovery period, whilst HCO3
- was still majorly depleted. 
Combined, these findings suggest the key difference is the recovery of HCO3
- between the SBC 
and PLA and CON conditions to determine the resultant performance effects. These findings 
are synonymous with Robergs et al. (2005), reporting post-exercise recovery profiles of pH 
and HCO3
- varied at a low level of hypoxia (1570 m) following an alkalotic supplement 
(NaHCO3 and sodium citrate; 0.2 g
.kg-1 BM of each). Perhaps therefore, monitoring the 
recovery of the SID is more appropriate, as this displayed similar recovery patterns in all 
treatments and is arguably a more valid reflection of acid base balance (Stewart, 1983). There 
was also no dose-dependent effects of NaHCO3 on the recovery of acid base balance, whereby 
at 40 min recovery, no significant differences in pH, HCO3
- or the SID were observed. This 
suggests that both SBC2 and SBC3 are sufficient to accelerate acid base balance recovery to a 
similar extent. Therefore, athletes will not compromise the post-exercise recovery of acid base 
balance if they select a lower dose of NaHCO3. 
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The full recovery of pH, HCO3
- and the SID to baseline was achieved between 20 and 40 min 
following both SBC2 and SBC3 in the current study. This recovery was accelerated compared 
to PLA and CON, whereby at 40 min recovery pH was close to baseline, however HCO3
- and 
the SID were markedly lower. Subsequently, these changes may be beneficial to subsequent 
exercise, as the existing acid base balance perturbation that would normally occur following 
high-intensity exercise is mitigated via NaHCO3 ingestion. The current study did not feature a 
subsequent bout however, which provides an avenue for future research. Moreover, the 
recovery in the current study was achieved at a faster rate compared to Robergs et al. (2005), 
who reported over 45 min was required following co-ingestion of NaHCO3 and sodium citrate. 
This longer recovery time frame however, is likely explained by the exercise intensity of the 
initial fatiguing bout between studies (Robergs et al. 2005, 110% workload at VO2max to 
exhaustion vs. 4 km TT). Specifically, the absolute changes in HCO3
- were similar from post-
exercise to 40 min recovery in both studies (Robergs et al. 10.4 vs. SBC2 10.3 ± 1.3, SBC3 
10.5 ± 1.5 mmol.l-1), suggesting both supplements are useful to achieve the recovery of acid 
base balance. Nonetheless, similar changes in the SBC2 treatment of the present study were 
observed compared to Robergs et al. (2005) who also used 0.2 g.kg-1 BM NaHCO3, however 
with an additional 0.2 g.kg-1 BM sodium citrate. This finding suggests there is arguably no need 
for the additional sodium citrate, considering the absolute recovery of acid base balance was 
similar. Furthermore, as NaHCO3 is more readily available to athletes, a single dose of 
NaHCO3 is arguably more suitable.   
 
6.5 Conclusion 
The present study shows that ingestion of two separate amounts of NaHCO3 individualised to 
a pre-determined time to peak HCO3
-, improves 4 km TT cycling performance in acute 
moderate hypoxic conditions. Whilst the SBC3 treatment displayed a greater performance 
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effect compared to SBC2 in magnitude based inference analysis, the individual responses were 
varied. Individuals should therefore trial both amounts to assess which is the most ergogenic. 
The selection of dose may be dependent on the GI discomfort responses, as SBC3 displayed 
significantly greater severity and instances of GI discomfort compared to SBC2. Lastly, both 
SBC treatments displayed a similar recovery of acid base balance back to baseline, which was 
also faster compared to PLA and CON. This suggests that both treatments may improve 



























Chapter 7 – The Effects of Sodium Bicarbonate 
Ingestion on Repeated 4 km Time Trial 











Repeated bouts of high-intensity exercise are a frequent feature of training and competition in 
athletes (Monedero and Donne, 2000, Barnett, 2006). The recovery between these bouts is an 
essential component to determining the effectiveness of the subsequent performance bout. 
Enhanced recovery can allow athletes to tolerate higher training loads in the subsequent bout, 
potentially enhancing the post-training adaptation to training as a result (Barnett, 2006). 
Whereas, in competition, enhancing recovery is an important component to sustain 
performance within the subsequent bout. This is applicable to sports such as track cycling, 
swimming or a rowing regatta series which involve heats, semi-finals and finals within a short 
amount of time (Al-Nawaiseh et al., 2016, Monedero and Donne, 2000). Specifically, the gap 
between the men’s team pursuit first round and the final at the Rio 2016 Olympics was 
separated by just 60 mins. Considering that most national and Olympic records are achieved 
within the preliminary rounds of these events (Al-Nawaiseh et al., 2016), this could suggest 
full recovery is not always possible during these time frames, or that current recovery practices 
are sub-optimal. Therefore, interventions to improve recovery and sustain subsequent exercise 
performance could be important.  
 
A major factor that may hamper the subsequent bout of exercise is the metabolic disturbance 
that occurs following an initial high-intensity exercise bout. Ward et al. (2016) reported the 
decline in pH and HCO3
- following a 4 km cycling time trial (TT) (team pursuit distance) was 
substantial, and reflective of metabolic acidosis (pH 7.16 ± 0.08, HCO3
- 11.9 ± 2.3 mmol.l-1). 
In practice however, such disturbances have been commonly inferred by high levels of post-
exercise lactate, whereby researchers have based the quality of recovery on the clearance of 
this metabolite (for review see Barnett, 2006). It is well known however, that lactate is not a 
valid reflection of acid base balance status (Robergs et al., 2004). Specifically, Chapter 6 of 
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the current thesis reported significantly greater blood lactate at 10 and 20 min post a 4 km 
cycling TT following sodium bicarbonate (NaHCO3) supplementation, in comparison to a 
placebo and control condition. Yet, both blood pH and bicarbonate (HCO3
-) were significantly 
higher in the NaHCO3 treatment at the same time points. This displays that lactate is not an 
appropriate marker of acid base balance recovery following high-intensity exercise, and 
instead, the pH and HCO3
- recovery kinetics is more important.  
 
Callaghan et al. (2017) reported the recovery from a 4 km TT could take longer than 75 min, 
as HCO3
- was 6.2 mmol.l-l below baseline at this point (19.5 ± 1.4 vs. 25.7 ± 1 mmol.l-1), whilst 
pH was close to baseline. Consequently, in the scenario whereby only 60 min is available for 
recovery such as that during track cycling events, an existing acid base balance perturbation 
will be evident. This may hamper performance considering a low pH has been suggested to be 
detrimental to muscle force production, due to the concomitant increases in hydrogen (H+) ion 
accumulation (Cairns, 2006, Fitts, 2016). Although contentious (Westerblad, 2016, Chapter 6), 
critical rises in H+ accumulation are linked to a reduction in the release and uptake of calcium 
ions (Ca2+) from the sarcoplasmic reticulum (Allen et al., 2008b), disruption of key enzymes 
of the glycolysis pathway (Hollidge-Horvat et al., 1999), and a reduction in the strong ion 
difference (SID) (Cairns and Lindinger, 2008). In response, it is intuitive to suggest that 
interventions to accelerate the post-exercise recovery of acid base balance may be beneficial 
for a subsequent bout of exercise. 
 
The ingestion of NaHCO3 supplementation has been shown to accelerate post-exercise acid 
base balance recovery and subsequent exercise performance (Pruscino et al., 2008, Zabala et 
al., 2008, 2011, Gough et al., 2017). Indeed, Pruscino et al. (2008) reported a ‘trivial’ to 
‘moderate’ benefit in magnitude based inferences (MBI) analysis following pre-exercise 
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NaHCO3 ingestion in the second bout of a 2 x 200 m freestyle swim, interspersed with a 30 
min recovery. In addition, Gough et al. (2017) reported NaHCO3 ingestion 30 min into a 90 
min post-exercise recovery significantly improved subsequent cycling capacity at 100% peak 
mean minute power by 16.6%. Both studies also reported that pH and HCO3
- recovery was 
accelerated and above baseline at the end of the recovery period, whereas, the placebo condition 
failed to fully recover. Subsequently, this might explain why ergogenic effects were observed. 
Conversely, no effect of NaHCO3 ingestion has been reported on three repeated Wingate tests 
separated by 15 to 30 min (Zabala et al., 2008, 2011), or during three repeated high-intensity 
swimming bouts separated by 20 min (Pierce et al., 1992). These discrepancies could be evident 
due to the shorter recovery time frames employed by these studies however, as Zabala et al. 
(2011) reported that neither pH, nor HCO3
- recovered back to baseline levels at any time point 
during recovery between the three Wingate tests. As a result, the recovery back to baseline may 
be important for ergogenic benefits to be realised. Unfortunately, the other studies (Pierce et 
al., 1992, Zabala et al., 2008) did not report blood acid base balance data for comparison. 
Despite the promising effects of NaHCO3 to improve post-exercise acid base balance recovery 
and subsequent exercise performance in normoxia, this strategy has yet to be applied to acute 
hypoxia.   
 
During hypoxic training schedules athletes may complete multiple bouts of high-intensity 
exercise. The need for optimal recovery in this scenario is arguably more important compared 
to normoxia, considering the acid base balance perturbation is increased compared to normoxia 
for a given absolute workload (Adam and Welch, 1980, Hogan et al., 1999, Romer et al., 2007). 
The use of NaHCO3 may be applied to this scenario as a result, to dampen the heightened acidic 
stress during exercise and recovery and improve subsequent exercise performance. In the only 
published work to date, Robergs et al. (2005) reported the use of NaHCO3 combined with 
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sodium citrate achieved full recovery of pH and HCO3
- to baseline in around 50 min, at 1570 
m terrestrial altitude. It was unclear if participants were acclimatised however, and the level of 
hypoxia used is lower than the moderate levels of hypoxia typically employed for hypoxic 
training (2000 to 3000 m) (Sinnex et al., 2015). In response, Chapter 6 of the current thesis 
investigated the use of both 0.2 g.kg-1 BM and 0.3 g.kg-1 BM NaHCO3 on 4 km cycling TT 
performance, and post-exercise acid base balance recovery in acute moderate hypoxic 
conditions (FiO2 14.5%; 3000 m). Both NaHCO3 doses accelerated the recovery of acid base 
balance to baseline within 20 to 40 min, and significantly improved 4 km TT performance 
compared to a placebo. Neither Robergs et al. (2005) nor Chapter 6 included a subsequent bout 
of exercise however, and therefore it is unknown if this improved acid base balance recovery 
translated into a superior subsequent exercise performance. The aim of this study therefore, 
was to investigate the effects of both 0.2 g.kg-1 BM and 0.3 g.kg-1 BM NaHCO3 on repeated 
bouts of 4 km TT cycling performance, interspersed with a 40 min recovery. The hypothesis 
of this study was that ingestion of 0.3 g.kg-1 BM NaHCO3 would improve performance to a 




Ten trained male club-level cyclists (age 27 ± 8 years, body mass 82 ± 9, hypoxic maximal rate 
of oxygen consumption (VO2max) 48.5 ± 5.6 ml
.kg.min-1, hypoxic peak power output 331 ± 40 
W) volunteered for this study. Ethical approval was granted from the Universities Research 
Ethics Committee (URESC16-LG01), and all participants provided written informed consent. 
All participants training load was reflective of a ‘trained’ cyclist (De Pauw et al., 2013), as 




7.2.2 Experimental overview 
Following an initial VO2max test, participants visited the laboratory on six separate occasions 
in a randomised, crossover and double blind designed study (2 x identification of peak blood 
HCO3
-, and 4 x cycling TT’s). Participants followed the pre-experimental procedures outlined 
in Chapter 3 (section 3.1.4). The procedures to determine VO2max were conducted as described 
in Chapter 3 (section 3.4.2). Time to peak HCO3
- following NaHCO3 was determined using the 
same procedures detailed in Chapters 5a, 5b and 6. 
 
7.2.3 Time trial cycling protocol, supplementation of sodium bicarbonate, and blood 
measures 
Participants completed 2 x 4 km TT’s (TT1 and TT2) interspersed with a 40 min recovery. The 
protocols for the TT, including the self-selected warm-up were identical to those detailed in 
previous chapters (Chapters 5a and 5b). Following ingestion of one of either 0.2 g.kg-1 BM, 0.3 
g.kg-1 BM NaHCO3, or a taste-matched placebo (PLA) consisting of 0.07 g
.kg-1 BM sodium 
chloride (NaCl), participants remained seated until their respective pre-determined time to peak 
HCO3
- in normoxic conditions. Once reached, participants then entered the normobaric hypoxic 
chamber at a FiO2 of 14.5% (~3000 m) for 10 min, prior to beginning the TT1 warm-up. 
Following TT1, participants completed a passive recovery entailing a quiet seated rest for 40 
min, in the hypoxic environment. During this time, measures for blood acid base balance (pH 
and HCO3
-), electrolytes (K+, Na+, Ca2+, and Cl-), and saturation of oxygen (SpO2) were 
recorded at the same time intervals, as described in Chapter 6. Thereafter, participants 
completed a second warm-up, followed by a second 4 km TT (TT2). Additional blood samples 





7.2.4 Perceptual measures  
Ratings of perceived exertion for the legs (RPEL) and overall body exertion (RPEO) were 
recorded in TT1 and TT2, mimicking the procedures from Chapter 6. Equally, HR and SpO2 
were recorded during both TT1 and TT2 at every 500 m split, and at 10 min intervals during 
recovery, as per Chapter 6. Gastrointestinal (GI) discomfort was recorded at 10 min intervals 
upon ingestion of supplement (i.e. SBC2, SBC3, or PLA) up to the individual time to peak 
HCO3
-, and at 10 min intervals during recovery. At individual time to peak HCO3
-, participants 
were asked if they could determine which supplement they had ingested using the supplement 
belief questionnaire.  
 
7.2.5 Statistical analysis  
No evidence of a violation for normality and sphericity was evident in any assessed variable, 
and therefore the appropriate parametric statistical tests were employed. A paired t test was 
conducted for the following: both the time to peak and absolute change in pH and HCO3
-, and 
both the severity and aggregated score for GI discomfort following SBC treatments. 
Performance data (time to TT completion and mean power) and blood data (change in pH and 
HCO3
- during TT1, recovery, and TT2) were analysed using a repeated measures ANOVA. In 
addition, magnitude based inferences (MBI) with 90% confidence intervals (CI) were 
calculated for performance data and interpreted as per Chapter 3. Otherwise, a two-way 
[treatment x time] repeated measures ANOVA was conducted with a Bonferroni correction. 
Effect size for interactions are reported as partial eta squared (Pƞ2) and where appropriate, 
between treatment Hedge’s g effect sizes (g) are reported and interpreted as per the thresholds 
described in Chapter 3. Significant effects are displayed with 95% CI where appropriate. 
Reproducibility of blood responses (absolute changes in pH and HCO3
-) in the preliminary trial 
and the subsequent cycling trials was assessed using Intraclass correlation coefficients (ICC) 
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(Chapter 3). Data is reported as mean ± standard deviation (SD) and statistical significance was 
set at p <0.05. Data were analysed using a statistical software package, SPSS (V.22, SPSS Inc., 
Chicago, IL, USA). 
 
7.3 Results  
7.3.1 Preliminary trials to determine time to peak blood bicarbonate 
Time to peak pH ranged between 30 and 100 min in SBC2 (mean: 66 ± 22 min; median: 60 
min; CV: 34%), and between 40 and 120 min in SBC3 (mean: 76 ± 21 min; median: 75 min; 
CV: 27%; p = 0.04). The absolute change from baseline to peak pH was similar in SBC2 and 
SBC3 (0.08 ± 0.02 vs. 0.09 ± 0.02; p = 0.27). In the subsequent cycling trials, the 
reproducibility of the absolute change in pH was fair in SBC2 (r = 0.50, p = 0.09) and good in 
SBC3 (r = 0.60, p = 0.06). Moreover, time to peak HCO3
- was achieved between 30 and 110 
min in SBC2 (mean: 67 ± 21 min; median: 60 min; CV: 31%), compared to between 50 and 
100 min in SBC3 (mean: 77 ± 17 min; median: 75 min; CV: 22%; p = 0.20). The absolute 
change from baseline was greater (+1 mmol.l-1) in SBC3 compared to SBC2 (7.1 ± 1.2 vs. 6.0 
± 0.9 mmol.l-1; p = 0.04; g = 1.0). In the subsequent cycling trials, the reproducibility of the 
change from baseline to peak HCO3
- was good in SBC2 (r = 0.70, p = 0.04) and excellent in 
SBC3 (r = 0.77, p = 0.02).  
 
7.3.2 Performance 
The decline in performance from TT1 to TT2 was similar in all treatments (SBC2 8.0 ± 6.8 vs. 
SBC3 7.0 ± 6.3 vs. PLA 7.3 ± 6.4 s; p >0.05). In TT1, SBC3 improved performance compared 
to PLA by 1.4% ± 1.5% (400.2 ± 24.1 vs. 405.9 ± 26.0 s; p = 0.03; CI = 10.6, 0.8; g = 0.2; 
Figure 7.1), which was determined as a very likely benefit in MBI analysis. Meanwhile, SBC2 
displayed a likely benefit compared to PLA, improving performance by 0.9 ± 1.1% (402.3 ± 
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26.5 s; p = 0.14; g = 0.1; Figure 7.1). A likely benefit was also observed in SBC3 versus SBC2 
(p = 0.15; g = 0.1).  
 
Findings were similar in TT2, where SBC3 again displayed the fastest completion times by 
1.4% ± 1.1% compared to PLA (407.2 ± 29.2 vs. 413.2 ± 30.8 s; p = 0.01; CI = 10.5, 1.5; g = 
0.2), which MBI analysis determined this as a very likely effect. Whereas, SBC2 improved 
performance by 0.7% ± 1.2% compared to PLA (410.3 ± 30.8 s) and this was determined as a 
likely benefit (p = 0.35; g = 0.1; Figure 7.2). A possible benefit was determined for SBC3 
compared to SBC2 for TT2 completion time (p = 0.44; g = 0.1).  
 
Figure 7.1 Mean (± SD) and individual (horizontal lines) time to complete time trial one (TT1) 






Figure 7.2 Mean (± SD) and individual (horizontal lines) time to complete time trial two (TT2) 
(B) following SBC and PLA treatments. * denotes significantly improved compared to PLA (p 
<0.05).  
 
Mean power in TT1 was 4.1% greater in SBC3 compared to PLA (247 ± 41 vs. 258 ± 41; p 
=0.03; CI = 1.7, 19.6; g = 0.3), showing a very likely improvement. Meanwhile, SBC2 
improved mean power by 2.5% compared to PLA, also revealing a very likely benefit (vs. 254 
± 43 W; p = 0.68; g = 0.2). A likely benefit was determined for SBC3 versus SBC2 (p = 0.39; 
g = 0.1). Mean power in TT2 was improved by 3.8% in SBC3 compared to PLA (247 ± 46 vs. 
237 ± 47 W; p = 0.005; CI = 3.0, 15.5; g = 0.2), and demonstrated a most likely benefit. 
Whereas, a likely benefit was determined in SBC2 (vs. 242 ± 47 W; p = 0.34; g = 0.1). A likely 




7.3.4 Blood responses  
A [treatment x time] interaction was observed for HCO3
- (Pƞ2 = 0.65, p <0.001), as HCO3
- was 
greater post-supplementation of NaHCO3 in SBC3 compared to both SBC2 (p = 0.02; CI = 0.3, 
2.5, g = 1.5) and PLA (p <0.001; CI = 6.3, 7.9; g = 8.4; Figure 7.3). Whereas, SBC2 was greater 
than PLA only (p <0.001; CI = 4.4, 7.1; g = 5.7). Post TT1, HCO3
- was greater in both SBC2 
and SBC3 compared to PLA (both p <0.001), with no differences between SBC conditions (p 
= 0.38). There was a [treatment] effect for HCO3
- change during TT1 (Pƞ
2 = 0.69, p <0.001), 
whereby both SBC2 and SBC3 were greater than PLA (p <0.005), with a small effect size 
between SBC treatments (10.6 ± 3.4 vs. 11.5 ± 3.2 mmol.l-1; p = 0.63; g = 0.26). A significant 
[treatment x time] interaction was observed for pH (Pƞ2 = 0.36, p = 0.002), as pH was greater 
post-supplementation and post-TT1 warm-up in SBC3 compared to both SBC2 and PLA (both 
p <0.01), whilst SBC2 was greater compared to PLA (p <0.001). Blood lactate was greater 
post-TT1 in both SBC treatments compared to PLA (p <0.005). No difference was observed 
between SBC treatments at any time point during the study (all p >0.05; Figure 7.3).  
 
Overall, both SBC treatments elicited reductions in K+, Ca2+, and Cl-, and increases in Na+ 
compared to PLA (Figure 7.4). The SID at post-TT1 warm-up and post-TT1 was greater in both 
SBC treatments compared to PLA (p <0.005). However, the SID in SBC3 was greater than 
SBC2 post-NaHCO3 supplementation (p = 0.005; CI = 0.7, 3.5; g = 1.0) and post-TT1 warm-




























Figure 7.3 Mean (± SD) responses for (A) blood pH (B) bicarbonate (HCO3
-) and (C) lactate 
following NaHCO3 across time. SBC3 (*) and SBC2 (#) significantly greater than PLA. SBC3 
(†) significantly greater than SBC2 (p <0.05). Horizontal dotted lines represent baseline data. 






 Figure 7.4 Mean (± SD) potassium (A), sodium (B), calcium (C) and chloride (D) over time 
following SBC treatments. SBC3 (*) and SBC2 (#) significantly different compared to PLA. 
SBC3 (†) significantly different compared to SBC2 (p <0.05). Horizontal dotted lines represent 
baseline data. R = recovery. PW = post warm-up. 
 
During recovery, HCO3
- was greater following SBC3 compared to PLA at all recovery time 
points (p <0.01), however only greater at 20 (23.5 ± 1.7 mmol.l-1; 21.1 ± 2.7 mmol.l-1; p = 0.04; 
CI = 0.2, 4.7; g = 1.0) and 40 min (27.7 ± 0.8 vs. 25.7 ± 1.3 mmol.l-1; p = 0.006; CI = 0.6, 3.3; 
g = 1.8) compared to SBC2. Similarly, SBC2 was greater than PLA at all recovery time points 
(all p <0.01). The absolute change in HCO3
- from post TT1 to 40 min recovery was significantly 
greater compared to PLA (5.0 ± 1.5 mmol.l-1) in both SBC2 (10.1 ± 1.4 mmol.l-1, p <0.001; CI 





small effect size between SBC treatments (p = 0.45; g = 0.3). Moreover, compared to PLA (p 
<0.05), pH was greater at all time points during recovery in both SBC2 and SBC3, whilst SBC3 
was greater than SBC2 at 20 and 30 min of recovery (both p <0.05). Only at 40 min recovery 
was the SID greater in both SBC2 and SBC3 compared to PLA (both p <0.005; Figure 7.5). 
The absolute change in the SID from post-TT1 to 40 min recovery was only significantly greater 
for SBC3 compared to PLA (p = 0.05; CI = 0.01, 9.0; g = 1.2).  
 
Post warm-up in TT2, HCO3
- was greater in both SBC2 and SBC3 compared to PLA (p <0.001), 
however SBC3 was greater than any treatment (p <0.001). Post-TT2, HCO3
- was greater in both 
SBC2 and SBC3 compared to PLA (both <0.005), with no difference between SBC treatments 
(p = 0.17). There was a main [treatment] effect for HCO3
- change during TT2 (Pƞ
2 = 0.71, p 
<0.001), whereby both SBC treatments were greater than PLA (p <0.01), however, SBC3 was 
greater compared to SBC2 (10.7 ± 2.9 vs. 9.2 ± 2.7 mmol.l-1; p = 0.02; CI = 0.3, 2.6; g = 0.5; 
Figure 7.3). Post-TT2 warm-up, and post-TT2, pH in both SBC2 and SBC3 were greater than 
PLA (p <0.001), although no difference between SBC treatments were observed (p >0.05). 
Blood lactate was greater post-TT2 compared to PLA in both SBC2 (18.0 ± 4.2; vs. 14.4 ± 3.3 
mmol.l-1; p = 0.05; CI = -0.01, 7.2; g = 0.9) and SBC3 (18.6 ± 3.5; p = 0.009; CI = 1.1, 7.2; g 
= 0.9), however with no difference between SBC treatments (p = 0.424; g = 1.2). Post-TT2 
warm-up, the SID was greater for both SBC2 and SBC3 compared to PLA (p <0.001), however 
no difference was observed between SBC treatments (SBC2 35 ± 3 vs. SBC3 37 ± 3 meq/L; p 
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= 0.20; g = 0.6). Post-TT2, no differences in the SID were observed between treatments (p  
>0.05; Figure 7.5). 
Figure 7.5 Mean (± SD) strong ion difference (SID) responses over time following SBC 
treatments. SBC3 (*) and SBC2 (#) significantly greater than PLA. SBC3 (†) significantly 
greater than SBC2 (p <0.05). Horizontal dotted lines represent baseline levels. R = recovery. 
PW = post warm-up. 
 
7.3.5 Ratings of perceived exertion (RPE), heart rate (HR), and oxygen saturation (SpO2) 
During TT1, NaHCO3 did not affect RPEO (Pƞ
2 = 0.24, p = 0.07) or RPEL (Pƞ
2 = 0.10, p = 
0.38), HR (Pƞ2 = 0.07, p = 0.63), or SpO2 (Pƞ
2 = 0.18, p = 0.16). Similarly in TT2, no changes 
in RPEO (Pƞ
2 = 0.17, p = 0.12), RPEL (Pƞ
2 = 0.11, p = 0.35), HR (Pƞ2 = 0.07, p = 0.78) or SpO2 






7.3.6 Gastrointestinal (GI) discomfort  
In total, 6/10 (60%) participants suffered from GI discomfort in SBC2, whereas, 9/10 (90%) 
suffered from GI discomfort in SBC3. The most common GI discomfort symptom was belching 
(2/10) in SBC2, whilst in SBC3, diarrhoea, bowel urgency, and feeling of vomiting were most 
common (5/10). Both the aggregated GI discomfort and the severity of the most severe GI 
discomfort symptom suffered was greater in SBC3 compared to SBC2 (aggregated GI 
discomfort: 23 ± 19 vs. 8 ± 11; p = 0.02; g = 0.81; Severity: 7.1 ± 3.1 vs. 3.5 ± 3.4; p = 0.006; 
g = 0.9). On 3/30 (10%) occasions the supplement was correctly identified by the participant. 
 
7.4 Discussion 
This study investigated the effects of NaHCO3 on acid base balance recovery and repeated 4 
km TT’s in moderate acute hypoxic conditions. Both SBC2 and SBC3 improved TT1 and TT2 
performance compared to PLA, displaying ‘likely’ and ‘very likely’ beneficial effects in 
magnitude based inferences analysis, respectively. The current study findings suggest this 
occurred due to the significantly faster, and greater magnitude of acid base balance recovery 
following NaHCO3. A greater magnitude of performance improvement was observed in SBC3 
however, showing ‘likely’ and ‘possibly’ beneficial effects in TT1 and TT2 compared to SBC2, 
respectively. Accordingly, SBC3 is the most optimal to improve repeated efforts of high-
intensity exercise in acute moderate hypoxic conditions. One individual did display an ergolytic 
effect following SBC3 however, despite still gaining ergogenic effects from SBC2 versus PLA, 
which seemed to be due to the onset of severe GI discomfort. Individuals who display similar 
responses may therefore wish to select the SBC2 dose, although this will depend on this dose 




Positive effects on repeated exercise performance in acute hypoxic conditions were observed 
in the current study following NaHCO3, such that both doses of NaHCO3 displayed positive 
effects. These findings support the positive effects on subsequent performance reported in 
normoxia following NaHCO3 (Pruscino et al., 2008, Gough et al., 2017). The current study 
also displays the dose-dependent effects of NaHCO3 on subsequent exercise performance 
however, suggesting SBC3 is more suitable. The TE for the 4 km TT between the 
familiarisation trial and the placebo trial was 3.1 s in the current study, and in using this 
threshold, half of the sample improved more greatly SBC3 versus SBC2 in TT1. In contrast, 
only one participant displayed a greater benefit in SBC2 compared to SBC3. Furthermore, 
again in TT2, SBC3 improved performance within half of the sample compared to SBC2, 
compared to only two displaying greater improvements in SBC2 versus SBC3. These findings 
contrast with previous chapters (5a and 5b) reporting similar performance improvements 
between the same doses. The reduced effect from SBC2 in acute hypoxia may be due to the 
greater acidic stress compared to the same given absolute workload in normoxia however 
(Hogan et al., 1999, Romer et al., 2007, Adams and Welch, 1980), such that a larger amount 
of NaHCO3 is required. Chapter 6 supports these findings, such that a greater magnitude of 
performance enhancement following SBC3 was observed compared to SBC2 in a singly bout 
of exercise at acute hypoxia. This study also displays however that for repeated bouts of high-
intensity exercise, SBC3 is more suitable.  
 
The current study findings suggest the enhanced exercise performance in both bouts of exercise 
occurred due to the combination of the greater alkalotic state of the acid base balance prior to 
TT1, and the accelerated recovery prior to TT2. Specifically, the increase in pH, HCO3
- and the 
SID prior to TT1 was greater compared to PLA following both SBC2 and SBC3. Subsequently, 
the change in HCO3
- was increased following NaHCO3 (SBC2 +29%, SBC3 +34%), whilst 
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blood lactate was also greater compared to PLA (SBC2 +21%, SBC3 +23%). These changes 
suggest an increased H+ buffering from intramuscular to extracellular compartments, which 
leads to an increased anaerobic energy provision and glycolytic flux, as the intramuscular pH 
is better protected (Marx et al., 2002, Percival et al., 2015). It is argued however, that these 
indirect biomarkers of upregulated glycolytic flux may instead show a reduction in lactate by 
inactive tissue (Granier et al., 1996), and therefore provide no explanation for the improved 
performance in the current study. Furthermore, it is argued that acidosis has no implications on 
high-intensity exercise performance (Westerblad, 2016). Nonetheless, a recent study by Lopes-
Silva et al. (2018) has reported similar post-exercise HCO3
- and lactate responses to the current 
study and reported a 34% greater glycolytic energy contribution following NaHCO3. The 
changes in this study suggest therefore, that either acidosis is an important determinant of 
fatigue, or that NaHCO3 allows for an improved ability to increase anaerobic metabolism.  
 
Prior to TT2, both pH and HCO3
- following both SBC2 and SBC3 was increased, such that the 
absolute change in HCO3
- was over two-fold greater compared to PLA (SBC2 +51%, SBC3 
+55%), and the change in the SID was also more superior (SBC2 +29%, SBC3 +31%). These 
findings suggest a greater amount of H+ buffering occurred during this time, which 
subsequently facilitated a faster and more substantial recovery of acid base balance compared 
to PLA. Importantly however, SBC3 elicited both a faster, and a greater magnitude of acid base 
balance recovery, such that significantly greater HCO3
- values at 40 min recovery were 
observed for SBC3 (27.7 ± 0.8 vs. SBC2 25.7 ± 1.3 mmol.l-1), and a 10% increase in HCO3
- 
during TT2 was observed. Combined, these greater increases in blood acid base analytes may 




Interestingly, at 40 min recovery pH, HCO3
- and the SID were still rising in the SBC conditions. 
The observed pH values at 40 min recovery were 7.49 ± 0.02 in SBC3, which was identical to 
the increase prior to TT1 following the same dose (7.49 ± 0.01). This supports previous research 
in normoxia reporting that acid base balance at the end of recovery was reflective of increases 
typically seen with pre-exercise NaHCO3 ingestion (Pruscino et al., 2008, Callaghan et al., 
2017). Equally, in the current study, and others (Callaghan et al., 2017, Pruscino et al., 2008), 
acid base balance status was still significantly rising to a more alkalotic state. It is plausible to 
suggest therefore if a longer period of recovery was employed, a more pronounced performance 
effect may have been observed compared to PLA. Moreover, this also suggests that a full re-
dose of NaHCO3 following an initial fatiguing bout is not required, as acid base balance 
increased above baseline, despite no re-dosing of NaHCO3. Rather, a smaller top-up dose may 
be more suitable (i.e. 0.1 g.kg-1 BM NaHCO3) to elevate HCO3
- to similar levels observed in 
this study prior to TT1. These findings may be of importance to individuals who suffer from 
GI discomfort, as no instances were reported during recovery in the current study. In response, 
further research should investigate the performance responses on repeated exercise following 
NaHCO3 with a longer period of recovery, or with a top-up dose between bouts. 
 
One participant presented an ergolytic effect in both TT1 and TT2 after ingestion of SBC3. This 
was likely due to the occurrence of severe GI discomfort (diarrhoea = 10; aggregate score = 
63), as this participant still improved performance in SBC2. These findings support previous 
research whereby ergolytic effects were observed in participants who suffered from severe GI 
discomfort following 0.3 g.kg-1 BM NaHCO3 (Saunders et al., 2014b, Dias et al., 2015). 
Chapter 5a and 5b contrast these findings however, as ergogenic effects co-existed with the 
occurrence of GI discomfort. Nonetheless, this same participant in the present study did report 
more substantial GI discomfort compared to any participant in these chapters, which suggests 
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the greater severity observed by this participant might explain why ergogenic effects were not 
realised. Therefore, it is important to monitor the GI discomfort responses following NaHCO3 
on an individual basis, as those who display severe symptoms following SBC3 may instead 
benefit from ingesting SBC2. This use of SBC2 will be dependent on this dose still improving 
performance against a placebo. 
 
7.5 Conclusion 
This study investigated the effects of NaHCO3 ingestion on repeated 4 km TT performance and 
acid base balance recovery in acute moderate hypoxic conditions. Both amounts of NaHCO3 
employed in this study ensured recovery of acid base balance back to baseline or above within 
20 to 40 min, whereas for PLA this was not achieved. For the first time, such acid base balance 
recovery has translated into an improved subsequent bout of high-intensity exercise in acute 
hypoxic conditions. The performance improvement was greater in SBC3, which is likely due 
to the greater alkalotic status of acid base balance prior to TT1, and during recovery compared 
to SBC2 and PLA. The onset of GI discomfort was an issue with SBC3 however, and one 
participant displayed an ergolytic effect on performance following this dose. Individuals should 
therefore employ SBC3 to improve performance in acute hypoxic conditions, only if severe GI 

































By evaluating the effectiveness of NaHCO3 as an ergogenic aid, through scrutiny of the 
ingestion strategy, this thesis has presented new and in-depth evidence to enhance the practical 
application of this supplement. The following general discussion will focus on the key findings 
of this thesis by firstly presenting a summary analysis on the key outcomes. Hereafter, attempts 
shall be made to conceptualise the underpinning theoretical and practical implications. Whilst, 
limitations and future directions for NaHCO3 research are offered. 
 
8.2 Main discussion 
8.2.1 Implications of sodium bicarbonate ingestion timing 
The experimental chapters of this thesis investigated the time to peak pH and HCO3
- following 
both SBC2 and SBC3. Figure 8.1 displays the collective findings from these chapters from 
team sports players (n = 15) and cyclists (n = 35).  
 
In comparison to the previously recommended ingestion time of between 60 and 90 min 
(Renfree, 2007, Price and Singh, 2008, Carr et al., 2011b, Siegler et al., 2012), this work shows 
that 37 out of 50 participants failed to achieve peak HCO3
- during this time frame following 
NaHCO3. Furthermore, within this 60 to 90 min time frame there was also high inter-individual 
variation. Consequently, these findings question the common practices of ingesting NaHCO3 
at a set time frame for all participants. The current thesis instead corroborates with the growing 
body of literature, reporting similar high inter-individual variation to achieve time to peak pH 
and HCO3
- (Miller et al., 2016, Jones et al., 2016, Green and Siegler, 2017, Deb et al., 2017, 
2018a). It is unclear why this might occur, however this may be due to individual differences 
in blood flow, gastric emptying, or pre-ingestion diet (Paintaud et al., 1998; Barnett et al., 1999; 
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Limmer et al., 2018), which required further research. Nonetheless, as a result, it is important 
for individuals to identify their respective time to peak alkalosis prior to employing NaHCO3 
in training or practice. This will enhance individual buffering capacity more greatly and hence, 
increase the chance of an ergogenic effect. A drawback of implementing this strategy however, 
is that individuals will require access to a blood gas analyser or to a laboratory to determine 
their individual time to peak HCO3
-. Nonetheless, this will not be of great significance if the 

















Figure 8.1 Individual time to peak HCO3






At the conception of this thesis only one study had utilised an individualised NaHCO3 strategy, 
whereby Miller et al. (2016) supplemented NaHCO3 at a pre-determined time to peak pH. 
Whilst this displayed a positive effect on performance, no research had investigated the 
reproducibility of this time to peak pH. In response, Chapter 4 aimed to elucidate the most 
appropriate analyte (either pH or HCO3
-) to determine this time to peak alkalosis. The novel 
finding was that time to peak pH and HCO3
- generally displayed a good to excellent level of 
reproducibility following both SBC2 and SBC3. The time to peak HCO3
- revealed greater 
reproducibility compared to the time to peak pH following both SBC treatments however, 
suggesting this strategy is the most optimal. The more reproducible HCO3
- findings support 
Dias et al. (2015), reporting a much greater CV for the absolute change in pH compared to 
HCO3
- upon ingestion of NaHCO3 on four separate occasions (18% vs. 3%). The authors only 
conducted CV analysis on their data, which means that the present thesis provides increased 
statistical rigour, and thus, greater insight. Practitioners and athletes can therefore be confident 
that following the initial identification of time to peak HCO3
-, this can be reproduced 
consistently in training and/or competition. 
 
Table 8.1 – Intraclass correlation coefficient overview for the reproducibility of the absolute 
change in blood pH and bicarbonate (HCO3
-) from baseline to peak. 




Chapter 4     
r value 0.84 0.89 0.62 0.76 
P value 0.001 <0.001 0.04 0.01 
     
Chapter 5a     
r value 0.79 0.78 0.15 0.68 
P value <0.001 <0.001 0.34 0.01 
     
Chapter 6     
r value 0.56 0.66 0.48 0.76 
P value 0.02 0.04 0.11 0.01 
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Chapter 7     
r value 0.50 0.70 0.60 0.77 
P value 0.09 0.04 0.06 0.02 
ICC = Intraclass correlation coefficient. Bold = non-significant 
 
A further original finding of the current thesis was that the absolute changes from baseline to 
peak HCO3
- were more reproducible compared to pH across all experimental chapters (Table 
8.1). These findings also likely explain why the time to peak HCO3
- displayed a greater 
reproducibility compared to pH. Consequently, the pH kinetics following NaHCO3 ingestion 
should not determine the individualised NaHCO3 ingestion strategy, as this could lead to a 
‘false peak’ to be identified. The practitioner or athlete should instead monitor their absolute 
changes in HCO3
- with repeated NaHCO3 ingestion, as this will provide a more reliable marker 
of time to peak alkalosis and reproduce this response more effectively.  
 
8.2.2 Reproducibility of performance  
Chapter 5a investigated whether the reproducible blood HCO3
- responses following NaHCO3 
ingestion, translated into reproducible performance responses. This chapter showed following 
both SBC2 and SBC3, individualised to a time to peak HCO3
-, the reproducibility of 4 km TT 
performance was excellent. These findings contrast with the highly variable performance 
responses reported by Dias et al. (2015) within a group of healthy individuals. Instead, they 
agree with Carr et al. (2012) who reported a 2.1% CV for mean power during a 2000 m rowing 
TT within a group of highly trained rowers. The higher training status of the participants in 
Chapter 5a and Carr et al. (2012) may explain the greater reproducibility observed, as they are 
likely more able to attain more reproducible performances. Carr et al. (2012) reported that 
NaHCO3 ingestion had no effect on performance however, which may also explain the high 
reproducibility of performance. Although Chapter 5a did not include a placebo, a comparison 
with a control trial revealed an improvement in performance for both doses (range 2.1 to 2.3%), 
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which infers an ergogenic effect. Practitioners and athletes can therefore be confident that both 
the blood and performance responses are consistent, which may, in turn, improve performance.  
 
8.3 Overall efficacy to improve performance  
The overall effect of NaHCO3 was generally positive compared to PLA. Figure 8.2 displays 
the overall performance effects on a group and individual level for all participants who 
















Figure 8.2 – Mean (± SD) time to complete the 4 km TT for all participants (n = 46) (A) and 
individual responses (B). * denotes significantly different to PLA (p <0.001). No significant 





This evidence suggests that for exercise of similar intensities and durations to a 4 km TT, 
NaHCO3 can provide ergogenic effects in both normoxia and hypoxia. This is particularly 
important for athletes who participate in events such as the individual and team pursuit events 
in track cycling; or similar events such as the points race or the omnium whereby bursts 
equivalent to a 4 km TT distance are required. Moreover, NaHCO3 ingestion can partly mitigate 
the decline in performance typically observed in hypoxia. This is important for hypoxic training 
schedules as training intensity and volume may be sustained better, which may lead to 
improving the efficacy of hypoxic training methods to improve performance.  
 
Previous research suggests the performance effects following NaHCO3 are related to the 
absolute change in HCO3
- from baseline to peak, whereby greater increases lead to a more 
pronounced effect on performance (Carr et al., 2011a). Explicitly, it is suggested a minimum 5 
mmol.l-1 increase in HCO3
- is required to provide ergogenic benefits. The present thesis 
however, failed to observe any relationship between the absolute increase in HCO3
- from 
baseline to peak, and the resulting performance effect (Figure 8.3). The lack of a relationship 
is likely due to the high inter-individual variation in the absolute change of HCO3
- following 
NaHCO3 ingestion, as the present thesis displayed an 18.7% (SBC2) and a 16.7% (SBC3) 
within-group CV, despite the same NaHCO3 dose; which corroborates with previous research 
(Jones et al., 2016). Consequently, such a high inter-individual variation may explain why no 
clear pattern is observed in respect of the effects on performance. Therefore, it would seem 
other factors may be more important to explain the relationship with the resulting performance 




















Figure 8.3 – Scatterplots illustrating the relationship between the absolute change in HCO3
- 
and the resulting performance improvement in seconds following SBC2 (top, black dots) and 
SBC3 (bottom, grey dots) compared to PLA (n = 46). 
 
The current thesis speculates that heightening individual buffering capacity is more important 
than the absolute change in HCO3
- from baseline to peak per se. Jones et al. (2016) reported an 
average increase in HCO3
- of 8.2 ± 1.4 mmol.l-1 following 0.3 g.kg-1 BM NaHCO3 in healthy 
males, with other studies reporting similar increases in HCO3
- within non-trained individuals 
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(McNaughton, 1992a, Gough et al. 2017). In contrast, a much smaller 6.6 ± 1.1 mmol.l-1 
increase was observed within the trained cyclists of the present thesis, and as displayed in 
Figure 8.3, only three participants achieved over 8 mmol.l-1 following the same dose. Despite 
these smaller increases, significant ergogenic effects on performance were still observed. 
Furthermore, in Chapter 5a (pp.115) some participants improved more greatly following 
NaHCO3, despite reporting a lower absolute change in HCO3
- from baseline. This evidence 
suggests the required increase in HCO3
- is potentially much smaller in trained participants. This 
may be due to trained individuals already possessing a heightened buffering capacity compared 
to their untrained counterparts (Parkhouse et al., 1985). The dose-dependent blood and 
performance findings support this, as SBC2 increased pH and HCO3
- to a similar extent 
compared to SBC3 in many individuals. This suggests SBC2 was sufficient in maximising 
buffering capacity in these participants. Nonetheless, this requires confirmation as no study has 
directly compared trained versus untrained HCO3
- responses following NaHCO3 ingestion. 
 
8.3.1 Normoxia 
Chapter 5b investigated the effects of both SBC2 and SBC3 ingested at a pre-determined time 
to peak HCO3
- on 4 km TT performance. Correspondingly, both SBC treatments significantly 
improved performance compared to a placebo. These findings also support Chapter 5a, which 
inferred an ergogenic effect from NaHCO3 ingestion. They contrast with previous research 
however, that has reported no ergogenic effects on 4 km TT performance (Callaghan et al., 
2017, Oliviera et al., 2017). These latter studies administered NaHCO3 in capsules at a 
standardised time of 150 and 100 min prior to exercise however, which would have failed to 
maximise buffering capacity in some individuals (Miller et al., 2016, Jones et al., 2016). Using 
data from Jones et al. (2016) who also employed capsule NaHCO3 ingestion, only 3/16 
participants would have been at peak HCO3
- at these time points, respectively. Consequently, 
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this may explain why no ergogenic effects on performance were observed. Based on the current 




A further original finding was that both SBC2 and SBC3 improved performance to a similar 
extent in Chapter 5b, showing a minimal 0.1% difference in completion time. These 
performance effects were likely due to the similar increases in pH and HCO3
- at the post-
supplementation stage. Subsequently, the change in HCO3
- during exercise was similar 
between SBC treatments, suggesting buffering capacity was heightened to the same extent. 
These findings contrast with McNaughton (1992a) who reported that 0.3 g.kg-1 BM NaHCO3 
improved 60 s cycling TT performance more effectively than 0.2 g.kg-1 BM NaHCO3. The 
author employed a standardised ingestion strategy beginning 60 min prior to exercise however, 
which would likely have failed to maximise individual buffering capacity in some participants 
following SBC2. Specifically, in comparison to the current thesis, only 16 out of 50 participants 
achieved time to peak HCO3
- at this time point in SBC2. In contrast, by supplementing SBC2 
at a pre-determined individual time to peak HCO3
- in the current thesis, individual buffering 
capacity was likely enhanced more greatly and hence, the ergogenic effects were similar to 0.3 
g.kg-1 BM NaHCO3. The current thesis therefore suggests that 0.2 g
.kg-1 BM NaHCO3 is a 
physiologically optimal dose to maximise blood buffering capability and performance when 
supplemented this way. These findings are important to refine the best practices for NaHCO3 
ingestion, particularly for individuals who experience severe GI discomfort following 0.3 g.kg-





The performance findings in acute hypoxia did not corroborate the positive findings at 
normoxia for SBC2, as SBC3 provided greater performance benefits. Indeed, in Chapter 6, 
SBC2 significantly improved performance compared to both PLA and CON, which initially 
suggests this amount of NaHCO3 is suitable to provide ergogenic effects. The overall 
performance effect was superior with SBC3 however, such that a ‘likely’ benefit was observed 
in magnitude base inferences analysis. The greater ergogenic effects from SBC3 in hypoxia are 
likely due to the greater augmentation of pH and HCO3
- post-NaHCO3 ingestion compared to 
SBC2 in both hypoxic chapters (6 and 7). Alternatively, the exacerbated H+ accumulation in 
hypoxic conditions compared to normoxic conditions (Adams and Welch, 1980, Hogan et al., 
1999, Romer et al., 2007) may have rendered the SBC2 dose insufficient to enhance buffering 
capacity to an extent that outweighs this increased perturbation of acid base balance.  
 
It is important to note however, that ergogenic effects were still observed following SBC2 
compared to PLA in Chapter 6. Equally, the performance effects between doses displayed a 
high inter-individual variation, such that eleven out of fourteen participants displayed minimal 
differences between SBC treatments in Chapter 6. Subsequently, SBC2 is still optimal to 
improve performance for some individuals. Consequently, the selection of the NaHCO3 dose 
should be determined on an individual basis in hypoxia, as the SBC2 dose may be more suitable 
to some to enhance performance. A caveat to this however is the performance findings in 
Chapter 7, whereby SBC3 improved two repeated 4 km TT performances more greatly than 
SBC2. Importantly, there were lower inter-individual differences between doses, such that five 
out of ten participants improved performance more greatly following SBC3 compared to SBC2 
in TT2. Subsequently, athletes are more likely going to gain the greatest effect from NaHCO3 
ingestion in a 0.3 g.kg-1 BM dose. In Chapter 7 nonetheless, one participant did suffer from 
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severe GI and this seemed to lead to an ergolytic effect on performance following SBC3, and 
some individuals improved performance to a similar extent following SBC2. Therefore, the 
selection of the 0.3 g.kg-1 BM dose will require an individual approach. 
 
The positive performance findings in hypoxia from NaHCO3 ingestion in the current thesis 
support those of Deb et al. (2017, 2018b), who, replicated the individual time to peak alkalosis 
ingestion strategy of the current thesis. Conversely, the thesis findings contrast with previous 
research employing a standardised ingestion strategy supplementing NaHCO3 at 90 and 240 
min prior to exercise (Flinn et al., 2014, Saunders et al., 2014b). These current thesis findings 
add to the current body of knowledge on NaHCO3’s efficacy as an ergogenic aid in hypoxic 
environments. In addition, however, the current thesis also adds such positive effects can be 
obtained during a self-paced TT following NaHCO3 ingestion. Moreover, the dose-dependent 
effects were investigated in the hypoxic chapters, which highlighted that a lower dose of 
NaHCO3 may be suitable for some individuals. These findings therefore firstly stress that in 
practice, a prior knowledge of individual time to peak HCO3
- is acquired to heighten the change 
of an ergogenic effect, which is akin to the findings in normoxia. Whilst, some individuals can 
consider a smaller dose of NaHCO3, depending on both their GI discomfort and performance 
responses. 
 
Overall, NaHCO3 ingestion is a worthwhile supplement to improve acute bouts of high-
intensity exercise performance in a hypoxic setting. The precise dose needed to improve 
performance likely requires an individual approach however, as for some, SBC2 was suitable. 
This is an important finding in the context of sustaining training intensity and volume during 
intermittent hypoxic training schedules, such as ‘live-low, train-high’. In turn, this may 
alleviate the common fears of coaches and athletes of a detraining effect occurring during 
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hypoxic training schedules due to the reductions in performance negating the potential 
performance enhancement. A further avenue of work may be to investigate the effects of 
NaHCO3 ingestion on the resulting outcomes of hypoxic training schedules vs. no ingestion, to 
assess whether this supplement supports, or negates, training adaptations.   
 
8.4 Gastrointestinal discomfort 
In some of the early chapters of this thesis (4, 5a, and 5b) NaHCO3 was generally well tolerated, 
irrespective of the amount ingested. In later chapters (6 and 7) however, GI discomfort was 
moderate to severe and SBC3 caused a significantly higher severity and aggregated score of 
GI discomfort compared to SBC2. This highlights the high inter-individual variation in GI 
discomfort responses following NaHCO3, which agree with previous work reporting similar 
inter-individual variation (Price, Moss and Rance, 2003, Saunders et al., 2014b, Dias et al., 
2015, Gough et al., 2017). As a result, athletes and practitioners should be wary that ingestion 
of NaHCO3 causes mixed GI discomfort responses, regardless of the amount ingested. An 
individualised approach to NaHCO3 is therefore recommended.   
 
The experimental chapters of this thesis quantify the GI discomfort responses to a lower 0.2 
g.kg-1 BM dose of NaHCO3, to investigate if this may be practically useful. Generally, GI 
discomfort was reduced following SBC2 compared to SBC3 in all the present studies, whereby 
the symptoms of diarrhoea and bowel urgency were experienced by more than double the 
number of participants following SBC3 (SBC3 n = 17, SBC2 n = 8). Similarly, in Chapters 6 
and 7, both the severity of GI discomfort was significantly greater in SBC3 (severe) compared 
to SBC2 (moderate), and the aggregated score was more than two-fold greater. A further issue 
with SBC3 was the removal of one participant who vomited shortly following ingestion of 
NaHCO3 in Chapter 4, which supports previous research reporting similar issues (Jones et al., 
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2016, Gough et al., 2017). Clearly, this could have negative impacts on the athlete if this was 
to occur in competition or training scenarios. These findings expand upon those of 
McNaughton (1992a), who, anecdotally reported GI discomfort increased at higher doses of 
NaHCO3 compared to lower doses. Considering such varied GI discomfort responses, it is 
vitally important for the practitioner to gain subjective feedback from athletes on GI discomfort 
following NaHCO3. If tolerability is poor, a lower dose of NaHCO3 is a valid strategy to 
mitigate the common GI discomfort issues reported from SBC3. Nonetheless, the usefulness 
of this will be dependent on SBC2 also providing ergogenic effects on performance. 
 
This thesis displays for the first time the effects of repeated NaHCO3 supplementation on GI 
discomfort responses. In Chapters 4 and 5a, the symptom suffered following NaHCO3 
displayed high intra-individual variation, despite the amount ingested and pre-trial nutritional 
practices being the same. With no clear patterns evident throughout this thesis to explain such 
variation, this potentially hinders the use of NaHCO3, particularly if the symptom was to 
dramatically change in a competition setting. These findings contrast previous research 
suggesting repeating NaHCO3 loading may eventually lead to an acceptable level of GI 
discomfort (Burke, 2007, Carr et al., 2011a, Dias et al., 2015). It is worth noting however, in 
the current thesis, the amount of exposures to NaHCO3 was six separate ingestions over a short 
period of time (three to four weeks). Consequently, it is unknown if repeated ingestion over a 
longer period may allow for greater gut adaptation and hence, greater tolerability. Close 
monitoring of the GI discomfort responses in a more longitudinal manner is therefore required 
in future research. 
 
It is important to acknowledge that whilst GI discomfort is uncomfortable for the athlete, it 
does not always lead to an ergolytic effect on performance. In Chapter 5b, performance 
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improvements were maintained, despite some participants suffering from mild to severe GI 
discomfort. Conversely, one participant displayed ergolytic effects following SBC3 in Chapter 
7. This participant reported a severity of 10 and the highest aggregated score of 63 observed 
across all participants within this thesis. In contrast to this individual case however, multiple 
participants (n = 5) also displayed a high severity (10 rating) and aggregated score of GI 
discomfort (range = 16 to 50), yet still improved performance. Therefore, whilst it seems no 
clear pattern is apparent to explain the impact of GI discomfort on performance, individuals 
that display very severe GI discomfort may be negatively affected.  
 
Considering GI discomfort is a regular occurrence following NaHCO3, it is important to 
quantify what factors may contribute to such instances. Body mass is a plausible factor, as the 
absolute dose of NaHCO3 will increase in a linear fashion with body mass. In turn, this will 
lead to a greater ingested Na+ load, which may disturb the acid base balance more severely 
leading to GI discomfort (Jones et al., 2016). To assess this relationship, linear regression 
analysis was conducted to assess the relationship between the absolute amount of NaHCO3 and 
the severity (Figure 8.4), and aggregated score (Figure 8.5) of GI discomfort following both 
SBC2 and SBC3.  
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Figure 8.4 Scatterplots illustrating the relationship between the absolute amount of NaHCO3 
ingested and the resulting severity (n = 75) of GI discomfort in SBC2 (left, black dots) and 
SBC3 (right, grey dots). 
Figure 8.5 Scatterplots illustrating the relationship between the absolute amount of NaHCO3 
and the resulting aggregated score (n = 24) of GI discomfort in SBC2 (left, black dots) and 
SBC3 (right, grey dots).  
 
Overall, no relationships were observed in linear regression analysis following SBC2 for either 
severity (n = 75) or aggregated score (n = 24) of GI discomfort. Given that SBC2 was well 
tolerated in the participants used throughout this thesis, this finding is somewhat unsurprising. 
Equally, the participant of the largest mass (106kg) throughout this thesis only received 21.2 g 
of NaHCO3 (0.2 g
.kg-1 BM), and therefore such a reduction in the absolute load likely explains 
why GI discomfort was not a major issue. Subsequently, GI discomfort is likely unaffected by 
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the absolute load of NaHCO3 following SBC2. In contrast, a significant weak relationship was 
observed for the absolute amount of NaHCO3 and corresponding aggregated GI discomfort 
rating following SBC3 (r2 = 0.27, p = 0.01), whereby, as the absolute amount of NaHCO3 
increases, as does the aggregated score of GI discomfort. This shows the absolute NaHCO3 
dose explains 27% of the aggregated GI discomfort response. These findings may explain why 
greater GI discomfort has been reported following NaHCO3 ingestion within individuals of 
higher body mass (Cameron et al., 2010), compared to low body mass (VanMontfoort et al., 
2004). Subsequently, the use of SBC2 may have alleviated some of the GI discomfort reported 
by Cameron et al. (2010) and therefore been more suitable to their athletes. Importantly 
however, body mass only explained 27% of the aggregated GI discomfort response, and 
therefore further research is warranted.  
 
8.5 Implications of sodium bicarbonate as a recovery supplement 
Chapters 6 and 7 are the first to investigate the post-exercise recovery of acid base balance 
following NaHCO3 in acute moderate hypoxic conditions. Both SBC2 and SBC3 accelerated 
the recovery of acid base balance to baseline within 20 and 40 min compared to PLA. In 
contrast, PLA and CON failed to recover acid base balance back to baseline. In turn, individuals 
who train or compete with a short-term recovery may benefit from this strategy, as the existing 
post-exercise perturbation of acid base balance is alleviated with NaHCO3 ingestion. 
Furthermore, acid base balance was above baseline values and more reflective of metabolic 
alkalosis at the 40 min recovery time point following both SBC2 and SBC3. Collectively, this 
displays that there is potentially no need for athletes to re-dose NaHCO3 in between two 
exercise bouts. Nonetheless, at the end of the 40 min recovery (pre-TT2) HCO3
- was not at the 
same level compared to the levels observed following NaHCO3 ingestion prior to TT1. 
Therefore, it is plausible that a top-up dose may be worthwhile between bouts of exercise, 
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which further research should address. These findings are important for the practical 
application of NaHCO3, as this will moderate the risk of hyperosmotic diarrhoea, and reduce 
fluid retention compared to ingestion both pre, and post-exercise. These findings are also 
significant for individuals who suffer with GI discomfort following NaHCO3, or sports where 
weight is important to performance such as cycling and running (Burke, 2007). Lastly, the post-
exercise recovery kinetic profile suggested that following both SBC treatments, pH and HCO3
- 
were still rising at 40 min recovery. A larger recovery time frame may therefore be worth 
investigating, as this may recover acid base balance more substantially. In turn, this may 
positively influence subsequent exercise performance even further.  
 
Only one study has previously investigated post-exercise acid base balance recovery in hypoxic 
conditions of 1570 m, reporting over 45 min was required for recovery of acid base balance to 
baseline following co-ingestion of NaHCO3 and sodium citrate (Robergs et al., 2005). The 
current thesis findings report a faster time of recovery; however, this was largely due to the 
greater exercise intensity of the initial fatiguing bout employed by Robergs et al. (2005). 
Indeed, the change in HCO3
- was similar between SBC treatments in chapters 6 and 7, and 
Robergs et al. (2005). Nonetheless, based on the current thesis reporting recovery was similar 
with 0.2 g.kg-1 BM NaHCO3, however with no additional sodium citrate as used by Robergs et 
al. (2005), the latter supplement is probably not required. A single dose of NaHCO3 is therefore 
suitable to maximise the both the speed, and magnitude of post-exercise acid base balance 
recovery.  
 
A unique finding of Chapter 7 was that SBC3 was the most effective dose to improve 
subsequent exercise performance in hypoxic conditions. Significant effects on performance in 
SBC3 were observed in both exercise bouts (i.e. TT1 and TT2) compared to PLA, which was 
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determined as a ‘likely’ benefit for SBC3 versus SBC2 in magnitude based inferences analysis. 
Specifically, 50% (5/10) participants displayed greater benefits for SBC3 in TT2 versus SBC2, 
whilst 50% (10/20) of total bouts were also improved by more than the TE of the test following 
SBC3. A superior acid base balance recovery prior to TT2 was also observed for SBC3, 
suggesting this elicited the greater magnitude of performance improvement. Therefore, if 
athletes wish to gain the most out of NaHCO3 supplementation for performance and recovery 
in acute hypoxic conditions, SBC3 is recommended. Caution must be taken however, as one 
participant did display an ergolytic effect on performance following SBC3 compared to SBC2, 
which seemed to be due to the high rating of both the severity and aggregated score of GI 
discomfort. Importantly, this participant still improved in SBC2 compared to PLA. Therefore, 
if an ergolytic effect is observed following SBC3, a lower dose may still be a worthwhile 
strategy. 
 
8.6 General limitations of the thesis 
A limitation of this thesis is that fatigue arising from metabolite accumulation has been 
considered in isolation, despite fatigue being multifaceted and encompassing many areas of 
sport science (Amann et al., 2006, Marcora, Staiano and Manning, 2009). Furthermore, recent 
evidence has suggested that NaHCO3 may exert ergogenic effects from central mechanisms 
(for review see Siegler et al., 2016). In short, H+ accumulation has been related to changes in 
cortical output, spinal reflexes and muscle afferents. Indeed, Siegler and Marshall (2015) 
recently displayed voluntary activation, a gross estimate of central drive, was better protected 
with NaHCO3 ingestion during isometric knee extension exercise in combination with 
ischemia. Whilst in a further study by Siegler et al. (2013), NaHCO3 ingestion lead to an 
improved ability to rapidly generate force, which is a measure of central drive (motor unit 
recruitment). In both studies however, no subsequent effects on maximal force development or 
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peak resting twitch force were seen, suggesting the impact of these changes on performance 
are unclear. Clearly, the aims of this thesis were more closely aligned to investigating 
metabolite accumulation due to NaHCO3’s well reported positive effects on peripheral sites of 
fatigue (Chapter 2, section 2.3), which subsequently yielded novel findings. Equally, the 4 km 
TT employed in this thesis is symptomatic of peripheral fatigue (Chapter 2, sections 2.2 and 
2.5), of which metabolite accumulation and acid base balance homeostasis is suggested to be 
important. Nonetheless, future work may wish to continue investigating NaHCO3’s centrally 
derived acting mechanism during high-intensity exercise, to add a greater understanding to the 
multifaceted area of fatigue.  
 
The findings of this thesis show that supplementing NaHCO3 at a pre-determined time to peak 
HCO3
- is important to provide consistent ergogenic effects. This arguably makes NaHCO3 
more difficult to apply in practice however, as athletes would now require access to a blood 
gas analyser (and likely a laboratory) to determine their respective time to peak alkalosis. 
Despite this, athletes/teams serious about their performance should be willing to consume this 
cost, considering the outlay in other areas of performance enhancement. Nonetheless, future 
research may wish to identify portable, and cost-effective methods to identify peak alkalosis in 
the field. Moreover, no direct comparison of an individualised time to peak and a standardised 
NaHCO3 ingestion strategy was conducted in this thesis. It is unclear therefore if individuals 
may obtain further ergogenic effects from an individualised NaHCO3 ingestion strategy, as 
used throughout this thesis. The present thesis findings suggest a greater benefit to performance 
following this strategy will be observed however, based on both Oliveira et al. (2016) and 
Callahan et al. (2017) failing to report any ergogenic benefits during a 4 km TT using a 
standardised NaHCO3 ingestion strategy. Therefore, whilst a comparison with a standardised 
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ingestion strategy is needed, current evidence suggests that individuals should determine their 
individual peak HCO3
- following NaHCO3 to heighten the chance of ergogenic benefits.  
 
A small limitation of this thesis is the method of calculation for the SID. Only the collection of 
extracellular ionic shifts was considered in this thesis, which is typically described as the 
apparent SID. As a result, no intracellular ions were presented, which would have provided a 
greater view of ionic shifts in active musculature. Consequently, this may have led to a sub-
optimal reflection of the effects of NaHCO3 on action potentials and muscle excitability during 
high-intensity exercise. Nonetheless, the use of extracellular ions for analysis of acid base 
balance is well supported, as this view of the SID indicates movements of Na+, K+ and Cl- 
between the extracellular and intracellular fluid (Heigenhauser, 1991, Lückher et al., 2017, 
Worthley, 1999). Likewise, in a study by Lückher et al. (2017) minimal differences were 
observed between the apparent (capillary) and actual SID (venous) during exercise in a hypoxic 
environment. Nonetheless, as this is the only study to date, future work may wish to continue 
investigating both the intracellular and extracellular SID to provide a more robust interpretation 
of NaHCO3’s effects on action potentials and muscle excitability.  
 
In parts of this thesis the research design could have been improved. In Chapter 5a no placebo 
treatment was included within the study, which subsequently hampered the interpretations of 
the true performance effect of NaHCO3 ingestion. Whilst this is acknowledged as a limitation, 
Chapter 5b did include a placebo treatment in an attempt to quantify the true effects of 
NaHCO3. Moreover, in the hypoxic chapters there was no normoxic control, which would have 
allowed for determination of whether NaHCO3 ingestion was more effective in acute hypoxia 
compared to normoxia, in light of the exacerbated acidic stress. Nonetheless this was not the 
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primary aim of the hypoxic chapters of this thesis, and a decision between the logistical burden 
on the participants and impact of such further findings had to be considered. 
 
8.7 Future directions for sodium bicarbonate research 
The findings of this thesis have presented novel methods to enhance the application of NaHCO3 
as an ergogenic aid. As is the case with most research however, several further questions have 
been raised which warrant further investigation. Below, a summary is provided of areas which 
future research should focus on. 
 
The mechanisms to explain the high inter-individual variation in both the time to achieve time 
to peak alkalosis, and the absolute changes in HCO3
- following NaHCO3 ingestion remains 
unclear. The source of such variation could be multifaceted including influences from training 
status and prior nutritional intake, such as the potential renal acid load (PRAL) in the pre-trial 
diet (Carr et al., 2018). Whilst this thesis did not intend to explain why this variation occurs, 
the findings from Chapter 4 suggest that neither total calorie intake, nor macronutrient intake 
seemed to provide any explanations. Nonetheless, nutrition was only monitored for 24 hours 
prior to any trial, and the team sport players involved replicated their nutrition in each trial. 
Consequently, this may not have been sufficient to appropriately determine if nutritional intake 
can affect the blood responses. Future work may therefore wish to monitor nutritional intake 
in a more longitudinal manner and consider other aspects such as the PRAL load.  
 
The dose-dependent effects of SBC2 and SBC3 on performance in both normoxia and hypoxia 
requires further attention. Since the early dose comparisons by McKenize et al. (1986) and 
McNaughton (1992a), the findings of this thesis are the first to display limited differences on 
performance between these two amounts in normoxia (Chapters 4, 5a and 5b). The findings of 
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the present thesis are limited to exercise durations and intensities similar to a 4 km TT however, 
and future research may therefore wish to investigate the dose-dependent effects of NaHCO3 
on exercise of various durations and intensities. In hypoxia, SBC3 displayed a greater 
magnitude of improvement in performance for both single, and repeated bouts of exercise 
compared to PLA and SBC2 (Chapters 6 and 7). The current thesis did employ the upper 
threshold of moderate hypoxia (3000 m) however, meaning future research should continue to 
explore the dose-dependent effects of NaHCO3 at lower levels of altitude. This may allow the 
typical increases in pH, HCO3
-, and the SID observed following SBC2 to outweigh the 
exacerbated H+ production in hypoxic conditions and hence, improve performance.  
 
Individualising NaHCO3 ingestion to a pre-determined time to peak HCO3
- is supported by the 
findings of this thesis. Nevertheless, direct comparison with other common NaHCO3 ingestion 
strategies was not considered in this thesis. Such investigation could compare ingestion of 
NaHCO3 at a pre-determined HCO3
- vs. at a set time frame and vs. at a pre-determined 
individual time to peak pH within the same group of individuals. In turn, this would allow 
athletes to determine if going to the extra cost to determine their individual time to peak 
alkalosis strategy is worthwhile. Furthermore, investigating the individual time to peak pH and 
HCO3
- will provide more evidence on which NaHCO3 ingestion strategy is the most appropriate 
to elicit ergogenic effects if individual time to peak is identified.  
 
8.8 Conclusions and practical recommendations  
The results of this thesis provide support for NaHCO3 as an ergogenic aid in normoxia, when 
supplemented at a pre-determined time to peak HCO3
-. The use of this strategy also showed 
excellent reproducibility, and therefore athletes can consistently use NaHCO3 as an ergogenic 
strategy to improve performance. Furthermore, in normoxia, no dose-dependent effects on 
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performance were evident, meaning both amounts of NaHCO3 are useful to the athlete in this 
environment. Accordingly, the dose should be the amount that is more tolerable in respect of 
GI discomfort, which is likely to be SBC2. 
 
This thesis also provides support for NaHCO3 as an ergogenic aid in hypoxia, and as a recovery 
supplement to mitigate post-exercise acid base balance perturbations. In acute hypoxic 
conditions, a single bout of exercise (Chapter 6), post-exercise acid base balance recovery 
(Chapters 6 and 7), and subsequent exercise performance (Chapter 7) was improved with 
NaHCO3 ingestion. The most optimal amount of NaHCO3 to elicit ergogenic effects on 
performance is SBC3 however, as this dose showed the greatest magnitude of performance 
improvement compared to SBC2. Nonetheless, a high inter-individual variation between 
NaHCO3 doses was evident, with some displaying no further improvement in performance 
following SBC3 versus SBC2. Furthermore, one participant displayed ergolytic effects in 
SBC3 and not SBC2, which seemed to be due to severe GI discomfort following the larger 
dose. An individual approach is warranted in hypoxia therefore, as in some instances, athletes 
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